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Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic bacterium, 
responsible for causing life threatening infections amongst fibrosis (CF) patients. 
Mucoid phenotypes of P. aeruginosa are characterised by overproduction of 
alginate, an extra-cellular polysaccharide (EPS) composed of β-D-mannuronic acid 
and α-L-guluronic acid, which is involved in bacterial biofilm formation and results in 
a multi-drug antibiotic resistance profile.  
Guanosine diphosphate-mannose dehydrogenase (GMD), a NAD+-dependent 
dehydrogenase responsible for production of the feedstock sugar-nucleotide 
building block guanosine diphosphate-mannuronic acid (GDP-ManA), has been 
identified as a strategic biosynthetic enzyme to investigate potential inhibition of 
alginate production. This oxidation is mediated by a catalytic Cys268 residue, 
providing a template for rational structure-based design of sugar-nucleotide tools. 
This thesis describes the synthesis of GDP-ManA, the native tool for studies into 
alginate biosynthesis. A chemical strategy employing a P(V)-P(V) 
pyrophosphorylation approach towards the target was complemented by an 
enzymatic synthesis using the native enzyme, GMD.  
To permit further mechanistic study of GMD, the synthesis of a series of structurally 
defined GDP-Man analogues was presented via a chemoenzymatic approach, to 
investigate substrate specificity and identify functionalities capable of interacting with 
Cys268. Modified GDP-Man analogues were accessed chemically from differentially 
protected C6-OH and C4-OH mannose building blocks. Following a series of 
functional group interconversions, transformation to the respective sugar-
nucleotides was evaluated using guanosine diphosphate-mannose 
pyrophosphorylase (GDP-ManPP). The synthesised GDP-Man analogues were 
then evaluated as substrates of GMD, providing a foundation for the future design 
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Chapter 1: Introduction 
1.1 Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder that was reported to 
affect over 10500 people in the UK alone in 20171, with 200-300 new diagnoses 
occurring annually.2 The disease affects exocrine organs, primarily the respiratory 
and gastrointestinal tracts and the pancreas, whilst also having secondary effects 
on the reproductive organs.3 In approximately 75% of cases, CF is diagnosed before 
the age of two, with the major physiological marker being an increased concentration 
of electrolytes in sweat due to the reduced permeability of epithelial apical 
membranes to chloride ions.4 The ‘sweat test’ measures the amount of chloride in 
sweat, and remains one of the most commonly performed initial tests in suspected 
cases of CF.5  
The condition is characterised by a build-up of abnormally thick, sticky mucus that 
is hard to clear mechanically, i.e. by coughing (Figure 1.1). Consequently, non-
inflammatory response mechanisms against foreign substances, such as inhaled 
allergens and pathogens, become redundant. This leads to inflammatory response 
mechanisms, such as those of antibodies and macrophages, prevailing which leads 
to a vicious cycle of recurrent/chronic bacterial infections and excessive 
inflammation, primarily within the lungs.6 Other symptoms of the disease include 
malnutrition, resulting from the suppression of pancreatic function, and infertility, 





Figure 1.1: Comparison between normal (left) and CF (right) airways.8  
1.1.1 Pathogenesis 
CF is caused by a mutation in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene (Figure 1.2). Discovered in 1989 by Riordan et al.9, the CFTR 
locus was found to be located on chromosome 7 and deletion of a phenylalanine 
residue was identified within CF patients. Since discovery of the gene over 1600 
alternative mutations of the CFTR have been described, however deletion of 
phenylalanine, denoted the ΔF508del mutation, remains the most common, being 
found in 70% of CF chromosomes.10 Found in a variety of epithelial tissues, the main 
function of the CFTR exists as a cyclic adenosine monophosphate (c-AMP) 
regulated chloride ion channel, however it has also been identified to regulate other 
ion channels such as epithelial sodium channels (ENaC). The CFTR maintains the 
liquid volume on epithelial surfaces, which is essential for effective clearance of 
mucus and foreign particles contained within it, providing the body with a crucial non-





Figure 1.2: Crystal structure of human CFTR gene determined by electron 
microscopy.11 
The human airway is comprised of two aqueous layers. The first is a mucus layer 
that traps any inhaled allergens and pathogens, whilst the second is a thin layer 
known as the airway surface liquid (ASL). The ASL spans the surface of the 
epithelium, creating a microenvironment that allows cilia to clear mucus from the 
airways, known as mucociliary clearance (MCC).12 The ASL is maintained by both 
secretory (+ve) and absorptive (−ve) processes of the CFTR and ENaC, 
respectively. In CF patients, absence of the CFTR protein leads to the defective 
secretion of chloride ions, in turn disrupting osmotic gradients that control fluid 
release which causes dehydration of the ASL. This process leads to thickening of 
the mucus and causes the cilia to collapse, impairing MCC, as shown in Figure 






Figure 1.3: Comparison of ion transport mechanisms and ASL volume in normal 
(left) and CF (right) airways.  
The mutation present in the CFTR gene results in a variety of protein defects, from 
total absence of the protein, failure to produce mature CFTR protein or the absence 
of the protein in its usual location at the apical plasma membranes of epithelial 
cells.14 Given this wide variation between individuals, precisely how the defective 
CFTR gene leads to airway disease has been highly disputed, with several opposing 
theories presented in the literature.  
The ‘low volume’ hypothesis is the most commonly accepted explanation, whereby 
the depleted volume of ASL drastically reduces MCC so the patient is unable to clear 
opportunistic bacteria. The bacteria then colonise, inducing chronic lung infections 
and extensive lung damage over a prolonged period of time.12 This is supported by 
in vitro findings that showed that ASL volume/depth in CF epithelia was reduced 
from a normal level of approximately 7 µm to 3-4 µm.15  
 
Alternatively, a ‘high salt’ hypothesis suggested that elevated salt concentrations in 




epithelia are readily colonised by P. aeruginosa and other bacteria as it is unable to 
eradicate them.16 Although studies have suggested that a difference in osmolality 
between normal and CF ASL does exist, the CF ASL was found to be either 
hypotonic or isotonic, not hypertonic as would be expected from this hypothesis.10 
1.1.2 Treatments and prognosis 
In recent years, improved management of CF has considerably increased patient 
survival rates, with epidemiological studies indicating that the median life expectancy 
of babies born in the 21st century now exceeds fifty years of age.17 Nevertheless, 
the quality of life for patients is still impaired due to the need for regular treatment, 
either at home or in hospital, reliance on medication and the possibility of surgical 
intervention due to irreparable lung damage caused by fibrosis.  
A variety of airway clearance techniques, known as chest physiotherapy, help to 
keep the airways as clear as possible, involving a series of breathing and postural 
exercises which dislodge and remove mucus via coughing.13 Although these 
techniques are initially performed by trained physiotherapists/nurses, they can be 
performed by parents and friends at home, minimising disruption to daily life.  
Several medications are also available to treat the symptoms of CF, including 
bronchodilators to widen airways, and agents such as mannitol dry powder to reduce 
the thickness of the mucus. The latter treatments work by inducing an osmotic 
gradient, to permit the flow of water into the lumen of the airways, leading to mucus 




At present, few drugs are available that target the CFTR gene mutation directly.  
Ivacaftor 1 (Figure 1.4) marketed as Kalydeco® by Vertex Pharmaceuticals, was the 
first drug licensed for use by the Food and Drug Administration (FDA).  
Unfortunately, this treatment is only effective for 4% of the UK population, as very 
few CF sufferers have the gene mutation for which this treatment is suitable (at least 
one G551D mutation or a R117H mutation in the CFTR gene). Described as a CFTR 
potentiator, the drug binds to the channel directly, stimulating ion function of 
activated cell-surface CFTR by increasing the probability of the gates being open 
which increases ASL volume and promotes MCC.19  
 
Figure 1.4: Chemical structures of Ivacaftor 1 and Lumacaftor 2. 
On the other hand, the combination medicine Orkambi® can treat around 50% of the 
UK population, being suitable for patients who have two copies of the most common 
ΔF508del mutation. In addition to 1 it contains Lumacaftor 2 (Figure 1.4), a CFTR 
corrector, which acts to increase the amount of CFTR protein at the cell surface. 
Though the drug is licensed for use in people with CF over the age of two, it was 
rejected for use on the National Health Service (NHS) by the National Institute for 
Health and Care Excellence (NICE), who stated that the benefits did not justify the 
significant cost of £105,000 per patient per year. As data suggested that the drug 




pressure from CF sufferers and their families and offered Vertex a deal worth £500 
million over a five-year period, which was initially rejected. In October 2019, a deal 
with Vertex Pharmaceuticals was agreed to enable access to these medicines on 
the NHS.20  
Arguably of most importance for CF patients is antibiotic therapy to combat acute 
and chronic bacterial infections caused by Haemophilius influenza, Burkholderia 
cepacia and the life-threatening Pseudomonas aeruginosa (P. aeruginosa). The 
type of bacteria and extent of colonisation within the airways determines the best 
course of antibiotics to effectively treat the infection. In mild infections, oral 
antibiotics are usually sufficient, however in more serious infections patients are 
often hospitalised to receive intravenous treatment.13 Unfortunately, antibiotic 
resistance is leading to many antibiotics becoming ineffective against bacterial 
infections, proving extremely damaging for CF patients and contributing to the high 





1.2 Pseudomonas aeruginosa  
P. aeruginosa is an opportunistic, Gram-negative bacterium that grows readily 
between 25-42 °C in both aerobic and anaerobic conditions, allowing it to survive in 
a range of environments. Its genome is relatively large (5.5-7.0 Mb) and consists of 
a single circular chromosome, of which 8% encodes for regulatory genes that enable 
its adaptation to difficult growth environments. P. aeruginosa also encodes many 
virulence factors which lead to serious infections in immunocompromised patients, 
such as those with CF and hospitalised patients, such as those with burn 
wounds.21,22 
1.2.1 Pathogenesis 
1.2.1.1 Adhesins and secretion of toxins/exoenzymes  
P. aeruginosa exhibits its pathogenesis via several mechanisms. A minimum of 
three adhesins are associated with P. aeruginosa, allowing it to colonize, obtain 
nutrients and proliferate in host tissues. Type IV pili are flexible filaments comprised 
of pilin protein that mediate bacterial adhesion to epithelial cells. The single flagellum 
of P. aeruginosa also plays an important role in adhesion and motility, targeting 
mucins that exist to lubricate and protect tissues from pathogens. P. aeruginosa with 
defective flagella has been shown to have reduced pathogenicity.23  
Lipopolysaccharide (LPS) is a major outer-membrane component of Gram-negative 
bacteria including P. aeruginosa. Structurally, LPS consists of a hydrophobic lipid 
section (Lipid A), a hydrophobic core polysaccharide chain and a hydrophilic O-





Figure 1.5: a) Structure of Gram-negative bacterial cell wall.  
b) Outer-membrane components of Gram-negative bacteria.25 
 
The carbohydrate component of LPS is recognised for its role in inducing strong 
immune responses in human cells, whilst also providing protection against bile salts 
and lipophilic antibiotics. Lipid A is an important endotoxin capable of causing septic 
shock.24  The P. aeruginosa LPS outer core recognises CFTR amino acid sequence 
108-117, and this interaction leads to internalization of the bacteria. Overproduction 
of mucus due to defective CFTR protein provides a favourable environment for its 
survival. 
P. aeruginosa also delivers virulence factors through a series of five complex 
secretion systems, either to the extracellular environment or directly into the cytosol 
of host cells. The mechanism by which each system delivers virulence factors vary, 






binding cassette transporter. Type  II and V secretion systems take place via a two-
step process, whereas type III and VI utilise needle-like structures to inject toxic 
proteins directly into the cytosol.26 Examples of toxins and exoenzymes secreted by 
P. aeruginosa include Endotoxin A, elastase, alkaline protease, phospholipase C 
and rhaminolipid, each of which contribute to bacterial virulence through disruption 
of receptor and cell signalling pathways.  
1.2.1.2 Mucoid conversion 
Infections caused by P. aeruginosa are one of the leading causes of morbidity and 
mortality amongst CF patients. Strains of bacteria colonising the lungs and 
respiratory tract undergo conversion to a mucoid phenotype that is characterised by 
overproduction of the extracellular polysaccharide (EPS) alginate.27  
1.2.1.3 Alginate: structure and function 
Alginate belongs to a family of unbranched linear, non-repeating copolymers, 
comprising variable amounts of β-D-mannuronic acid (ManA) and its C5-epimer, α-
L-guluronic acid (GulA), joined by β-1,4 glycosidic linkages (Figure 1.6).  
The ratio of monosaccharides within the polymer diversifies its chemical and 
physical properties, with the alginate source determining both the ratio and specific 






Figure 1.6: Chemical structure of alginate. 
Alginate is commercially available through harvesting of brown seaweed 
(Phaeophyceae), but aside from being produced by P. aeruginosa, only one other 
genera of bacteria, Azotobacter, has been discovered to produce alginate. In P. 
aeruginosa, alginate is a key virulence factor, providing protection from host immune 
response by decreasing the amount of phagocytosis by neutrophils and 
macrophages. It has also been shown to influence expression of other virulence 
factors, such as the flagellum and type III secretion system. In combination, this 
leads to the persistence of P. aeruginosa in the airways and reduces susceptibility 
of the bacteria to antibiotic treatment. Opposed to P. aeruginosa, in Azotobacter 
vinelandii alginate plays a structural role in the formation of desiccation resistant 
cysts.28 Alginate is also important in both the food and beverage and pharmaceutical 
industries, whereby the varying properties of alginate, ranging from viscous solutions 
to gel-like structures when in the presence of divalent cations such as Ca2+, can be 






Figure 1.7: An overview of the properties and uses of alginate in the presence of 
sodium and calcium cations. 
1.2.1.4 Alginate Biosynthesis  
The biosynthesis of alginate occurs via a protein complex that is encoded within the 
alg operon (Figure 1.8), which was reported by Chitnis and Ohman in 1993.30 At the 
transcriptional level, alginate production is regulated by a sigma factor known as 
AlgT/U, where upon binding to the alg promoter, transcription is initiated.31  
Conversion to the mucoid phenotype during chronic infection in CF is associated 
with mutations in the algT/U mucABCD gene cluster, which encodes for an extreme 
stress response system that is highly conserved amongst Gram-negative bacteria. 
This system comprises the AlgT/U sigma factor and four other regulatory proteins 
including MucA, an inner membrane protein that inhibits AlgT/U and the periplasmic 
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In non-mucoid strains of P. aeruginosa, transcription of AlgT/U is usually inactive. 
This is due to the actions of anti-sigma factors MucA and MucB which sequest 
AlgT/U to prevent transcriptional activation. During CF infections, loss of function 
mutations in MucA or reduction in MucA/MucB interactions have been observed, 
leading to reduced levels of MucA available for direct complexation with AlgT/U. This 
leads to upregulation and continual transcription of the alg operon, ultimately 
resulting in mucoid conversion and oversecretion of alginate.  
  
 
Figure 1.8: Genetic structure of the alg operon, where genes are colour coded by 
their proposed function.21 
Following transcription, alginate biosynthesis can be divided into four stages: 
precursor synthesis, polymerisation and cytoplasmic membrane transfer, 






Figure 1.9: An overview of the alginate biosynthetic pathway.29 
1. Precursor Synthesis  
The first stage, conversion of sugar metabolites into guanosine diphosphate 
mannuronic acid (GDP-ManA), is well characterised and occurs in the cytosol of the 
bacterial cell. First, a carbon source is converted into a pyruvate intermediate via the 
Entner-Douderoff (ED) pathway. This pathway uses two unique enzymes, 6-
phosphogluconate and 2-keto-deoxy-6-phosphogluconate (KDPG) aldolase to 
catabolise glucose. Next, pyruvate is converted into acetyl CoA which enters the 
tricarboxylic acid cycle (TCA cycle). The oxaloacetate formed in this cycle 
undergoes gluconeogenesis to form fructose 6-phosphate, which is then 
















2. Polymerisation - alg8, alg44 
3. Modification - algF, algG, algK, algI, algL, algX 









phosphomannose isomerase (PMI), encoded for by algA – a bifunctional protein that 
also has GDP-mannose pyrophosphorylase (GDP-ManPP) activity. Directed 
towards the alginate biosynthetic pathway, mannose 6-phosphate is directly 
converted into mannose 1-phosphate via phosphomannomutase, a gene product of 
algC. Next, the GDP-ManPP activity of algA is utilised, catalysing the conversion of 
mannose 1-phosphate into GDP-mannose (GDP-Man). The final stage is the 
oxidation of GDP-Man into GDP-ManA via GDP-mannose dehydrogenase (GMD), 
algD. 28,29 
2. Polymerisation and Cytoplasmic Membrane Transfer  
Prior to polymerisation, the GDP-ManA precursor must be transferred across the 
cytoplasmic membrane into the cytosol. Polymerisation is one of the most poorly 
understood aspects in this biosynthetic pathway, as a suitable polymerase has not 
been purified and fully characterised to date.28 The most plausible alginate 
polymerase enzyme was suggested as alg8 in 2006 from 14C-labelling studies.33 
This gene is thought to be related to class II glycosyltransferases (GTs), enzymes 
that catalyse reactions between glycosyl acceptors and donors to form 
oligosaccharides. Additionally, it has also been found to have structural similarities 
with other functionally-related enzymes such as cellulose synthase.29 The inner 
membrane protein Alg44 is also known to be required for polymerisation, with no 
secretion of alginate fragments shown in alg44-deletion mutants.34 Binding of Alg44 
to the signalling molecule bis(3’-5’)-cyclic dimeric guanosine monophosphate (c-di-
GMP) is imperative for alginate biosynthesis and provides further control of the 




two gene products is still under scrutiny, with the two likely interacting as part of 
wider signalling pathways, amongst other proteins involved in later stages of alginate 
biosynthesis.  
3 & 4. Periplasmic Transfer, Modification and Export  
Once polymerised, the polymannuronate chain is translocated across the periplasm 
via a multiprotein scaffold, known to contain the periplasmic proteins algG, algK and 
algX. These proteins direct the polymer and protect it from the action of periplasmic 
lyase enzymes such as algL, responsible for the degradation of alginate.35 
Modification, the penultimate stage of alginate biosynthesis, takes place exclusively 
in the periplasm, implying that all modification appears to take place at polymer level 
opposed to monomer level.28 The first step in modification is acetylation of the 
polymannuronate chain, utilising a series of acetyltransferase enzymes, encoded for 
by algI, algJ, algF and algX. Occurring solely on ManA residues, O-acetylation takes 
place at C2 and C3 positions, preventing the epimerisation of ManA into GulA  – a 
process catalysed by C5-mannuronan-epimerase, algG. Additionally, as O-
acetylation also prevents the action of algL degrading the alginate chain this process 
is key to controlling both ManA/GulA ratio and chain length. AlgG is the only enzyme 
that has been discovered with epimerase activity in P. aeruginosa to date36, with the 
isolated alginate found to contain a majority of ManA residues which are 
interspersed randomly with GulA residues. The final stage in alginate biosynthesis 
is export, involving the genes algE and algK. Considerable information is known 
about algE, with the crystal structure being deduced by Whitney et al. in 2011.37 




been found to have an electropositive pore structure which has high selectivity for 
negatively charged alginate, proving essential for its intact secretion. Deletion 
mutants of algK suggest that it is involved in the localisation of algE, therefore it is 
thought that the two proteins may interact to form a unique secretin structure that is 
different from other bacterial polysaccharide secretory complexes.21 
1.2.2 Biofilm formation 
Defined as “surface-attached communities of bacteria embedded in an extracellular 
matrix of biopolymeric substances”, biofilms present many difficulties in the areas of 
sanitation and healthcare as they are capable of growing on a variety of mediums, 
including water pipes and primary care medical devices such as catheters.38 A 
variety of components, including microbial EPS, proteins and extracellular DNA 
(eDNA) are present within the matrix. Biofilm formation is also commonly observed 
during chronic infections caused by P. aeruginosa (Figure 1.10), where they play an 
important role to provide the bacteria with structural stability and protection from 
host-defence mechanisms and antibiotic treatment.  
 
Figure 1.10: P. aeruginosa biofilm from an infected CF lung obtained using 




In a biofilm, the bacteria exist in architecturally and biochemically distinct forms 
compared to their free-swimming counterparts, and it is reported that when 
contained within a mature biofilm, they can develop an antibiotic resistance profile 
that is up to one thousand times greater than that of its planktonic equivalent.27,39 
Given the abundance of alginate produced by mucoid strains of P. aeruginosa, this 
EPS serves as the main matrix component of such biofilms and contributes to the 
formation of large finger-like microcolonies. A mature biofilm can be formed in as 
little as 5-7 days in vitro, with the final composition consisting of several layers of 
cells encompassed within the matrix, of which pieces can detach and colonise new 
areas of the airway.42,43  
1.2.2.1 Psl and Pel 
In contrast, the biofilm composition of wild-type, non-mucoid strains of P. aeruginosa 
is not dependent on the presence of alginate, instead being rich in two alternative 
EPS: Psl and Pel. 
Encoded by the Psl operon, the chemical structure of Psl is proposed as a neutral 
pentasaccharide containing D-mannose, L-rhamnose and D-glucose in a 3:1:1 
ratio.21 This structure is widely disputed, as anti-Psl monoclonal antibodies targeting 
one epitope were unable to bind synthetic Psl oligosaccharides synthesised by Li et 
al. in 2013 (Figure 1.11), suggesting additional modifications to the structure of Psl 
are yet to be discovered.44 Psl plays an important role in the initiation of biofilm 
formation, promoting both cell-cell and cell-surface interactions. In mature biofilms, 
Psl is associated with caps of mushroom-like microcolony formation to form a 




providing cells with protection against oxidative stress and a broad spectrum of 
antibiotics.45–47 
 
Figure 1.11: Proposed chemical structure of Psl. 
The chemical structure of Pel has been recently described as a partially acetylated 
N-acetylgalactosamine and N-acetylglucosamine containing polysaccharide, joined 
by 1,4-glycosidic linkages. Under acidic conditions, Pel is positively charged, 
permitting crosslinking to eDNA within biofilms.48,49 In addition to its involvement in 
cell-cell interactions, its most important role is in the formation of a pellicle at the air-
liquid interface, which comprises a layer of proteins embedded within the 
extracellular matrix.50 
The biosynthetic pathways of Psl and Pel have not yet been fully elucidated, 
however they are believed to be synthesised by two opposing biosynthetic 
mechanisms. Evidence suggests that the Psl pathway resembles an isoprenoid lipid 
carrier dependent mechanism, similar to that of Escherichia coli group 1 capsular 
and extracellular polysaccharides. The psl operon is predicted to code for at least 




On the other hand, Pel biosynthesis is likely to proceed via a mechanism more 
closely related to that of alginate and bacterial cellulose biosynthesis, that is lipid 
carrier independent. As information regarding Pel is limited, with only a handful of 
the seven Pel gene products (Figure 1.12) having been experimentally examined, 
the biosynthetic model cannot yet be confirmed. Research does however suggest 






Figure 1.12: Genetic structure of the Psl and Pel operons, where genes are colour 





1.2.3 Antibiotic resistance 
P. aeruginosa is ranked amongst ‘superbugs’ such as Methicillin-resistant 
Staphylococcus aureus  (MRSA) and Clostridium difficile because of its multi-drug 
resistant profile.52 The difficulty faced in treatment of infections caused by P. 
aeruginosa can be associated to two categories of resistance. Intrinsic resistance 
refers to chromosomally encoded resistance mechanisms, whereas acquired 
resistance is achieved via chromosomal DNA mutations that modify existing 
proteins. This can often be the result of genetic material transfer from alternative 
species or genera.53   
The P. aeruginosa genome naturally encodes for several resistance genes, 
including at least two classes of β-lactamases. The class C β-lactamase, 
cephalosporinase, is encoded by ampC and the class D variant oxacillinase is 
encoded by poxB. When exposed to benzylpenicillin or narrow-spectrum 
cephalosporins, ampC expression is induced by two mechanisms: induction and 
derepression. When significantly high levels of ampC are reached, P. aeruginosa 
becomes resistant to almost all classes of β-lactams except carbapenems, which 
are reserved for serious infections involving multi-drug resistant bacteria.54,55 
Resistance to aminoglycoside antibiotics by P. aeruginosa is caused by 
chromosomally encoded or acquired aminoglycoside-modifying enzymes, of which 






Reducing the amount of antibiotic that can accumulate in the cytoplasm is also an 
important resistance mechanism for P. aeruginosa, of which two mechanisms exist: 
membrane impermeability and efflux-mediated resistance.  
The outer membrane of Gram-negative bacteria naturally prevents the passage of 
large hydrophilic molecules into the cell, therefore in order to enter they must pass 
through a porin, most likely OprF. Several classes of antibiotic including β-lactams, 
aminoglycosides, tetracyclines and quinolones can diffuse into the cell via this 
protein channel; however, dysfunction of such porins decreases the susceptibility of 
P. aeruginosa to antibiotic treatment. Whilst alterations to OprF does not correlate 
significantly to antibiotic resistance, mutations that result in decreased transcription 
and translational production of the OprD porin is linked to resistance against 
carbapenems.57 
Efflux pumps belonging to the resistance-nodulation-division family are the most 
significant contributors to antibiotic resistance in P. aeruginosa, with a total of twelve 
systems encoded by the genome. Involved in intrinsic resistance, such pumps 
comprise a periplasmic membrane fusion protein (MFP), outer membrane factor 
(OMF) and cytoplasmic membrane transporter. The MexAB-OprM efflux pump was 
the first multi-drug efflux pump identified in P. aeruginosa, responsible for the export 
of numerous classes of antibiotic out of the cell, including β-lactams, tetracyclines, 





1.3 Strategic Bacterial Biosynthesis Enzymes 
The opportunistic nature of P. aeruginosa presents a major threat to 
immunocompromised patients, given its high level of intrinsic resistance 
mechanisms that leads to a multi-drug resistance profile. As this bacterium becomes 
more resistant to antibiotics, alternative approaches are vital to ensure such 
infections can be treated, with research currently ongoing into immunotherapy and 
vaccination. Conversion of P. aeruginosa to its mucoid phenotype is a major 
virulence factor, contributing to high morbidity and mortality rates amongst infected 
patients. Given the breadth of information available regarding the biosynthesis of 
alginate, many enzyme targets could be investigated as potential alternative 
treatments for such infections.   
One of the most promising targets is guanosine diphosphate-mannose 
dehydrogenase (GMD), which catalyses the conversion of GDP-Man 3 into GDP-
ManA 4 (Scheme 1.1), the constituent building block of alginate.  
 




Evidence for its role as a key regulatory enzyme in alginate biosynthesis was 
discovered following metabolic studies in 1993, which revealed that 3 accumulated 
in all strains of P. aeruginosa, whilst the product 4 was only detected in mucoid 
strains at considerably lower concentrations than those of 3.60 GMD is a logical 
target to block alginate biosynthesis as there is no equivalent enzyme found in 
humans, hence the possibility of detrimental side effects from its inhibition is 
considerably reduced. 
1.3.1 NAD+-dependent dehydrogenases 
GMD belongs to the family of nicotinamide adenine dinucleotide (NAD+) dependent 
four-electron-transfer dehydrogenases, that catalyse the oxidation of a pyranose to 
a uronic acid using NAD+ as co-factor. This reaction occurs within a single active 
site without the release of an aldehyde intermediate.  
Examples of related dehydrogenases include uridine diphosphate-glucose 
dehydrogenase (UGD) and uridine diphosphate-N-acetyl-mannosamine 
dehydrogenase (UNAcMD). These enzymes share a common catalytic cysteine 
residue and employ similar reaction mechanisms but show some variation in 
sequence homology and domain organisation.  
Two other enzymes, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA 
reductase) and histidinol dehydrogenase (HisD) also belong to this family. However, 





1.3.1.1 UDP-glucose dehydrogenase and UDP-N-acetyl-mannosamine 
dehydrogenase 
The enzymatic activity of UDP-glucose dehydrogenase (UGD) was first reported in 
1954 following its isolation from bovine liver. Catalysing the oxidation of UDP-
glucose to UDP-glucuronic acid, this sugar-nucleotide is an important building block 
in biosynthesis of glycosaminoglycans such as heparan sulfate and capsular 
polysaccharides. It is also essential for Phase II glucuronidation, an important 
biotransformation in preparation for excretion in mammals and bacteria. 
Exhaustive studies of UGD suggested the enzyme followed a ‘bi-uni-uni-bi ping-
pong’ mechanism which was catalysed by a Cys260 residue. Following oxidation of 
UDP-glucose to the aldehyde, the reaction proceeds via thiohemiacetal and 
thioester intermediates before hydrolysis and release of UDP-glucuronic acid.61  
Cys260 was proven to be the catalytic residue in both mammalian and bacterial UGD, 
with studies showing Cys260Ser mutants form covalently bound ester intermediates 
that were hydrolysed slowly and accumulated.62 
Uridine diphosphate-N-acetyl-mannosamine dehydrogenase (UNAcMD) catalyses 
the conversion of UDP-N-acetyl-mannosamine to UDP-N-acetyl-mannosaminuronic 
acid. N-acetyl-mannosaminuronic acid is a key component of many bacterial 
capsular polysaccharides including those of Staphylococcus aereus. This 
dehydrogenase adopts the same dimeric conformation as UGD and utilises a 
catalytic Cys258, with the residues responsible for acid/base catalysis, tetrahedral 
intermediate formation and hydride transfer also conserved. Whilst this suggests the 




a redox-switch mechanism and tyrosine phosphorylation, a conserved mechanism 
for bacteria to control EPS production.63 
1.3.1.2 HMG-CoA reductase and histidinol dehydrogenase (HisD) 
HMG-CoA reductase catalyses the interconversion of HMG-CoA to mevalonate, the 
first step in isoprenoid biosynthesis. Unlike other reductases in the family, the 
involvement of catalytic cysteine residues was disproved following site-directed 
mutagenesis. Instead, glutamate and histidine residues that are essential for 
catalysis have been identified.64 
HisD is a homodimeric zinc metalloenzyme that catalyses the conversion of L-
histidinol to L-histidine. It was initially thought that Zn2+ had a direct role in catalysis, 
however this was disproved in 2002 by Barbosa et al. who concluded that the Zn2+ 
was only required for positioning of the reaction intermediates and the catalytic 





1.3.2 GDP-mannose dehydrogenase (GMD) 
1.3.2.1 Crystal structure and catalytic mechanism 
The crystal structure of GMD was solved by Snook et al. in 200366, and revealed 
two distinct domains of similar size, connected by a long α-helix consisting of 33 
residues. The monomer exists in an unusual open conformation with N- and C- 
terminal domains located on opposite sides of the connecting α-helix. Two 
monomers associate to form an intertwined dimer that places the N-terminal domain 
of monomer A in close contact with the C-terminal domain of monomer B. Therefore, 
GMD can be described as a domain-swapped dimer, unlike in UGD where chains 
from the same monomer pack against one another.  
Similarly to UGD, the active site of GMD is made up of 80 residues, approximately 
half from each monomer, forming a large binding pocket for NAD+ and GDP-ManA 
4 that lies within a cleft between the two domains. The N-terminus is responsible for 
NAD+ cofactor binding and the C-terminus makes contacts with the 
substrate/product. The total surface area of the active site spans 1900 Å2 and the 
ligands were found to be deeply buried, with only the edges of their purine bases 
exposed to solvent.  
Based on information known about UGD, GMD catalysis has been proposed to take 
place via a ‘bi-uni-uni-bi ping-pong’ reaction mechanism in 4 discreet steps, outlined 






Scheme 1.2: Proposed mechanism of GMD catalysed oxidation of GDP-Man 3 to 





The C6-OH of GDP-Man 3 is first oxidised to an aldehyde, utilising one equivalent 
of NAD+. Following the addition of the Cys268 side chain into the carbonyl to form a 
thiohemiacetal intermediate, further oxidation using a second equivalent of NAD+ 
affords a thioester intermediate which is hydrolysed to deliver GDP-ManA 4.  
The nucleophilic thiol residue was proposed to be Cys268, with the crystal structure 
showing distances of 3.3-3.5 Å between Cys268 and the carboxylate oxygen atoms 
in GDP-ManA 4 (Figure 1.13). Upon rotation this distance is further reduced to 2.4 
Å and given the potency of the nucleophile it was proposed that the thiolate anion 
acts as the active species. Cysteine side chains have a typical pKa value of 9.0, 
therefore factors stabilising the thiolate anion would be expected within the active 
site. The residue proposed to facilitate this is Lys271, which upon rotation of the side 
chain is within 3.0 Å of the thiolate. Alternatively, a helix dipole effect may stabilise 
Cys268, as it is located immediately prior to an α-helix in the C-terminal domain 
therefore the partial positive charge of the dipole could result in stabilisation.   
The residue proposed as the general acid/base catalyst is Lys210 from monomer A, 
located 2.9 Å from the carboxylate oxygen or a tetrahedrally coordinated water 
molecule. Hydrolysis of the thioester intermediate is achieved by the activation of a 





Figure 1.13: Molecular docking image showing GDP-ManA 4 in the active site of 
GMD in close proximity to Cys268.66 
 
1.3.2.2 Structure-based inhibitor design 
Even before the identification of the key Cys268 residue, microbial metabolite 
screening results indicated that the macrolide antibiotic erythromycin A 5 and 
penicillic acid 6 (Figure 1.14), a mycotoxin produced by many species of Penicillium 
and Aspergillus fungi, inhibited alginate production.  
                  
Figure 1.14: Chemical structures of erythromycin A 5 (left) and penicillic acid 6 




Morphological changes of a mucoid strain of P. aeruginosa to a non-mucoid colony 
in the presence of these compounds was observed on agar plates, and were 
successfully correlated to the inhibition of GMD through use of HPLC to estimate the 
total amount of alginate production per bacterial cell.68  
Previous reports also indicated that 6 was an inhibitor of alcohol and lactic 
dehydrogenases, however the mechanism by which GMD was inhibited was not yet 
understood.69 Penicillic acid 6 contains a conjugated π-system, suggesting it 
irreversibly inhibits GMD by acting as a Michael acceptor to form a series of covalent 
adducts. Though 6 is too cytotoxic to be of relevance in vivo, the results revealed 
that it was not exclusively directed at the GMD active site and had low potency, with 
mass spectrometry data showing that several cysteine residues, including Cys213, 
Cys246 and the catalytic Cys268 residue were alkylated by penicillic acid.70 
Based on this knowledge, a necessity for rational structure-based inhibitor design is 
apparent, however the synthesis of such biological probes has not been reported, 
with the exception of a publication in 1992 describing the synthesis of a GDP-6-
ethynyl-mannose analogue 7 (Figure 1.15).71 Although this analogue was reported 
to show 75% inhibition of GMD at a concentration of 0.1 mM, the associated 
experimental procedures and characterisation data and inhibition studies were 





Figure 1.15: Chemical structure of GDP-6-ethynyl-Man analogue 7. 
Nevertheless, the work provided an important foundation for the rationale behind the 
synthesis of such derivatives, with potential for an array of functional groups capable 
of acting as inhibitors of GMD. Electrophilic GDP-Man probes incorporating alkyne, 
α,β-unsaturated carbonyl, epoxide or nitrile functionalities (compounds 8 to 11 
respectively) are all plausible species that could intercept a nucleophilic cysteine 
residue with the potential to reduce or inhibit the production of GDP-ManA. The 
proposed mechanism of each analogue is outlined in Figure 1.16. 
 
Figure 1.16: Functional groups that could be incorporated into GDP-Man 
analogues to explore the mechanism of GMD: alkyne, α,β-unsaturated carbonyl, 




1.4 Synthetic Carbohydrate Chemistry  
The importance of oligosaccharides and sugar-nucleotides in medicinal chemistry 
and in biochemical applications cannot be understated. Despite this, progress in 
synthetic carbohydrate chemistry lags in comparison to other areas, complicated by 
a lack of general methods for their routine preparation. Hindering the development 
of robust synthetic methods are their high polarity, poor solubility in organic solvents 
and the susceptibility of glycosidic and diphosphate linkages to hydrolysis.72  
1.4.1 Background to carbohydrate glycosylation  
Given the inherent reactivity of hydroxyl groups present in free sugars, carbohydrate 
syntheses are reliant on protecting group strategy. This methodology relies on the 
orthogonal nature of protecting groups, essential to exploit the varying reactivity of 
hydroxyl groups, i.e. 1° versus 2° alcohol reactivity to allow selective protection in 
the synthesis of increasingly complicated structures. Coupled with the difficult 
production of oligosaccharides with the desired glycosidic stereochemistry, this 
unfortunately leads to long, multi-step reaction sequences that often require 
purification between each step, diminishing yields of the target structures.  
Central to carbohydrate chemistry is the formation of the glycosidic bond, with the 
earliest method reported by Koenigs and Knorr at the beginning of the 20th century.73 
The original reaction involved the coupling of acetobromoglucose 12 (glycosyl 
donor) with methanol (glycosyl acceptor) using silver carbonate (Ag2CO3) as the 





Scheme 1.3: Original Koenigs-Knorr glycosylation conditions. 
Anomeric substitution is considered to take place by both SN2 and SN1 mechanisms, 
with some substrates capable of reacting through both pathways. The mechanism 
by which substitution takes place determines the anomeric stereochemistry of the 
product, outlined in Scheme 1.4. An SN2 reaction proceeds via a concerted 
mechanism, with the nucleophile attacking from the opposite face at 180° to the 
leaving group (backside attack). Upon departure of the leaving group, the resultant 
product has an inversion of stereochemistry. In an SN1 reaction, the leaving group 
must be suitably activated prior to its removal, which then results in the formation of 
a planar oxocarbenium ion intermediate. The nucleophile can attack either face of 





Scheme 1.4: SN2 and SN1 mechanisms of anomeric substitution.  
The 6-membered ring of a monosaccharide primarily exists in two isomeric chair 
conformations, denoted 4C1 and 1C4. The letter C stands for chair and the numbers 
correspond to the carbon atoms situated above or below the plane of the chair, which 
is made up of C2, C3, C5 and the ring oxygen. Pyranoses can also adopt several 
other conformations, including half-chair, boat and skew however the chair 
conformation predominates.74 
The conformation in which a pyranose exists is governed by the relative stability of 
its two possible chair conformations, with one of which often being energetically 
unfavourable due to undesired repulsion between 1,3-diaxial ring substituents 




This is observed in β-D-glucopyranose, where the 4C1 conformation is favoured over 
1C4 and results in a free energy difference of 25 kJ/mol between the two chair forms. 
Conversely, the energy difference between the two chair conformations of β-D-
idopyranose is small therefore both conformations can be observed in its 1H NMR 
spectra. 
 
Scheme 1.5: Comparison of 4C1 and 1C4 chair conformations in pyranoses. 
The identity of the group at the C2 position on the donor must be considered carefully 
in glycosylation reactions, as the anomeric stereochemistry is controlled by two 
different effects. When the group at C2 is a non-participating group, such as O-
benzyl, the anomeric effect dominates. Two explanations for the origin of the 
anomeric effect are described in the literature: endo and exo. In both instances a 
non-bonding electron pair on the endocyclic 2sp3 hybridised oxygen atom plays an 
important role, forming a dipole pointing in the exocyclic direction. The polarised 




In 4C1 conformations, electron density from the non-bonding 2sp3 lone pair of oxygen 
is donated into the empty anti-bonding (σ*) orbital of the C-X bond, where X is an 
electronegative substituent such as fluorine, oxygen, or sulphur. As the orbitals are 
aligned in a syn-periplanar configuration when the C-X bond adopts an axial 
position, they can mix and a hyperconjugative η-σ* interaction is established. This is 
the endo-anomeric effect, made energetically possible due to the reduction in energy 
of the σ* orbital by the electronegative substituent, resulting in a longer, weakened 
C1-X bond and a shorter, stronger O-C1 bond. The thermodynamically stable α-
anomer is formed preferentially over the β-anomer, which cannot be stabilised as 
the orbitals are incorrectly aligned for overlap (Figure 1.17). 
 
Figure 1.17: The endo-anomeric effect. 
Alternatively, the exo-anomeric effect arises from rotation around the exocyclic C1-
X bond, where the non-bonding electrons from the anomeric heteroatom occupy 
different three different positions. The most favourable is rotamer (b) as an overlap 
between a non-bonding orbital and σ*orbital of the endocyclic O-C1 bond is possible. 
Whilst this is also possible in (c), it is less favourable because the bulky R-substituent 





Figure 1.18: The exo-anomeric effect. 
Alternatively, if the group at C2 is an ester, such as an O-acetyl or N-phthalimido 
group, the stereochemistry can be controlled via neighbouring group participation 
(NGP). Such groups can form 5-membered intermediates which lower the energy of 
the transition state, directing the mechanism by which the product forms by blocking 
either the top (β) or bottom (α) face of the ring (depending on the C2 
stereochemistry). As illustrated in Scheme 1.6, following initial formation of the 
planar oxocarbenium ion intermediate in per-O-acetylated mannose 14, the C2 ester 
attacks to form a 5-membered intermediate on the β-face. As this face is effectively 
blocked, the acceptor can only open the ring through attack from the α-face to yield 





Scheme 1.6: Mechanism for formation of 15 from per-O-acetylated mannose 14 
using NGP. 
1.4.2 Sugar-nucleotides 
Sugar-nucleotides (nucleoside diphosphate sugars) are composed of a sugar linked 
to a nucleoside diphosphate and have important functions in carbohydrate 
metabolism and biosynthesis of glycoconjugates. These important species are of 
particular interest as carbohydrate-based tools to study biosynthetic pathways and 
as potential enzyme inhibitors. In mammalian cells, sugar-nucleotides most 
commonly contain a uridine or guanosine nucleoside diphosphate however 
thymidine nucleoside diphosphate sugars are also present in bacterial systems, with 





Figure 1.19: Chemical structures of mammalian and bacterial NDP-sugars. 
The chemical synthesis of sugar-nucleotides most commonly involves the coupling 
of two monophosphate precursors, as shown in Scheme 1.7. The first is a glycosyl 
1-phosphate, the source of the sugar moiety and the second is an activated 
nucleoside diphosphate species, which is attacked by the glycosyl 1-phosphate to 
form a diphosphate bond.  
 




1.4.2.1 Synthesis of glycosyl 1-phosphates 
The synthesis of glycosyl 1-phosphates can be achieved through both chemical and 
enzymatic methodologies, with many literature procedures available for their 
preparation. The most well-established methods are discussed herein.  
In 1962, MacDonald reported the synthesis of glycosyl 1-phosphates of glucose and 
galactose through reaction of their respective per-O-acetylated counterparts with 
H3PO4 (s) at elevated temperatures under high vacuum (Scheme 1.8).75 Though its 
use has since been applied widely, the reaction scope is limited by the requirement 
for strictly anhydrous conditions and poor yields, typically ≤45%. 
 
Scheme 1.8: MacDonald phosphorylation of per-O-acetyl-glucopyranose 25 to 
afford α-D-glucopyranosyl phosphate 26. 
Methodologies developed since this procedure usually involve the synthesis of an 
appropriate glycosyl donor, such as a thioglycoside or trichloroacetimidate which 
can be reacted with dibenzyl phosphate (DBP) in the presence of an promoter. 
Deprotection of the resultant glycosyl 1-phosphate is achieved by hydrogenolysis 
using palladium catalysts, shown in Scheme 1.9. This method was employed by Zou 
et al. in the synthesis of a series of mannose 1-phosphate analogues for use as 





Scheme 1.9: Synthesis of a 3-methoxy-mannopyranosyl phosphate 29 from 
thioglycoside donor 27. 
An alternative approach derives from the hemiacetal, where the corresponding 
glycosyl 1-phosphate can be synthesised from a variety of phosphorus sources 
either directly at the P(V) oxidation level or via a P(III) species, followed by oxidation. 
Schultz et al. utilised the electrophilic P(V) reagent tetrabenzyl pyrophosphate 
(TBPP) with lithium diisopropyl amide (LDA) as the base in their synthesis of 4-fluoro 
derivatives of GalNAc and GlcNAc. Modified glycosyl 1-phosphates 30 and 31 were 
afforded in high yields (>70%) with high α-selectivity reported.77 The opposing 
strategy employs a phosphoramidite reagent, iPr2N(OBn)2 with tetrazole activation 
then subsequent oxidation to the desired P(V) species using mCPBA. This method 
has been used successfully towards the synthesis of octose 1-phosphate 33 and 6-






Scheme 1.10: Summary of strategies to access glycosyl 1-phosphates via a 
hemiacetal.  
The enzymatic synthesis of glycosyl 1-phosphates from their corresponding 
hemiacetal using kinases is also frequently reported in the literature. This 
transformation can be complicated by unwanted phosphorylation at the C6-position 
and the limited substrate scope of many kinases with non-native sugars. In general, 
bacterial enzymes display greater promiscuity, hence greater promise to access 
modified target glycosyl 1-phosphates for use as chemical tools. 
Kinases are regularly employed in one pot multi-enzyme (OPME) approaches 
towards the synthesis of sugar-nucleotides. Examples include SpGalK, a 




phosphate derivatives, and a new bacterial galactokinase LgGalK.80 This enzyme 
demonstrates high tolerance towards a broad range of substrates including deoxy 
and deoxy-fluoro galactose analogues. Recently, it has been utilised for the 
synthesis of C6-position modified galactose 1-phosphates using galactose oxidase 
(GOase-M1). Following oxidation to the corresponding aldehyde and in-situ 
reductive amination, an array of 6-amino-6-deoxy-galactose 1-phosphate 
derivatives were afforded (Scheme 1.11).81 
 
Scheme 1.11: One pot access to C6-position modified galactose 1-phosphates 35-
37 using GOase-M1 and LgGalK. 
In 2015, Muthana et al. reported the use of the bacterial glucuronokinase AtGlcAK 
for a OPME approach to access UDP-uronic acids. The enzyme accepted 
galacturonic acid (GalA) and ManA in addition to glucuronic acid (GlcA) (38-40), 
producing the desired uronic acid 1-phosphates 41, 42 and 43 in 31%, 95% and 
quantitative yields respectively for substrate evaluation against two GDP-sugar 
pyrophosphorylases (Scheme 1.12). The synthesis of uronic acid 1-phosphates 
using kinases is less well documented in the literature and any advances in this area 






Scheme 1.12: Synthesis of uronic acid glycosyl 1-phosphates 41-43 using 
AtGlcAK. 
1.4.2.2 Chemical synthesis of sugar-nucleotides 
The chemical synthesis of sugar-nucleotides remains non-trivial, with commonly 
encountered problems including poor solubility of reaction components in organic 
solvents, elongated reaction times and susceptibility to hydrolysis. Furthermore, 
purification of the species is often complex due to the presence of multiple charged 
species in the crude reaction mixture that often co-elute during strong anion-
exchange (SAX) chromatographic purification. Several comprehensive reviews 
cover this field, including an initial survey by Wagner et al. presented in 2008 and a 
more recent overview by Ahmadipour et al. in 2017.83,84  
As introduced earlier, the dominant method to synthesise sugar-nucleotides is via 
formation of a pyrophosphate bond between two monophosphate precursors, of 
which one is activated (Scheme 1.13). The original procedure was first established 
by Roseman et al.85, and despite being reported over 50 years ago it remains 
amongst one of the most commonly used methods to date. It involves the coupling 
an activated nucleoside phosphoromorpholidate species to a glycosyl 1-phosphate. 
Several nucleoside phosphoromorpholidates are commercially available, however 





Scheme 1.13: Synthesis of GDP-mannose 3 using phosphoromorpholidate 
methodology. 
The popularity of this method can be attributed to the fact that the anomeric 
configuration of the glycosyl 1-phosphate precursor is retained in the product. 
However, the reaction does present problems, particularly the in requirement for 
strictly anhydrous conditions and the poor solubility of some NMP-morpholidates in 
pyridine. Thus, reaction times are very long, in some cases up to 9 days, and the 
yields are variable. This is due to the increased likelihood of hydrolytic degradation 
as the reaction time is lengthened.72  
As sugar-nucleotides have limited stability, use of elevated temperatures or strongly 
acidic/basic conditions cannot be employed in attempts to improve their yield using 
synthesis. In 1997, Wittman et al.86 reported the use of tetrazole as a catalyst in the 
synthesis of sugar-nucleotides (Scheme 1.14). As morpholine must be protonated 
before acting as a suitable leaving group in the condensation reaction, addition of 
an acid catalyst was a logical step to improve reaction outcome. Acting as both a 
Brønsted acid (pKa = 4.9) and a nucleophile, experimental results showed that both 
properties were essential for effective catalysis, with reactions using a variety of 





Scheme 1.14: Tetrazole catalysed NDP-sugar synthesis. 
Use of tetrazole resulted in a significantly shorter reaction time in comparison to the 
original procedure, with the most notable improvement being the synthesis of GDP-
β-L-fucose where the reaction time was reduced from 9 to 2 days and the yield 
improved by 35%.72 This method is arguably the most significant breakthrough in 
the chemical synthesis of sugar-nucleotides, being reliable and high yielding across 
a range of natural and modified sugar-nucleotides. Unfortunately, rising concerns 
about the safety of tetrazole, due to its explosive nature, has led to a gradual decline 
in its use and alternative catalysts have been investigated.  
Reported by Tsukamoto et al. in 2011, N-methylimidazolium chloride (N-MIC) 46 
(Figure 1.20) was shown to be more active and affordable than tetrazole. It is 
proposed that N-MIC not only acts as an acid but also as a nucleophile to form 
cationic intermediates that are more susceptible to nucleophilic displacement by a 




nucleobase modified sugar-nucleotides, 5-iodo-UDP-Gal and 5-iodo-UDP-GlcNAc 
for evaluation as glycosyltransferase inhibitors. The optimised conditions used 3.3 
equivalents of freshly lyophilised N-MIC and DMF as the solvent to afford the desired 
sugar-nucleotides in consistent yields between 40 and 43%.88 In 2014, 4,5-
dicyanoimidazole (DCI) 47 (Figure 1.20) was also employed as an activator in the 
synthesis of sugar-nucleotides.89 Whilst its catalytic activity was comparable to that 
of N-MIC, it had improved solubility in DMF and was less hygroscopic, making 
handling easier.  
 
Figure 1.20: Chemical structures of N-MIC 46 and DCI 47. 
The strategy employing DCI featured a phosphoropiperidate approach, a less 
commonly used activated nucleoside monophosphate in the literature, shown in 
Figure 1.21. It is suggested to be a more reactive species than the respective 
phosphoromorpholidate due to its increased pKa value of 11.2 compared to 8.26.  
 




Work in the last decade has identified several other strategies for NDP-sugar 
synthesis. A notable advance was made by Wolf et al.90, who presented the 
synthesis of an impressive library of 25 sugar-nucleotides containing varying sugar 
moieties and nucleobases using new cyclo-saligenyl (cyclo-Sal) nucleotides 49 as 
active ester building blocks. Their reaction with glycosyl 1-phosphates proceeds via 
nucleophilic displacement and subsequent hydrolysis, illustrated in Scheme 1.15, to 
afford purine and pyrimidine sugar-nucleotides in yields ranging from 60-87%. To 
ensure sufficient electrophilicity at phosphorus, the cyclo-Sal moiety featured 
electron-withdrawing 5-nitro or 5-methylsulfonyl groups. 
 
Scheme 1.15: Formation of NDP-sugars using cyclo-Sal nucleotides via 
nucleophilic displacement by a glycosyl 1-phosphate. 
One of the most interesting advances was made in 2012 by Tanaka et al., describing 
the one-pot synthesis of NDP-sugars from commercially available materials in 
deuterium oxide (D2O).91 The resultant NDP-sugars were used as donors in 
glycosyltransferase-mediated synthesis. Employing a phosphoroimidazolide 




was reacted with imidazole to form the active ImIm species 51, which produces the 
NMP-Im 52 component in-situ (Scheme 1.16).  
 
Scheme 1.16: Formation of NMP-Im from DMC and imidazole. 
Not only did use of D2O permit facile monitoring of the reaction by NMR, it also 
ensured a respectively high concentration of the active NMP-imidazole component, 
which was significantly decreased when the experiment was repeated in H2O. 
Unfortunately, these coupling reactions are generally limited to small scale 
syntheses as only 10% of the NMP introduced into the reaction is converted to 
product. However, recent literature has described the synthesis of several 
nucleoside 5’-polyphosphates in H2O/acetonitrile, using the same ImIm activation 
procedure in improved yields of 31-70%.92 Nevertheless, this procedure permits 
access to sugar-nucleotides for those without experience in performing protecting 
group manipulations and moisture-sensitive reactions.  
In 2017, Dabrowski-Tumanski et al. reported a protecting group free, MgCl2-
promoted strategy to access NDP-sugars using the same nucleoside 5’-
phosphoroimidazolide species. Use of a metal chloride provided several 
improvements to the procedure; these included increased solubility of reagents in 




monophosphate precursors to form a diphosphate (Scheme 1.17). The optimised 
conditions used 2.0-4.0 equivalents of MgCl2 and was applied to a range of 
nucleosides (A, G and U) and glycosyl 1-phosphates (Glc, Gal, Fuc), with yields 
ranging from 63-92%.93 
 
Scheme 1.17: MgCl2-promoted NDP-sugar synthesis.  
1.4.2.3 Enzymatic synthesis of sugar-nucleotides  
In comparison to the chemical synthesis of sugar-nucleotides, enzymatic methods 
proceed with much greater efficiency, with reaction times dramatically reduced and 
problems associated with poor solubility removed. Several nucleotidylyl-
transferases and glycosyltransferases have been investigated in the synthesis of 
native and modified sugar-nucleotide analogues by many research groups, offering 
facile approaches towards the synthesis of these important structural probes to 
investigate a variety of biochemical processes. A review detailing recent advances 
in this field was published in 201894, with only the most common methods to 
synthesise GDP-Man analogues, which are of key significance for this project, 
discussed in this section. 
In the literature, the most frequently used enzyme to access GDP-Man and its 




studies into its substrate specificity have been undertaken. With previous work 
having already established that the C6-OH group does not take part in enzyme-
substrate recognition, Watt et al. reported the synthesis of a number of deoxy 
mannopyranosyl phosphate derivatives to investigate the role of the other hydroxyl 
groups in substrate recognition.95 Vmax values were least affected by removal of C3-
OH and similarly affected by removal of C2- and C4-OH groups but the effect on Km 
value was more significant, with 2-deoxy-glucose 1-phosphate being the worst 
substrate, suggesting that all four hydroxyl groups contribute to binding in GDP-
ManPP. Nevertheless, GDP-2-deoxy-glucose and GDP-lyxose could both be 
synthesised on preparative scale, yielding useful probes to investigate 
mannosyltransferase (ManT) activity and N-glycan biosynthetic pathways. 
Alternative modified mannopyranosyl phosphates including C2,3,4 and 6-azido and 
methoxy derivatives, shown in Scheme 1.18, have also been used to probe the 
substrate specificity of GDP-ManPP.76,96 All analogues were transformed to their 
corresponding GDP-Man analogue with varying conversion rates.  
 





Though limited examples are reported in the literature, Mizanur et al. characterised 
archaeal enzymes capable of synthesising GDP-Man, one of which is the 
bifunctional PMI/GDP-ManPP, ManC.97,98 Isolated from hyperthermophile 
Pyrococcus furiosus, GDP-Man 3 was accessed in yields exceeding 85% (Scheme 
1.19). Furthermore, this enzyme was shown to be highly permissive, providing 
potential for the synthesis of both natural and non-natural sugar-nucleotides 
containing a range of nucleosides and glycosyl 1-phosphates that can be otherwise 
difficult to access chemically. 
 
Scheme 1.19: Synthesis of GDP-Man 3 from 44 by ManC. 
1.5 Carbohydrate Chemical Biology 
The interdisciplinary field of chemical biology encompasses all branches of 
chemistry that are used to improve understanding of biological systems on a 
molecular level. Biological macromolecules of interest to the chemical biologist 
include peptides, oligodeoxynucleotides, oligosaccharides and sugar-nucleotides.99 
As discussed previously, sugar-nucleotides are interesting small molecules that play 
vital roles in bacterial systems with relevance in the area of health and disease.  
Therefore, it is essential to synthesise such structures for use in elucidation of 
complicated biochemical pathways, with the potential to identify new therapeutic 




of small molecule probes that have been designed for a specific purpose based on 
biochemical analyses, for example the crystal structure of an enzyme.  
1.5.1 Sugar-nucleotides as chemical biology tools 
The use of sugar-nucleotide probes for elucidation of biochemical mechanisms is 
well documented in the literature. Such probes have been designed to act in varying 
capacities, such as participating as key intermediates of reaction pathways or acting 
as chain terminators, with several key examples reported in recent years discussed 
herein. 
In 1997, Campbell et al. described the chemoenzymatic synthesis of UDP-α-D-
gluco-hexodialdose 53 (Figure 1.21), the putative intermediate in UGD catalysed 
oxidation of UDP-Glc to UDP-GlcA, discussed earlier in Section 1.3. This probe was 
designed to investigate the kinetic parameters surrounding this key oxidation step, 
as UDP-GlcA is used by pathogenic bacteria such as Streptococcus pneumoniae to 
construct antiphagocytic capsules. This work proved that the aldehyde was 
kinetically viable as a reaction intermediate, disproving earlier suggestions that 
UDP-Glc was converted directly to an enzyme-linked imine to provide new insights 
into the oxidation mechanism.100  
 





In nature, the biosynthesis of heparin, the most widely studied glycosaminoglycan, 
involves glycosyltransferases and epimerases to afford a series of alternating 1,4-
linked α-L-IdoA, β-D-GlcA and β-D-GlcN residues. Access to structurally defined 
heparin oligosaccharides is key to further understanding its interactions with 
proteins, therefore Wïewer et al. synthesised UDP-IdoA 54 and UDP-HexUA 55 
analogues to evaluate a chemoenzymatic synthesis of heparin (Figure 1.22). The 
substrate specificity of glucosyltransferases was explored, and whilst 54 was 
accepted only GlcA was incorporated into the products suggesting further enzymatic 
processes, such as isomerisation were yet to be understood. On the other hand, 55 
was not accepted and could not be used as a chain terminator to create defined 
molecular weight range heparin oligosaccharides.101  
 
Figure 1.22: Chemical structures of UDP-IdoA 54 and UDP-HexUA 55. 
In 2009, the synthesis of GDP-Glc-2,3-diNAcA 56 (Figure 1.23), a key intermediate 
in cell surface polysaccharide biosynthesis amongst respiratory pathogens such as 
P. aeruginosa, was reported by Rejzek et al.102 Access to this sugar-nucleotide was 
vital for biochemical investigation of enzymes associated with its biosynthetic 
pathway, notably epimerases, and aided identification of a revised mechanism for 





Figure 1.23: Chemical structure of GDP-Glc-2,3-diNacA 56. 
Recent literature has frequently described the synthesis of fluorinated sugar-
nucleotides for use as chemical biology tools. In 2016, Lin et al. reported the 
chemical synthesis of UDP-5-fluoro-Gal 57 to study the mechanism of action of 
UDP-galactopyranose mutase (UGM). Catalysing the interconversion of UDP-Galp 
17 to UDP-Galf 59, shown in Figure 1.24, this enzyme is important in pathogenic 
bacteria such as Mycobacterium tuberculosis, where Galf residues are found on the 
cell surface.103  
 
Figure 1.24: Chemical structure of UDP-5-deoxy-fluoro-Gal 57 used to probe the 







Though the field of sugar-nucleotide synthesis has undoubtedly progressed over the 
past two decades, improved chemical synthesis methods to access these important 
molecules and their precursors are still required. Due to their high moisture-
sensitivity, access to sugar-nucleotides is still limited to those with prior training in 
performing reactions under inert conditions, however recent examples show promise 
of overcoming this in the near future.  
Arguably the most important advance in this field has been the widespread use of 
chemoenzymatic strategies, which has permitted access to native and crucially, non-
native sugar-nucleotides to study biological pathways implemented in various 
diseases. Accessibility of these strategies, however, is limited to those with relevant 
biological/biochemical training and access to appropriate facilities to undertake 
syntheses of this nature.  
As more enzymes capable of producing sugar-nucleotides are discovered, more 
probes are required to explore structure-activity relationships of these enzymes, to 
assess their promiscuity, particularly in the synthesis of non-native sugar-
nucleotides. Furthermore, many sugar-nucleotide utilising enzymes that play crucial 
roles in pathogenesis are yet to be explored, requiring the synthesis of new sugar-






1.7 Work described within this thesis 
As outlined in this chapter, sugar-nucleotides are useful synthetic targets to probe 
biosynthetic mechanisms implemented in bacterial pathogenesis. P. aeruginosa 
causes chronic bacterial infection amongst cystic fibrosis patients, with its 
pathogenesis characterised by biosynthesis of alginate. The strategic biosynthesis 
enzyme GMD has been identified as a potential target to reduce alginate production, 
with minimal research into this enzyme reported in the literature.  
This thesis aimed to synthesise and evaluate a series of modified sugar-nucleotide 
tools to provide new insights into substrate specificity of this important regulatory 
enzyme, with the view to creating analogues capable of interacting with a key active 
site Cys268 residue to reduce or inhibit production of GDP-ManA. 
First, Chapter 2 details two complimentary approaches to synthesise the feedstock 
sugar-nucleotide, GDP-ManA, the key building block for alginate biosynthesis in P. 
aeruginosa. Access to this material is essential for studies into alginate biosynthesis. 
Chapter 3 describes efforts towards the synthesis of eight modified GDP-Man 
analogues using a chemoenzymatic strategy. These tools were designed to bear a 
range of functionalities at the C6 and C4 positions of mannose, with the view to 
probe substrate specificity of GMD and the mechanism of oxidation of GDP-Man to 
GDP-ManA via an active site Cys268 residue. Finally, Chapter 4 investigates the 
activity of the synthesised GDP-Man analogues against GMD using a colorimetric 
assay, which was performed in collaboration with the group of Prof. Rob Field at the 




Chapter 2: Synthesis of GDP-ManA 
2.0 Introduction and aims 
The bacterial nucleoside diphosphate sugar GDP-ManA 4 (Figure 2.1) is the native 
tool for studies into alginate biosynthesis. The chemical synthesis of uronic acid-
containing sugar-nucleotides is less well documented in the literature, and an 
opportunity to expand knowledge within this important area was presented. Several 
approaches towards the synthesis of uronic acid containing NDP-sugars are 
described herein. 
 
Figure 2.1: Chemical structure of GDP-ManA 4. 
As discussed in Chapter 1.5.1, Schultz et al. reported the chemical synthesis of 
UDP-IdoA 54 for use in studies towards the chemoenzymatic synthesis of heparin. 
Three approaches were attempted towards the synthesis of the IdoA 1-phosphate 
required for UDP-sugar synthesis, with the formation of a glycosyl bromide followed 
by displacement with the tetrabutylammonium salt of phosphoric acid found to be 




monophosphate was then reacted with UMP-morpholidate to afford UDP-IdoA in a 
modest yield of 26%.101  
A contrasting method to synthesise uronic acid NDP-sugars involves the oxidation 
of the C6-OH post sugar-nucleotide synthesis (Scheme 2.1). Developed by Rejzek 
at al., this work describes the use of a platinum-catalysed oxidation using molecular 
oxygen at elevated temperature (100 ºC). Attempted use of 2,2,6,6-
tetramethylpiperidin-1-yl)oxyl (TEMPO) as a catalyst resulted in over-oxidation of 
the ribose ring, via competing secondary oxidation to an unstable diketone.104  
 
Scheme 2.1: Platinum based oxidation of NDP-sugars. 
This method was successfully employed in the chemical synthesis of GDP-Glc-2,3-
diNAcA 56. Following reaction of the respective monophosphate with UMP-
morpholidate, UDP-Glc-2,3-diNAc was afforded in 49% yield after 14 days. The 
platinum-catalysed oxidation procedure was then used to afford the corresponding 
uronic acid 56 in an impressive 69% yield.102 
In 2017, Codée et al. published the first chemical synthesis of GDP-ManA 4 using a 
protected phosphoramidite P(III) approach. Generation of the P(V)-P(III) 
intermediate was catalysed by DCI, which was then oxidised to with tert-butyl 
hydroperoxide (tBuOOH) and deprotected. 4 was isolated in a reasonable yield of 





Scheme 2.2: Synthesis of GDP-ManA 4 using a phosphoramidite approach. 
Access to GDP-ManA 4 was sought via a simpler route that would require fewer 
protecting group manipulations and use the more robust P(V)-P(V) strategy to 
access this key building block. A series of four differentially protected glycosyl 1-
phosphates, 60, 42, 62 and 63, were designed to permit assessment of any solubility 
differences on pyrophosphorylation. Exploration of additional reaction parameters 
such as activator and solvent choice were also proposed. To facilitate this 
investigation, scalable access to mannopyranuronic acid derivatives was required, 










2.1 Synthesis of glycosyl 1-phosphates  
2.1.1 Synthesis of α-D-mannopyranuronic acid derivatives: acetyl protected methyl 
uronate series  
 
The synthetic strategy towards differentially protected α-D-mannopyranuronic acid 
derivatives 60 and 42 was derived from D-mannose 64, outlined in Scheme 2.4. 
Following selective tritylation of the C6-OH and per-O-acetylation, compound 65 was 
obtained via recrystallisation from absolute EtOH as the β-anomer. Removal of the 
trityl moiety was achieved using HBr/AcOH (33% w/w) to afford C6-alcohol 66. 
 
Scheme 2.4: Synthesis of methyl uronate 68. 
Problems were encountered when scaling up the TEMPO/BAIB oxidation of 66 to 
67 above 500 mg, with a significant decrease in yield observed. To address this, 
alterations to the solvent ratio and equivalents of TEMPO/BAIB were explored, as 
illustrated in Table 2.1. The optimised conditions used 0.5 and 5.0 equiv, of TEMPO 
and bis(acetoxy) iodobenzene (BAIB) respectively (Table 2.1, Entry 3). The work-up 
was also modified to deliver the product without a need for column chromatography, 
through acidification of the aqueous layer and subsequent extraction of the product 




of 78% on scales exceeding 2 g 106, which was subsequently esterified using methyl 
iodide (MeI) and K2CO3 to afford 68. 
Entry 66 (g) DCM:H2O TEMPO (equiv.) BAIB (equiv.) Yield (%) 
1 1.0 2:1 0.2 2.5 36 
2 0.5 2:1 0.5 10.0 30 
3 2.0 2:1 0.5 5.0 78 
 
Table 2.1: Optimisation of TEMPO/BAIB mediated oxidation of 66. 
Attempted synthesis of a thioglycoside donor 
The synthesis of α-D-mannopyranuronic acid derivatives was first attempted via 
synthesis of thioglycoside 69, shown in Scheme 2.5. Two different Lewis acids, 
boron trifluoride diethyl etherate (BF3•OEt2) and trimethylsilyl trifluoro-
methanesulfonate (TMSOTf), were evaluated.   
 
Scheme 2.5: Optimisation of TMSOTf mediated thioglycoside formation. 
Methyl uronate 68 is considered a poor glycosyl donor due to the inactivation of its 
anomeric centre by the electron-withdrawing C6 uronate.107 Furthermore, the use of 
acetate protecting groups further disarms the donor. Reaction times with BF3•OEt2 
as Lewis acid were long, despite use the of 5.0 equivalents, and desired 
thioglycoside 69 was not isolated. Alternatively, use of TMSOTf showed complete 




isolated as an anomeric mixture in addition to an orthoester by-product 70, common 
to glycosylation reactions with participating 2-O-acetyl substituents.  
Entry Temperature (°C) Time (h) Yield (%) α/β 69 69α/70 
1 –15àRT 18 63c 5:1 4:1 
2 0àRT 6 42c 5:1 8:1 
3 0 6 15p 5:1 25:1 
4 0 32 17p 6:1 33:1 
 
Table 2.2: Optimisation of TMSOTf mediated formation of thioglycoside 69.  
c = crude yield and p = yield after purification. 
The products could be distinguished by chemical shift of the anomeric proton 
resonances (69α = δH 5.60 ppm and 70 = δH 6.21 ppm). The proposed mechanism 
for formation of by-product 70 is illustrated in Scheme 2.6.  
 
Scheme 2.6: Proposed mechanism for the formation of α-thioglycoside 69 and 





To investigate supressing the formation of 70, the reaction temperature was 
increased from –15 °C to 0 °C (Table 2.2, Entry 2). In comparison to previous 
attempts, which afforded an average product/orthoester ratio of 4:1, the ratio was 
improved to 8:1 but the side reaction was not completely stopped.  
Isolation of pure 69 was difficult given the similarity in Rf values between the α/β-
anomers and orthoester 70. Although separation from 70 could be achieved on 
larger scale (≥500 mg) attempts to further minimise its formation were made and the 
reaction repeated with the temperature maintained at 0 °C for 6 h (Table 2.2, Entry 
3). This reaction did not reach completion and 69 was isolated in only 15% yield 
(44% returned 68). These results suggested that product/orthoester ratio worsened 
upon increasing temperature, however when maintained at 0 °C the product formed, 
but slowly. 
Finally, the reaction was maintained at 0 °C for a longer time period (Table 2.2, Entry 
4), with the hope of completely suppressing orthoester formation and improving 
conversion to 69. Though the product/orthoester ratio was dramatically improved 
(33:1), the conversion of starting material was again very slow and gave a poor 





Synthesis of a trichloroacetimidate donor 
Due to the problems encountered with orthoester formation the route was changed 
to explore a trichloroacetimidate donor (Scheme 2.7). 
 
Scheme 2.7: Synthesis of α-D-mannopyranuronic acid derivatives 60 and 42. 
Selective removal of the anomeric acetate in methyl uronate 68 was attempted using 
established literature procedures for related substrates. Cleavage using ethylene 
diamine (EDA) and AcOH108 was not reproducible, and afforded highly variable 
yields of hemiacetal 71 between 20-64%. The use of 3(dimethylamino)-1-
propylamine (DMAPA) had recently been reported to remove pyranose anomeric 
acetate groups in high yield.109 Unfortunately, adoption of this procedure did not yield 
71. Finally, hydrazine acetate anomeric deacetylation110 was attempted and 




Reaction of 71 with trichloroacetonitrile in the presence of K2CO3 afforded 
trichloroacetimidate donor 72 which was used crude in the synthesis of protected 
ManA 1-phosphate 73. Reaction of 72 with dibenzyl phosphate (DBP) in the 
presence of TMSOTf successfully afforded 73, although the average yield was only 
49%. Attempts to improve this yield, through more rigorous drying procedures and 
use of various batches of DBP from a range of suppliers were unsuccessful. 
Following purification, the expected 31P NMR resonance for the anomeric phosphate 
(δP −3.2 ppm) and characteristic doublet of doublets for the anomeric proton (JH1-P 
= 6.4 Hz, JH1-H2 = 2.0 Hz) were observed.76  
Deprotection of 73 via hydrogenolysis using Pd/C catalysis successfully yielded the 
desired ManA 1-phosphate 60, which was isolated as the bis-triethylammonium salt 
following concentration in vacuo with Et3N. A resonance at δP –0.9 ppm with a JH1-P 
of 7.0 Hz was identified in the 31P spectrum. This material was then fully deprotected 
through treatment with Et3N in MeOH/H2O, to afford 42 in 90% yield, which was 
confirmed by 31P NMR (δP 1.4 ppm, JH1-P = 8.6 Hz) and HRMS, where the m/z peak 
corresponding to [42–H]– was calculated as 273.0013. The desired α-D-
mannopyranuronic acid derivatives 60 and 42 were accessed over 8 or 9 steps in 
respective overall yields of 5 and 4%, from 64 for use in the chemical synthesis of 





2.1.2 Synthesis of α-D-mannopyranuronic acid derivatives: acetyl protected benzyl 
uronate series  
As hydrogenolysis of protected glycosyl 1-phosphate 73 is necessary to deprotect 
α-D-mannopyranuronic acid derivatives, the precursor synthesis was modified to 
form a benzyl protected uronate, illustrated in Scheme 2.8. This would permit 
simultaneous hydrogenolysis of the benzyl ester and benzyl phosphate ester 
protecting groups, proposed to furnish an additional α-D-mannopyranuronic acid 
derivative 62 with a different solubility prospect to evaluate towards synthesis of 
GDP-ManA 4. 
 
Scheme 2.8: Attempted synthesis of 62. 
Compound 75 was synthesised in two steps, following successive benzylation and 
anomeric acetate cleavage using the previously established conditions for 71. 




reacted with DBP in the presence of TMSOTf and monitored for 24 h. During this 
time, TLC analysis did not indicate any formation of protected glycosyl 1-phosphate 
77 and only 75 was recovered by column chromatography.  
Attempted purification of donor 76 to improve purity of the starting material was 
unsuccessful, only resulting in decomposition despite the addition of 2% v/v Et3N to 
the column eluent. When the experiment was repeated using increased equivalents 
of promoter, 31P NMR analysis revealed two resonances at δP –3.0 and –3.2 ppm. 
Given that both values were in the expected chemical shift range for protected 
dibenzyl phosphate derivatives, it appeared that a mixture of anomers may have 
formed.  
Changing the promoter from TMSOTf to silver trifluoromethanesulfonate (AgOTf) 
also delivered the same result, with crude 31P NMR analysis revealing two 
resonances in a similar region, δP –3.1 and −3.3 ppm, to previous compound 73 with 
a resonance at δP −3.2 ppm. Batches of DBP from various suppliers were also 
screened, however no improvement to the yield was observed, which ranged from 
11-14%. The synthesis of derivative 62 was unsuccessful using these conditions 





2.1.3 Synthesis of α-D-mannopyranuronic acid derivatives: benzoyl protected 
uronate series 
To enrich the substrate scope for evaluation of chemical sugar-nucleotide synthesis 
of GDP-ManA 4, a route towards benzoyl protected α-D-mannopyranuronic acid 
derivative 63 (Figure 2.) was also designed to evaluate any difference in solubility 
compared acetyl protected compound 62. The route is outlined in Scheme 2.9.  
 
Figure 2.2: Chemical structure of target glycosyl 1-phosphate 63. 
Following one-pot tritylation and benzoylation of 64, purification by column 
chromatography afforded 78 as a mixture of inseparable anomers (5.8:1 α/β). 
Cleavage of the trityl group to reveal the C6-OH for oxidation was initially performed 
using HBr/AcOH (33% w/w) in AcOH. The starting material was less soluble in AcOH 
in comparison to the acetyl counterpart 65 therefore 79 was only afforded in 27% 
yield and alternative conditions were sought. Use of catalytic p-Toluenesulfonic acid 
(pTsOH) (0.22 equivalents) in DCM/MeOH had been used previously for trityl 
removal on a similar substrate111, however these conditions did not lead to complete 
deprotection. The procedure was repeated using varying equivalents of pTsOH, with 
the optimised procedure requiring 1.2 equivalents to afford 79 in a yield of 80% (4:1 




Scheme 2.9: Synthesis of protected uronates 81 and 82. 
Oxidation to the uronic acid was performed using TEMPO/BAIB conditions, 
producing 80 in an average yield of 54%. The optimised purification procedure 
discussed earlier in this chapter could not be applied to these derivatives due to their 
different solubility profile, and column chromatography was required to afford pure 
80. Successful oxidation was confirmed by identification of a new resonance at δC 
171.8 ppm corresponding to CO2H. Esterification of 80 with MeI or benzyl bromide 
(BnBr) under basic conditions afforded desired compounds 81 and 82 respectively 
for use in thioglycoside formation. 
With protected uronates 81 and 82 in hand, installation of a thioglycoside donor was 
attempted using BF3•OEt2, outlined in Scheme 2.10. 
 




Attempted glycosylation of thiophenol (PhSH) with 81 in the presence of BF3•OEt2 
was sluggish, and a further 2.0 equivalents of promoter was added in an attempt to 
induce conversion. After 48 h, the reaction was quenched as no conversion to 83 
was observed by TLC and only starting material could be recovered. The reaction 
of 82 with PhSH under the same conditions also showed no conversion of 82 even 
after 32 h. Further attempts using increased quantities of BF3•OEt2 (3.0-4.0 
equivalents) and a different promoter, TMSOTf (2.0-3.0 equivalents) also failed to 
afford 84. All attempts to synthesise a phenyl thioglycoside donor failed under the 
conditions attempted. 
Next, attention was focused on preparation of a thioglycoside using ethanethiol 
(EtSH), which is more reactive than PhSH, illustrated in Scheme 2.11.  
 
Scheme 2.11: Attempted synthesis of 63 via ethyl thioglycoside 85. 
First, benzyl uronate 82 was dissolved in DCM with EtSH and activated with 
BF3•OEt2. The reaction was very sluggish, with little conversion of 82 observed even 
with 4.0 equivalents of promoter. Following purification, desired product 85 was 




An alternative procedure reported by Sail et al.112 used dichloroethane (DCE) as 
solvent. Following this procedure, 1.8 equivalents of promoter was used, however 
the isolated yield was only 19%. Increasing the quantity of promoter to 2.0-3.0 
equivalents had little effect on yield on scales up to 250 mg, and it was observed 
that hydrolysis began to occur before conversion of starting material was complete. 
Therefore, the reaction mixture was quenched before completion to prevent loss of 
the product. Following purification by column chromatography desired thioglycoside 
85 was isolated, with the optimised procedure giving 85 in a yield of 41%, (66% 
based on returned starting material) which could be scaled up to ≥1 g. A clear upfield 
shift of the anomeric proton from δH 6.79 ppm to δH 5.71 ppm was observed in NMR 
of 85, with resonances corresponding to the -CH2 and -CH3 protons of the ethyl 
thioglycoside functionality identified as a quartet at δH 2.87 ppm (J = 8.0 Hz) and a 
triplet at δH 1.35 ppm (J = 8.0 Hz).  
Activation of thioglycoside 85 with N-iodosuccinimide (NIS)/AgOTf in the presence 
of DBP afforded glycosyl 1-phosphate 86 in a modest yield of 29%. The anomeric 
phosphate resonance was identified at δP –3.1 ppm with JH1-P 7.3 Hz and further 
confirmed by HRMS, with a m/z peak of 874.2625 corresponding to the [86+NH4]+ 
species.  
Finally, 86 was subjected to hydrogenolysis to cleave the benzyl protecting groups. 
The starting material was dissolved in EtOH/THF (1:1) and stirred vigorously under 
an atmosphere of H2 with Pd/C for 36 h, where TLC analysis appeared to show 
conversion of 86 to a baseline Rf value spot. Following work-up, a white powder was 




presence of a CH2 resonance suggesting incomplete deprotection. The residue was 
reconstituted in MeOH/H2O and hydrogenolysis continued however no further 
change by TLC, using a more polar eluent system, was observed even after 24 h. 
Analysis of the crude residue by NMR still suggested incomplete benzyl removal.  
Deprotection of 86 was repeated using the previous conditions and within 24 h, 
conversion of 86 to two lower Rf value spots was observed by TLC. At this time, the 
catalyst was replaced, and the residue suspended in MeOH for a further 8 h where 
only one baseline Rf value spot was observed by TLC. Following work-up and 
concentration in vacuo, the resultant residue was poorly soluble in MeOD-d4 and 
CDCl3 leading to poorly resolved NMR spectra that could not be fully characterised. 
Again, the HSQC-DEPT spectrum indicated presence of at least one -OCH2Ph 
group and the 31P was now a very broad, poorly resolved singlet at δP –2.2 ppm. 
HRMS analysis did not find the correct molecular ion for the proposed structure. 
Compared to the acetyl protected uronate series, benzoyl protected uronate donors 
were, as expected, less reactive. Whilst the reaction of 68 with PhSH did proceed 
but slowly, no equivalent reaction was observed with benzoyl counterpart 81. 
Thioglycoside synthesis was possible when using EtSH to produce 85. 
Advantageously, no competing formation of an orthoester by-product was observed 
during this transformation, unlike in the synthesis of acetylated thioglycoside 69. This 
eased purification and reduced the overall number of steps in the synthetic route but 
unfortunately, hydrogenolysis failed and target glycosyl 1-phosphate 63 could not 
be isolated. This may be attributed to the limited solubility profile of 63 and in future 




2.2 Synthesis of GDP-ManA 
With two protected glycosyl 1-phosphates 60 and 42 in hand, the final stage of this 
route was formation of the pyrophosphate linkage to afford GDP-ManA 4. The 
phosphoromorpholidate methodology was selected to complete this transformation, 
therefore access to the activated monophosphate precursor guanosine 5’-
phosphoromorpholidate (GMP-morpholidate) 87 was required. This reagent is 
commercially available, but it is expensive (~ £100 per 100 mg), therefore it was 
important to be able to access this species in larger quantities to enable optimisation 
of the pyrophosphorylation step.  
The predominant methods used in the literature to synthesise 87 are those of 
Khorana113 and Mukaiyama114 from guanosine 5’-monophosphate (GMP) 88, of 
which both were attempted (Scheme 2.12) to afford 87 in 27 and 30% yields 
respectively.    
 





2.2.1 Chemical synthesis 
The chemical synthesis of GDP-ManA 4 was first attempted using per-O-acetylated 
methyl uronate 60 and N-MIC as the activator (Scheme 2.13 and Table 2.3, Entry 
1).87 The monophosphate components were exchanged to their triethylammonium 
salt forms prior to phosphorylation to improve solubility and co-evaporated with 
anhydrous pyridine or toluene. 
 
Scheme 2.13: Chemical synthesis of GDP-ManA 4.  
The optimum TLC system to monitor sugar-nucleotide synthesis was 
IPA/NH4OH/H2O (6:3:1) and analysis was performed on large 7 × 7 cm plates in two 
sections that were stained with H2SO4/MeOH and orcinol (Figure 2.3).  
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(0.04) 
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Table 2.3: Evaluation of glycosyl 1-phosphates 60 and 42 for chemical synthesis of 
GDP-ManA 4. 
After 60 h, a lower Rf value spot was observed, however crude 31P NMR (CDCl3) 
analysis revealed only one resonance at δP 0.4 ppm, inconsistent with the two 
expected resonances for a sugar-nucleotide, reported between δP –11.0 and –14.0 
ppm for the diphosphate linkage.91 Though care was taken to avoid presence of H2O 
in the reaction, N-MIC was clearly hygroscopic and was a source of moisture leading 
to hydrolysis of 87 to afford GMP 88 (δP –0.7 ppm in D2O). These conditions were 
not repeated, however it was reported in the literature that lyophilisation of N-MIC 
prior to use effectively reduces residual moisture.115  
Synthesis of 4 was next attempted using DCI (Table 2.3, Entry 2) which was 




different lower Rf value spot than the previous attempt. Following removal of DMF, 
crude 31P analysis (CDCl3) showed two broad singlets in the expected region for a 
diphosphate linkage at δP –11.4 and –14.6 ppm. Two other resonances were present 
in the spectrum at δP 0.2 and –2.7 ppm, corresponding to 88 and 60 respectively. 
The resultant residue was reconstituted in MeOH/H2O and Et3N added until pH = 9, 
until conversion to a lower Rf value spot was observed. 
Several methods are described in the literature for the purification of sugar-
nucleotides, primarily involving strong-anion exchange (SAX) chromatography. The 
first buffer attempted for sugar-nucleotide purification was triethylammonium 
bicarbonate (TEAB), which was prepared by bubbling CO2 through a 1M aqueous 
solution of Et3N until pH = 8.5.101,105 During methodology development, this buffer 
caused issues with the Bio-Rad purification system, including reduced flow rates and 
blockages as buffer concentration was increased.  
Ammonium bicarbonate (NH4HCO3) was next evaluated, which presented fewer 
problems. Multiple flow rates, buffer gradients and injection concentrations/volumes 
were screened during optimisation, with the best protocol developed at a flow rate 
of 3.0 mL/min with a concentration gradient of 0 → 100% 1.0 M NH4HCO3 over 33 
min. Standards of GMP 88, guanosine 5’-diphosphate (GDP) and GDP-Man 4 were 
collected for comparison.  
When the crude residue was applied to the column, 4 was isolated in poor yield 
(<5%). During purification, a large UV peak co-eluted in the area of interest; after 
running a standard of DCI, this was confirmed to be the impurity. As the activator 




via a HyperSep C18 column (eluting with H2O) to remove most of the contaminant 
prior to application to the SAX column. 
The pyrophosphorylation reaction was repeated using a variety of conditions, 
including reduced equivalents of DCI (1.0) to prevent purification problems and 
evaluation of DMF and pyridine as solvents. Reducing the equivalents of activator 
almost doubled the reaction time (Table 2.3, Entries 2 and 3). Changing the reaction 
solvent to pyridine provided the best improvement, furnishing 4 in 46% yield using 
1.0 equivalents of DCI (Table 2.3, Entry 5). Whilst the uncatalysed reaction still 
afforded 4, the yield was reduced by over half to 22% and the reaction time was very 
long (Table 2.3, Entry 4). 
Synthesis of 4 was also attempted using fully deprotected glycosyl 1-phosphate 42. 
The reaction was attempted in both DMF and pyridine (Table 2.3, Entries 6 and 7), 
however in both instances no reaction of 42 with 87 was observed. The addition of 
DCI did not improve conversion, and in all attempts unreacted GMP-morpholidate 
87 could be observed by 31P NMR confirming that hydrolysis did not cause the failure 
of the reaction. This could be attributed to the poorer solubility of glycosyl 1-
phosphate 42 in both DMF and pyridine. 
2.2.2 Enzymatic synthesis  
As discussed in Chapter 1.3, GDP-ManA 4 is produced via oxidation of GDP-Man 3 
by GMD in the presence of NAD+. Access to a standard of 4 was desired as a 
reference to aid purification of chemically prepared crude mixtures of 4 by SAX 
chromatography. Prior to the reaction, standards of NAD+, NAD(H) and GDP-Man 3 




of NAD+ to NAD(H) by monitoring absence and appearance of the corresponding 
peaks. Recombinant GMD from P. aeruginosa was provided by the Field group, and 
incubation of GDP-Man 3 with GMD in the presence of NAD+ at RT with gentle 
shaking afforded 4 (Scheme 2.14), however, conversion was only 20% in the first 
attempt. Re-expression of GMD to produce fresh aliquots for use in the enzymatic 
synthesis later improved conversion to 70%.  
 
Scheme 2.14: Enzymatic synthesis of GDP-ManA 4 using GMD 
The peak of interest was collected and lyophilised to afford GDP-ManA 4 which was 
characterised by 1H, 31P NMR and HRMS. The characteristic JH1-P was calculated 
as 8.0 Hz, and the smaller JH1-H2 coupling constant identified at 1.7 Hz. 31P analysis 
showed two resonances at δP −11.2, −13.7 ppm respectively and HRMS found the 





2.3 Conclusions and Future Directions 
In conclusion, this work presented efforts towards the synthesis of four differentially 
protected glycosyl 1-phosphates for evaluation in the chemical synthesis of GDP-
ManA 4. Of the routes attempted, two were successful, yielding 60 and 42. The 
precursor, acetyl protected methyl uronate donor 68, presented low reactivity and 
phenyl thioglycoside synthesis was hindered by competing orthoester formation. 
The optimum route towards these derivatives instead proceeded via a 
trichoroacetimidate donor, following removal of the anomeric acetate. 
The same route was adopted for a benzyl protected uronate counterpart, with 
transformations towards its corresponding trichloroacetimidate donor largely 
straighforward. Unfortunately, target glycosyl 1-phosphate 62 could not be isolated 
due problems encountered during glycosylation of DBP. Despite use of multiple 
activation conditions, only a mixture of products, which may correspond to α/β 
anomers, were consistently formed in low yields.  
The final route towards target 63 used benzoyl protected uronate donors, which 
showed further unreactivity compared to acetyl protected uronate donors. No 
reaction occurred with PhSH to form a phenyl thioglycoside, however use of the 
more reactive EtSH successfully yielded ethyl thioglycoside donor 85, though only 
in moderate yield. No competing formation of an orthoester was observed during 
this synthesis. Formation of 63 via hydrogenolysis failed, thought to be attributed to 
solubility issues.  
The optimum conditions for chemical sugar-nucleotide synthesis used protected 




balance between reaction time and isolated yield. Deprotected glycosyl 1-phosphate 
42 was poorly soluble in the solvents screened and no conversion to GDP-ManA 4 
was observed.  
In contrast, the enzymatic route permitted fast access to 4 in a single step. However, 
this transformation is reliant upon expression of GMD and the sugar-nucleotide 
GDP-Man 3, which is available commercially, but is expensive. The chemical 
methodology permitted access to multimilligram quantities of 4, whereas the 
enzymatic route only generated milligram amounts; this was key however to aid 
analytical methodology development in the final purification of chemically 
synthesised GDP-ManA 4.116  
The approaches described compliment the P(III)-P(V) strategy published by Zhang 
et al.105, providing a total of three routes to access 4, the native sugar-nucleotide 
used for alginate biosynthesis in P. aeruginosa. Nevertheless, both chemical 
methodologies are multi-step routes that deliver the target material in overall yields 
of less than 10%. Exploration of transformations such as a C6 oxidation post-
phosphate installation (TEMPO/NaOCl)117 or C6 oxidation (Pt, O2)104 post sugar-
nucleotide formation would be logical steps to improve this in the future, as problems 





Chapter 3: Sugar-nucleotide tools for GMD 
3.0 Introduction and aims 
As outlined in Chapter 1.5, the synthesis of sugar-nucleotide probes for chemical 
biology applications is well established in the literature for elucidation of biochemical 
mechanisms amongst pathogenic bacteria. For P. aeruginosa alginate biosynthesis 
however, comparatively little research of this nature has been reported.  
Following identification of GMD as a therapeutic target, recent work within the Miller 
group presented the synthesis of the first series of C6-modified GDP-Man analogues 
as tools to probe this enzyme.118 A series of five diastereomerically pure, isotopically 
enriched analogues bearing deuterium or methyl substituents (Figure 3.1) were 
accessed via functionalisation of a common C6-aldehyde building block. 
Transformation to the corresponding sugar-nucleotide was accomplished using 
GDP-ManPP from S. enterica.  
 





The five analogues were evaluated as substrates of GMD, with C6-methyl 
analogues shown to reversibly inhibit GMD, via formation of a ketone during 
oxidation that could be identified by HRMS. This intermediate however, was not 
tightly bound, and upon spiking with the substrate, GDP-Man 3, NAD(H) production 
was resumed.  
To further this investigation, design and synthesis of structurally defined GDP-Man 
analogues to act as potential substrates of GMD was required. Access to these 
materials is crucial to advance knowledge of the GMD catalysed oxidation, with the 
view to gaining further insight into substrate specificity of this strategic enzyme. The 
analogues were proposed to bear electrophilic groups or present alternative 
electronic/structural properties and were categorised as follows: C6-modified, C4-
modified and active site intermediate analogues.  
Considering the recent literature detailing the synthesis of other sugar-nucleotide 
analogues discussed previously, the route towards these structure-function tools 
was proposed via a chemoenzymatic strategy, outlined in Scheme 3.1. First, 
modified glycosyl 1-phosphates were to be prepared chemically from protected C6-
OH or C4-OH building blocks, where following a series of functional group 
interconversions, new analogues could be accessed. Several methodologies to 
install the anomeric phosphate were described in the literature, of which two will be 
evaluated in this work. Finally, formation of the corresponding GDP-Man analogues 
using GDP-ManPP from S. enterica, commonly utilised in the literature for syntheses 










3.1 C6-modified GDP-Man analogues 
3.1.1 Biological rationale 
Targeted covalent inhibition strategies retain importance across both areas of 
chemical biology and drug discovery, a recent example being Acalabrutinib. 
Approved by the FDA in 2017 for treatment of non-Hodgkin lymphoma, this tyrosine 
kinase inhibitor bears a Michael-acceptor in its structure. Furthermore, Amgen have 
recently reported the structure of AMG510, which was found to covalently inhibit a 
mutant form of the cancer target KRas. This proceeds through attack of a cysteine 
residue at an electrophilic Michael acceptor within AMG510. This discovery evolved 
from a sugar-nucleotide tool used in preliminary studies of the target enzyme.119,120 
With these recent examples in mind, the first series of sugar-nucleotide probes as 
structure function tools for GMD were designed to feature alternative functionalities 
at the C6-position of mannose (Figure 3.2). Inert to native oxidation, the first two 
probes in this category, featuring a chloride and a nitrile group, are intended to 
interact with the active site Cys268 residue of GMD through covalent attachment to 
the sugar-nucleotide analogue. The third probe, containing an azide moiety, was 
designed to investigate the substrate specificity of GMD and the final probe bearing 











3.1.2 Optimisation of MacDonald Phosphorylation 
Originally published in 1962, the MacDonald phosphorylation procedure uses high 
temperature (50 °C) and low pressure to form a melt of crystalline H3PO4 and per-
O-acetylated sugar, leading to glycosylation of the anomeric position and release of 
AcOH (Scheme 3.2).75 The utility of this methodology has been demonstrated by 
several research groups95,101,121 to access both native and modified glycosyl 1-
phosphates, however the procedure is often low yielding and requires a significant 
excess of H3PO4 (10.0 equivalents). Nevertheless, given the simplicity of this 
method, we sought to optimise and explore the scope of this reaction further in our 
synthesis of modified glycosyl 1-phosphates.122 
 
Scheme 3.2: General overview of MacDonald phosphorylation. 
One of the main problems associated with MacDonald phosphorylation is undesired 
hydration of crystalline H3PO4 due to its hygroscopicity, where upon exposure to the 
atmosphere, the material quickly turns from an opaque crystalline solid to a paste. 
Presence of water leads to diminished yields of the desired glycosyl 1-phosphate, 
as it competes in the anomeric substitution reaction to form a hemiacetal by-product.  
Initial investigation began using per-O-acetylated galactose 93 (Scheme 3.3), where 
to overcome the issue of hydration, transfer of H3PO4 to a Schlenk tube containing 




atmosphere. The first attempt was performed on 500 mg scale with 10.0 equivalents 
of H3PO4 (Table 3.1, Entry 1). The melt was stirred for 3 h at 50 °C under vacuum, 
then saponified using 1M LiOH. Following filtration through a Whatman filter and 
neutralisation, the filtrate was concentrated in vacuo to afford a white solid.  
 
Scheme 3.3: Optimisation of MacDonald phosphorylation to synthesise 94. 
Purification by strong anion exchange chromatography permitted facile removal of 
the uncharged hemiacetal by-product by initial washing with 3 column volumes (CV) 
of H2O, followed by 3 CV of 1M NH4HCO3 to afford the desired glycosyl 1-phosphate 
94 in improved yield of 68%. This presented an increased yield in comparison to the 




Temperature (°C)* Yield (%) Scale (mg) Time (h) 
1 10.0 50 68 500 3 
2 10.0 50 65 100 3 
3 10.0 50 69 50 3 
4 10.0 40 62 80 3 
5 5.0 40 67 300 3 
 
Table 3.1: Summary of optimised conditions for MacDonald phosphorylation. 





Subsequent reactions were performed on smaller scales to assess any effect on 
isolated yield, as in the synthesis of modified glycosyl 1-phosphates less material is 
generally available. When performed on 50-100 mg scales (Table 3.1, Entries 2 and 
3), the desired glycosyl 1-phosphate was still isolated in pleasing yields exceeding 
60%. Lowering the temperature to 40 °C also maintained the yield of 94 (Table 3.1, 
Entry 4), however, lowering the temperature further to 30 °C lead to inefficient 
formation of the melt. The final modification to the procedure investigated the effect 
of reducing the equivalents of H3PO4 from 10.0 to 5.0. This offered the best balance 
between reaction time and full conversion of the starting material by TLC at 40 °C 
(Table 3.1, Entry 5). 
With an improved procedure available, per-O-acetylated mannose 14 was evaluated 
as a substrate, which was isolated in 55% yield (Scheme 3.4) following SAX 
chromatography. The structure was confirmed by 31P NMR analysis, where a 
resonance at δP 2.0 ppm (JH1-P of 8.5 Hz) was observed. Having improved the yield 
for the synthesis of 44, this provided scope to synthesise modified mannose 1-
phosphate analogues using this methodology, discussed in further detail during this 
chapter.  
 





3.1.3 Studies towards the synthesis of 6-chloro-6-deoxy-α-D-mannopyranosyl 
phosphate  
Literature precedent and proposed mechanism of action 
To further expand the toolkit and permit investigation of GMD mediated oxidation, 
we sought to synthesise sugar-nucleotide probes containing a C6-halogen 
substituent. Installation of such functionalities that act as leaving groups could lead 
to the formation of a covalent bond between Cys268 and the analogue, GDP-6-
chloro-6-deoxy-mannose 89, shown in Figure 3.3, with the potential to inhibit GMD 
mediated GDP-ManA production.  
 
Figure 3.3: Proposed interaction of Cys268 with 89. 
To support the design of such probes molecular docking of an electrophilic GDP-
Man analogue was completed with GMD. The corresponding covalent adduct 
formed following the proposed alkylation by Cys268 is illustrated in Figure 3.4. 
 




Attempted synthesis of 6-Chloro-6-deoxy-mannopyranosyl phosphate 
The route towards 6-Chloro-6-deoxy-mannopyranosyl phosphate 95 was designed 
from alcohol 66 (Scheme 3.5), that was transformed by Appel halogenation 
conditions (PPh3 and CCl4). After heating at reflux for 6 h, TLC analysis confirmed 
complete conversion of starting material and precursor 96 was isolated in 61% yield. 
Successful installation of the C6-Cl moiety could be confirmed by 13C NMR, showing 
a new resonance that had shifted upfield to δC 42.9 ppm from δC 61.4 ppm. 
 
Scheme 3.5: Attempted synthesis of glycosyl 1-phosphate 95.  
Following preparation of the reaction mixture in a glove box, the tube was heated to 
35 °C under vacuum. At this temperature, the melt did not form evenly hence 
temperature was increased to 45 °C. After stirring gently for 4 h, two new Rf value 
spots could be observed via TLC, however the Rf value was higher than usually 
observed for a protected glycosyl 1-phosphate (0.50 as opposed to baseline). 
Following saponification and SAX chromatography, hemiacetal and the proposed 




Though 31P NMR data showed only one resonance at δP 2.0 ppm, the anomeric 
proton resonance did not show the diagnostic doublet of doublets splitting pattern, 
instead appearing as an apparent triplet with J = 6.8 Hz. In the 13C spectrum, 
coupling constants of JC1-P = 3.2 Hz and JC2-P = 4.4 Hz were observed. Analysis by 
HRMS confirmed displacement of the chloride functionality had occurred, with the 
major ion identified at m/z 241.0116, corresponding to species [97-H]−. It was 
proposed that during phosphorylation of 96, intramolecular substitution of the C6-Cl 
through the anomeric oxygen afforded 97, as shown in Scheme 3.6.  
 
Scheme 3.6: Proposed mechanism for formation of 97. 
X-ray crystallographic data could not be obtained for 97, therefore its anomeric 
configuration remains unconfirmed, however density functional theory (DFT) 
calculations suggest preference for the β-anomer, with a H1-H2 dihedral angle of 
40.3º predicted (Figure 3.5). This supports assignment of 97 as the β-anomer, 
suggesting interconversion between α/β anomers may occur under the acidic 
conditions employed for this transformation. Consultation of the literature showed 





Figure 3.5: DFT energy minimised 3CO conformation of 97 (β-anomer). 
The reaction was repeated at 35 °C and monitored every 30 min by TLC with the 
hope of isolating desired glycosyl 1-phosphate 95 prior to cyclisation. Unfortunately, 
within 1 h formation of 97 had occurred, and following saponification and work-up 
the resultant spectral data matched those previously obtained. It was concluded that 
96 was an unsuitable substrate for MacDonald phosphorylation and the 
functionalised glycosyl 1-phosphate analogue could not be isolated using this 
methodology.  
Work into the synthesis C6-halogenated glycosyl 1-phosphate analogues was 
continued by another member of the research group, with the results summarised in 
Scheme 3.7. Attempted synthesis C6-Br analogue 100 showed the same result, with 
exclusive formation of 97 observed. However, the C6-F analogue 101 could be 
isolated in a 3:1 ratio of 101:97 when the reaction was performed at 30 °C for 6-7 h. 
These findings followed the expected trend based on knowledge of leaving group 










3.1.4 Studies towards the synthesis of α-D-mannopyranosylurononitrile phosphate 
Literature precedent and proposed mechanism of action 
Nitriles are known to react with both serine and cysteine residues of proteases to 
form imidate or thioimidate covalent adducts, respectively. Relevant examples 
include Vildagliptin 102123,124, which interacts with an active site Ser610 residue within 
DPP-4 for the treatment of Type 2 diabetes (Scheme 3.8) and Cathepsin K inhibitors 
that interact with active site cysteine residues as a treatment for osteoporosis.125  
 
Scheme 3.8: Proposed mechanism of action of Vildagliptin 102. Attack of DPP-4 
Ser610 residue at the nitrile moiety forms a covalent imidate adduct.124 
Based on this information, it was proposed that novel analogue GDP-6-nitrile-
mannose 90 may act as an inhibitor of GMD, providing a ‘sink’ for Cys268 by forming 
a covalent adduct with this key active site residue (Figure 3.6). In turn, this may lead 
to disruption of the oxidation of GDP-Man by GMD. Molecular docking of 90 with 
GMD supported a potential interaction, with a distance of 3.47 Å observed between 





Figure 3.6: Proposed interaction of Cys268 with GDP-Man analogue 90. 
Synthesis of acetyl protected 6-mannopyranosyluronitrile derivatives 
The strategy towards C6-nitrile derivatives was designed from work reported 
recently by Mende et al.126, which proceeded from a C6-aldehyde via an oxime 
intermediate (Scheme 3.9). Alcohol 66 was treated with Dess-Martin periodinane 
(DMP), affording aldehyde 103 in 84% yield that was immediately reacted with 
hydroxylamine hydrochloride (NH2OH•HCl) in the presence of Na2CO3 for 15 h. 
Following purification by column chromatography, 104 was successfully isolated in 
a moderate yield of 34%. 
 





Oxime 104 was then subjected to treatment with phosphoryl chloride (POCl3) at 65 
°C, to produce nitrile 105. It was noted that the concentration of the reaction mixture 
was 0.02 M (Table 3.2, Entry 1) in the original procedure, which made conversion of 
104 slow, requiring a reaction time of 9 h.  
Entry [104] (M) Time (h) Isolated yield (%) 
1 0.02 9.0 43 
2 0.04 4.0 37 
3 0.05 3.0 29 
4 0.08 2.5 31 
5 0.10 2.0 28 
 
Table 3.2: Optimisation of POCl3 mediated synthesis of nitrile 105. 
Following purification by column chromatography desired analogue 105 was 
isolated, however a small amount of 104 was also recovered. The experiment was 
repeated at higher concentration of 0.1 M with respect to starting material (Table 
3.2, Entry 5), where conversion of 104 was complete within 2 h and 13C NMR 
analysis revealed a resonance at δC 114.7 ppm, corresponding to C≡N. It was noted 
that the isolated yield decreased by 15% when the reaction was performed at 0.1 M, 
therefore the reaction was performed at a range of intermediate concentrations 
(Table 3.2, Entries 2, 3 and 4) to evaluate the effect on the isolated yield. The 
investigation showed a relationship between concentration and isolated yield, with 






Following optimisation, nitrile 105 was subjected to anomeric acetate removal using 
established literature procedures (Scheme 3.10). Use of hydrazine acetate or 
NH3/MeOH did not afford the desired hemiacetal, with TLC and NMR analysis 
showing no new product and only unreacted 105, despite multiple optimisation 
attempts. Next, benzylamine (BnNH2) anomeric acetate removal was attempted. 
This procedure uses Et2O as the solvent, in which nitrile 105 was poorly soluble. 
THF was added to improve homogeneity, however no conversion of starting material 
was observed and only 105 was recovered.  
 
Scheme 3.10: Attempted anomeric acetate removal of 105. 
Given the difficulty faced in removal of the anomeric acetate group, next formation 
of thioglycoside 107 was attempted, illustrated in Scheme 3.11. This transformation 
was performed using BF3•OEt2 and TMSOTf, however in both instances, despite 
use of a large excess of Lewis acid (> 3.0 equivalents) and elongated reaction times 
(> 72 h) no conversion of starting material was observed and only 105 was 





Scheme 3.11: Attempted synthesis of thioglycoside 107 using BF3•OEt2 and 
TMSOTf. 
The final methodology screened to install the anomeric phosphate directly from 105 
was MacDonald phosphorylation (Scheme 3.12). Several temperatures were 
attempted (see Table 3.3), however formation of a melt was difficult at lower 
temperatures. 
 
Scheme 3.12: Attempted synthesis of 108 via MacDonald phosphorylation. 
Entry Scale (mg) Temperature (ºC) Time (h) Result 
1 115 60 2.5 Decomposition 
2 125 45 4 Decomposition 
3 95 40 3 Hemiacetal formation 
 






In the first two attempts (Table 3.3, Entries 1 and 2), TLC analysis suggested some 
conversion of 105 was occurring, but following saponification and work-up no 
corresponding resonances were observed in the 1H NMR or 31P spectra, indicating 
decomposition to an unknown material. In the final attempt (Table 3.3, Entry 3), no 
conversion of starting material to a baseline Rf value spot was observed, and only 
hemiacetal was observed in the corresponding 1H NMR spectrum indicated by 
observation of a doublet at δH 5.19 ppm. 
The poor reactivity of acetyl protected C6-nitrile analogue 105 matched previous 
observations made in Chapter 2 during the synthesis of acetyl protected uronate 
donors. Whilst anomeric acetate removal could be achieved for uronate donor 68 
(Chapter 2.1.1, page 67), the corresponding transformation on compound 105 failed 
using multiple reagents. Similarly, synthesis of a thioglycoside donor of 68 (Chapter 
2.1.1, pages 64-66) was very slow and low yielding, with the equivalent reaction with 
105 resulting in no formation of a thioglycoside. Even in the presence of H3PO4, a 
strong Brønsted acid, no reaction at the anomeric centre was observed for 105. The 
route towards 105 was not viable using this strategy and no further work was carried 




Synthesis of benzyl protected 6-mannopyranosyluronitrile derivatives 
Accordingly, the route was changed to use benzyl protecting groups to produce a 
suitably armed donor. Starting from D-mannose 64, successive per-O-acetylation 
and glycosylation of PhSH in the presence of BF3•OEt2 afforded 15. Global 
deacetylation using sodium methoxide (NaOMe) and selective protection of C6-OH 
with a trityl group produced 110, which was subsequently benzylated using BnBr in 
the presence of sodium hydride (NaH). Finally, the trityl group was cleaved using 
pTsOH in DCM/MeOH to furnish the desired C6-OH thioglycoside donor 112 in 29% 
yield over six steps on multigram scale (Scheme 3.13). 
 
Scheme 3.13: Synthesis of thioglycoside donor 112 from D-mannose 64. 
Oxidation of 112 using Parikh-Doering conditions yielded aldehyde 113; this was 
confirmed by 1H NMR analysis, where a new singlet at δH 9.73 ppm was observed. 
This material was used immediately, without further purification, to form oxime 114. 
Subsequent treatment with POCl3 afforded the desired analogue 115 with the 
optimum conditions for this transformation using concentration of 0.025 M with 




nitrile functionality was confirmed by 13C NMR, with a resonance at δC 117.1 ppm 
corresponding to C≡N identified (Scheme 3.14) and HRMS, where m/z 538.2055 
was found corresponding to [115+H]+.   
 
Scheme 3.14: Synthesis of protected glycosyl 1-phosphate analogue 116. 
Next, the phosphate functionality was introduced by reaction of 115 with DBP using 
NIS/AgOTf activation conditions. After stirring for 1.5 h at -30 °C, TLC analysis 
showed complete conversion of 115 to a lower Rf value spot. Following purification 
by column chromatography, protected glycosyl 1-phosphate analogue 116 was 
isolated in a pleasing yield of 61%. 31P{1H} NMR analysis revealed a singlet at δP –





Finally, protected glycosyl 1-phosphate 116 was subjected to hydrogenolysis using 
Pd/C and Pd(OH)2/C catalysis (Scheme 3.15).  
 
Scheme 3.15: Attempted synthesis of 108 via hydrogenolysis. 
Following stirring of 116 under H2 for 24 h in EtOH/THF, the reaction mixture was 
filtered over CeliteTM and the solvent exchanged for MeOH/H2O. After stirring for a 
further 48 h, ion-exchange and lyophilisation, NMR analysis still showed the 
presence of one benzyl group. The material was reconstituted in MeOH/H2O with 
Pd(OH)2/C and hydrogenolysis continued for a further 24 h, however no further 
benzyl removal was observed. Finally, the partially deprotected phosphate was 
dissolved in H2O with Pd(OH)2/C and stirred for a further 24 h. Unfortunately, 
following ion-exchange and lyophilisation, NMR analysis suggested that the 
compound had decomposed. In subsequent attempts, the same conditions were 
used with reaction times of up to 48 h, however 13C NMR analysis showed absence 
of the diagnostic C≡N resonance at ~ δC 115.0 ppm, at confirming that in addition to 
benzyl removal reduction of the nitrile moiety was occurring. To try and prevent 
undesired reduction, the reaction was monitored more closely by TLC (~ every 2 h) 
and the reaction time was shortened. Unfortunately, the same observation was 




Hydrogenolysis was attempted using only Pd/C catalysis in EtOH/THF. After stirring 
for 9 h, conversion of starting material to lower Rf value spots was observed and the 
solvent was exchanged for MeOH/H2O and stirred for a further 6 h. 31P NMR analysis 
showed 4 resonances, indicating presence of differentially benzylated compounds 
due to incomplete hydrogenolysis. In a final attempt, a new batch of Pd(OH)2/C was 
used alongside Pd/C. Unfortunately, even after stirring in multiple solvents for 30 h, 
31P NMR analysis still showed incomplete conversion of 116 to the deprotected 
glycosyl 1-phosphate 108. Two singlets were observed at δP 2.6 and 0.4 ppm and 
resonances in the aromatic region (δH 7.80-7.30 ppm) were also present in the 1H 
NMR spectrum.  
Analogue 108 not be accessed using the Pd/C and Pd(OH)2/C hydrogenolysis 
conditions described due to undesired reduction of the nitrile group. Consultation of 
the literature for chemoselective hydrogenolysis catalysts was unsuccessful. Sajiki 
et al. reported the use of Pd/C(en) for the selective hydrogenation of alkene and 
alkyne functionalities in the presence of nitriles127,128, however no equivalent 
examples that permitted chemoselective benzyl group hydrogenolysis were found. 
Alternative conditions for this transformation such as oxidative debenzylation 
(NaBrO3/Na2S2O4)129 could not be attempted due to time constraints, and should be 





3.1.5 Synthesis of 6-azido-6-deoxy-α-D-mannopyranosyl phosphate  
Literature precedent  
For the purposes of our structure-function investigation, we wished to exploit the 
azido group to explore substrate specificity of GMD. Previous work by Marchesan 
et al. described the synthesis of a series of GDP-azido-mannose analogues to probe 
ManT activity.96 In their synthesis of GDP-6-azido-6-deoxy-mannose 91, the 
phosphate group was installed via a P(III) reagent, diallyl diisopropyl 
phosphoramidite upon reaction with hemiacetal 117, which was oxidised to the 
corresponding P(V) species using 3-chloroperbenzoic acid (mCPBA). Deprotection 
was achieved using tetrakis(triphenylphosphine) palladium followed by 
Et3N/MeOH/H2O, affording 119 in an overall yield of 33%. Transformation to the 
corresponding GDP-sugar 91 was afforded using GDP-ManPP from Salmonella 
enterica in 63% yield (Scheme 3.16). 
 




A new synthetic strategy towards 6-azido-6-deoxy mannopyranosyl phosphate 119 
was devised from accessible alcohol 66 (Scheme 3.17) with the view of installing 
the phosphate moiety via the recently optimised MacDonald phosphorylation 
procedure. Alcohol 66 was first converted to a bromide using Appel halogenation 
conditions (PPh3 and CBr4), proceeding in a good yield of 74%. The characteristic 
C6-Br resonance could be observed at δC 30.3 ppm, an upfield shift in comparison 
to alcohol 66 (δC 61.4 ppm).  
 
Scheme 3.17: Attempted synthesis of 120 via displacement of C6-bromide 98. 
Problems arose during displacement of 98 with NaN3 in the presence of 
tetrabutylammonium iodide (TBAI). Despite being heated at elevated temperatures 
for up to 48 h, the reaction did not reach completion, with monitoring of the reaction 
difficult due to the almost indistinguishable Rf values of 98 and 120 in several solvent 
systems, which made purification difficult. NMR analysis of isolated fractions from 
column chromatography revealed three products: unreacted 98, C6-N3 120 and an 
unidentified sugar, that may have corresponded to the C6-I counterpart of 66. 
Alternative reaction conditions including reducing the equivalents and complete 
removal of TBAI were attempted. In both instances despite heating and reaction 
times of 72 h, incomplete conversion of 98 was observed, and the resultant mixture 





Next, the literature procedure was attempted, which utilised a tosylate leaving group 
for azide introduction (Scheme 3.18). Reaction of 66 with para-toluenesulfonyl 
chloride (pTsCl) in pyridine afforded 121 in an excellent yield of 93%. Unfortunately, 
displacement of the active sulfonyl ester with NaN3 in DMF was initially 
unsuccessful, with minimal conversion to 120 observed despite long reaction times 
of up to 72 h and heating up to 40 °C (< 25% yield from crude NMR). 
 
Scheme 3.18: Synthesis of 120 via displacement of tosylate 121. 
Consultation of literature for alternative conditions suggested the use of 15-crown-5 
ether during azide formation.130 The reaction was repeated at 60 °C in the presence 
of 15-crown-5 ether, in the hope of increasing the nucleophilicity of the azide ion 
through complexation of the sodium counterion. After 15 h, it appeared that most of 
121 had been consumed, and isolation of the major product following column 
chromatography revealed the desired compound 120 but in a low yield of 29%.  
Next, the solvent was changed to MeCN, to evaluate any differences in solubility or 
isolated yield. After stirring for 24 h at 60 °C, TLC analysis showed clear formation 
of a new Rf value spot and unreacted starting material. Pleasingly, no other products 
were isolated following column chromatography unlike in previous experiments. 
Whilst the isolated yield of 120 was only improved by 3%, the material was obtained 




resonance identified at δC 50.8 ppm. This was further supported by HRMS data, 
showing the major ion at m/z 396.1039 corresponding to [120+Na]+. 
C6-N3 120 was subjected to MacDonald phosphorylation at 50 °C, as shown in 
Scheme 3.19. After stirring gently for 4 h, TLC analysis indicated formation of a 
baseline Rf value spot. Following saponification and work-up, the crude residue was 
applied to a SAX column affording the desired glycosyl 1-phosphate 119 as a white 
powder in 65% yield. 
 
Scheme 3.19: Synthesis of 119 by MacDonald phosphorylation. 
The resultant 1H and 13C NMR spectra were difficult to interpret, as the ring protons 
had similar chemical shifts resulting in a series of multiplets that could not be 
characterised fully. These observations however did mirror those of previously 
observed data96, and any attempted polishing of the sample, initially by repeated 
SAX chromatography followed by C18 chromatography, did not improve resolution. 
The anomeric proton was identified at δH 5.07 ppm, alongside the 31P resonance at 
δP 1.4 ppm, with the characteristic JH1-P of 8.4 Hz observed. Confirmation of the 
structure was further supported by HRMS analysis, which found the ion at m/z 
284.0288 corresponding to [119-H]– as the major peak. This analogue was evaluated 




3.1.6 Synthesis of 6-deoxy-6-thio-α-D-mannopyranosyl phosphate 
Literature precedent and proposed mechanism of action 
The final analogue discussed in this chapter, GDP-6-deoxy-6-thio-mannose 92, was 
designed to investigate the potential formation of a covalent bond between the thiol 
and Cys268 of GMD to form a disulphide adduct via oxidation (Scheme 3.20).  
 
Scheme 3.20: Proposed reaction of Cys268 with 92 to form a disulphide adduct via 
oxidation. 
This transformation would potentially prevent further turnover of GDP-ManA 4 as the 
key residue mediating this oxidation would be unavailable. The oxidation potential 
of a thiol in the active site of GMD is unknown, however disulphide probes to explore 
biosynthetic enzymes have been reported in the literature. An example is the 
synthesis of a 2-thiopyridyl containing UDP-3-deoxy-3-thio-galactose analogue used 
to probe the active site of β-1,4-galactosyltransferase which is involved in the 





Attempted synthesis of 6-Deoxy-6-thio-mannopyranosyl phosphate 
The strategy towards 6-Deoxy-6-thio-mannopyranosyl phosphate 122 was designed 
from per-O-acetylated starting materials as benzyl protected derivatives might have 
been incompatible during final deprotection stages, due to poisoning of palladium 
catalysts by sulphur.    
Common leaving groups employed in the literature for the installation of the 
thioacetate moiety include tosylate or bromide.126,132 Owing to the material available 
at the time of synthesis, 96 was reacted with potassium thioacetate (KSAc) at 
elevated temperature (75 °C) in DMF. This successfully furnished protected C6-
thioacetate derivative 123 in an excellent yield of 88% (Scheme 3.21).  
 






Comparison of literature NMR data for the 6-deoxy-6-thio-glucose counterpart 
supported the NMR assignment of 123, with key resonances identified at δH 2.32 
ppm, corresponding to the diagnostic C(O)CH3 of the thioacetate group and δC 194.9 
ppm for the thioacetate C=O.133  
With precursor 123 in hand, MacDonald phosphorylation was attempted at 40 °C. 
The reaction mixture was stirred gently for 5 h in total, forming a dark orange melt. 
TLC analysis indicated partial conversion of starting material to a baseline Rf value 
spot and as no further conversion was evident the mixture was saponified with 1M 
LiOH for 48 h. Following work-up and purification, two fractions were isolated, one 
corresponding to the hemiacetal and the other presumed to be 122.  
Initial 1H NMR analysis of the latter fraction showed a mixture of a minimum of two 
products: anomeric resonances were identified at δH 5.34 and 5.16 ppm in a 2.5:1 
ratio (shown in Figure 3.7) alongside corresponding resonances at δP 0.9 and 0.4 
ppm in the 31P spectrum. Analysis by HRMS identified two major ions at m/z 
548.9910 and 469.0239. The first ion corresponded to disulphide [124–H]–, whilst 
the lower m/z ion correlated to the formation of a mixed disulphide containing 122 
linked to the corresponding hemiacetal to afford [125–H]–. 
Theoretically, as SAX separates analytes based upon overall charge, the two 
species would be expected to have different retention times (4– versus 2–, 
respectively), however the homodimerization may occur after purification whilst 
standing in solution or during lyophilisation. This reaction was very low yielding, and 






Figure 3.7: 400 MHz 1H NMR spectrum of MacDonald phosphorylation of 122, 
showing 2 anomeric resonances and proposed structures of 124 and 125. 
The reaction was repeated on the same scale using the same procedure, where 
following SAX chromatography, 30 mg of the disulphide mixture was isolated, an 
improvement of 40%. As more material was available, the mixture was treated with 






Scheme 3.22: Attempted reduction of disulphides using TCEP. 
After stirring 124 and 125 with TCEP in H2O for 6 h, the crude mixture was applied 
immediately to a SAX column and eluted with H2O and 1M NH4HCO3 in a bid to 
isolate pure glycosyl 1-phosphate 122 opposed to a mixture of disulphides isolated 
in the previous attempt. Regrettably, this procedure did not lead to the isolation of 
pure 122 and no further work to access homogeneous samples of this analogue 
could be completed due to time constraints. The disulphide mixture was evaluated 






3.2 C4-modified GDP-Man analogues 
3.2.1 Biological rationale 
The next series of analogues were modified at the C4-position of mannose, 
producing tools to evaluate the substrate specificity of GMD. Retaining the C6-OH 
group maintains the possibility of oxidation of these analogues by GMD, if accepted 
as substrates by the enzyme. If this were observed, evaluation of differences in 
respective rates of oxidation may identify potential competitive inhibitors of GMD. 
3.2.2 Synthesis of 4-deoxy-4-fluoro-α-D-mannopyranosyl phosphate 
Literature precedent and proposed mechanism of action 
The introduction of fluorine to bioactive compounds is well documented in both 
medicinal chemistry and chemical biology. As the addition of fluorine does not result 
in a significant change from a steric perspective, interactions with enzyme active 
sites or receptor recognition sites are still possible. The greater electronegativity of 
fluorine, however, has the potential to notably alter biological responses.134   
As previously discussed, the use of fluorine-containing NDP-sugars as probes is 
common in the literature. Liu et al. reported the chemical synthesis of UDP-5-fluoro-
Gal 57 to study the mechanism of action of UGM135 and additionally, Schultz et al. 
published a chemoenzymatic synthesis of UDP-4-fluoro-Glc-NAc 126 and UDP-4-
fluoro-Gal-NAc 127 (Figure 3.8) for their evaluation as chain terminators in 





Figure 3.8: Chemical structures of fluorinated UDP-sugars 57, 126 and 127 used 
as probes in chemical biology applications. 
Given their importance in the elucidation of biochemical mechanisms, the novel 
sugar-nucleotide GDP-4-deoxy-4-fluoro-mannose 128 was chosen as a target, with 
a view to investigate binding potential and any electronic effects on the rate of 
oxidation (Scheme 3.23). 
 
Scheme 3.23: Overview of proposed GMD catalysed oxidation of 128. 
Furthermore, if shown to be a substrate of GMD, this tool may be useful in the 
investigation of other areas of the alginate biosynthetic pathway such as 
polymerisation. In this application, if oxidised by GMD, the product GDP-4-deoxy-4-
fluoro-ManA 129 may act as a chain terminator and prevent alginate polymerisation 





Synthesis of 4-fluoro-mannopyranosyl derivatives: 6-O-benzoyl series 
The synthetic strategy towards 4-deoxy-4-fluoro-α-D-mannopyranosyl phosphate 
130 was derived from tetra-ol 109, synthesised previously in this chapter (Scheme 
3.24).  
 
Scheme 3.24: Synthesis of C6-O-Bz building block 134. 
Formation of a benzylidene acetal at the C4 and C6 positions afforded 131 in 62% 
yield, which was subsequently benzylated using BnBr and NaH. Cleavage of the 
acetal was induced by pTsOH, before the C6-position was selectively benzoylated 
with benzoyl chloride (BzCl) in the presence of 4-dimethylaminopyridine (DMAP) to 
afford 134 in 88% yield.  
Introduction of the C4-fluoro was performed using  the nucleophilic fluorinating 
reagent diethylaminosulphur trifluoride (DAST) which had been reported in the 
literature for the synthesis of related compound 135.136 The proposed mechanism 
proceeds via an O-benzylated oxirane intermediate that can be opened to afford 





Scheme 3.25: Proposed mechanism for C4-fluorination of 135 using DAST to 
produce 136 and 137 via an oxirane intermediate. 
Initially, 134 was treated with 3.0 equivalents of DAST (Scheme 3.26). The reaction 
was stirred for 18 h at RT, whereby TLC analysis indicated complete conversion of 
134 into a higher Rf value spot and two other minor spots, all of which were close in 
Rf.  
 





Purification by column chromatography successfully separated this mixture, 
however following NMR analysis it was revealed that the higher Rf value spot still 
contained a mixture of both D-manno- and D-ido-configured products 138 and 139. 
Separation of the regioisomers was attempted, however this was not successful 
despite evaluation of a range of solvent systems (hexane/Et2O and Tol/acetone), 
and the crude mixture of regioisomers was isolated in a disappointing yield of 14%.  
A literature procedure using 8.0 equivalents of DAST was attempted with a view to 
improving reaction yield. The reaction was complete by TLC within 18 h, however 
column chromatography was again unsuccessful in the separation of the 
regioisomers. Adoption of this procedure did however result in a modest yield 
improvement to 26%. 
Given the difficulty in purification, the mixture of regioisomers was subjected to 
glycosylation with DBP under NIS/AgOTf activation conditions. Unlike in previous 
glycosylation reactions, this analogue required stirring at RT for 18 h to ensure 
complete conversion of 138/139, likely attributed to the electron-withdrawing nature 
of the C4-fluoro group reducing anomeric reactivity.  
Following work-up and column chromatography, characterisation of 140 by 1H NMR 
confirmed the desired D-manno-configuration through observation of an apparent 
triplet with a JH3-H4 of 9.3 Hz, supporting the trans di-axial relationship between these 
protons (see Figure 3.9). Furthermore, the JH4-F was calculated as 52.0 Hz, and a 
doublet at δF –202.9 ppm in the 19F spectrum showed a JC4-F of 179 Hz. A resonance 






Figure 3.9: Tree diagram showing splitting of H4 and 400 MHz 1H NMR spectrum 







Next, deprotection of 140 was attempted using a mixture of EtOH/THF and NaHCO3 
(5% aq. solution) as reaction solvents (Scheme 3.27). After stirring for 24 h, the 
reaction was still incomplete by TLC, and the solvent was exchanged for MeOH/H2O 
with NaHCO3 (5% aq. solution) and hydrogenolysis continued for 36 h. NMR 
analysis confirmed that all benzyl groups had been removed, by the absence of the 
diagnostic CH2Ph resonances by HSQC-DEPT analysis, yielding 141. 
Unfortunately, saponification was challenging, and several conditions were 
attempted (Scheme 3.27). In all instances, benzoate cleavage was not observed 
despite addition of multiple equivalents of base and stirring for several days. 
Cleavage of the benzoate group was also attempted prior to hydrogenolysis; 
however this was also unsuccessful and no further conditions were screened to 
access 130 via this C6-O-Bz series of derivatives. 
 




Synthesis of 4-fluoro-mannopyranosyl derivatives: 6-O-benzyl series 
Given the difficulty in benzoate removal encountered, precursor 132 was returned 
to. Conditions were adopted to selectively open the benzylidene acetal to give the 
C6-O-Bn and C4-OH configured product 142, with a view to permitting simultaneous 
hydrogenolysis of the benzyl ethers in one step, as illustrated in Scheme 3.28.  
 
Scheme 3.28: Synthesis of modified glycosyl 1-phosphate 130. 
I2/sodium cyanoborohydride (NaBH3CN) mediated reductive ring opening was 
reported to have high regioselectivity (> 95%) for the desired C6-OBn product in the 
literature.137,138 Unfortunately, these conditions gave rise to mostly benzylidene 
cleavage and 142 was only isolated in 10% yield. Alternative conditions of 
dimethylethylsilane (Me2EtSiH) (5.0 equivalents) and BF3•OEt2 (2.0 equivalents) 




improved yield of 41%, however a significant amount of diol 133 (18%) was still 
isolated. To optimise the method, the reaction was repeated with half the equivalents 
of Me2EtSiH (2.5 equivalents) and BF3•OEt2 (1.0 equivalents). The reaction was 
complete within 1 h, and the yield of 142 improved to 50%. 
With compound 142 in hand, DAST fluorination afforded a mixture of inseparable 
regioisomers 143 and 144, however the crude yield was improved by 11% in 
comparison to the equivalent reaction with C6-OBz counterpart 134. Glycosylation 
of DBP with 143/144 using NIS/AgOTf activation conditions afforded 145 in a 
satisfactory yield of 41%.  
In the 1H NMR spectrum of 145, the H4 JH4-F and JH4-H3 couplings were calculated 
as 52.0 and 9.3 Hz respectively, although this resonance was significantly 
overlapped by -CH2Ph protons. In the 19F NMR spectrum, a doublet of doublets 
resonating at δF –202.5 ppm revealed a JH4-F of 52.0 Hz and JH3-F of 12.7 Hz (Figure 
3.10). Additional data revealed a JC4-F of 179 Hz, and the dibenzyl phosphate 
resonated at δP –2.8 ppm, which agreed with spectroscopic data obtained for 








Figure 3.10: 376 MHz 19F spectrum of 145. 
Finally, protected glycosyl 1-phosphate 145 was dissolved in EtOH/THF (2:1) with 
Pd/C and Pd(OH)2/C and placed under a positive pressure of H2. After stirring 
vigorously for 20 h at RT, TLC analysis indicated that deprotection was complete. 
Standard purification afforded target glycosyl 1-phosphate 130 as a white solid in 
85% yield. 19F NMR analysis confirmed the structure of the product, with a doublet 
of doublets resonating at δF –205.3 ppm (JH4-F = 52.0 Hz, JH3-F = 13.3) identified. 
This was further supported by 31P NMR (δP –2.2 ppm) and HRMS data, where m/z 
261.0182 was identified, corresponding to [130−H]−. This analogue was evaluated 




3.2.3 Studies towards the synthesis of 4-deoxy-α-D-manno-hex-4-eno-1,5-
pyranosyl phosphate 
Literature precedent  
The final target in this category designed to probe GMD substrate specificity featured 
a double bond between the C4 and C5 positions of mannose, creating a 4,5-
unsaturated system (Figure 3.11). This analogue could be used investigate binding 
within the active site of GMD, as it would be expected to adopt an alternative 
conformation to a 4C1 chair. As oxidation of 146 would produce a conjugated system, 
it would be interesting to evaluate the rate of this transformation if accepted as a 
substrate. Furthermore, it would be of interest to explore 149 as a potential chain 
terminator of alginate production by inhibition of polymerisation. 
 
Figure 3.11: Chemical structures of alkene containing GDP-Man analogue 146. 
Anomeric acetate series 
The route towards this analogue was derived from alcohol 66, as shown in Scheme 
3.29. As used in studies towards the synthesis of C6-nitrile containing analogues, 
DMP mediated oxidation afforded aldehyde 103 in 84% yield. Elimination of the C4-
acetate was successfully induced by the addition of Et3N, where upon stirring for 2 
h at RT, compound 147 was isolated in 63% yield. The structure was confirmed by 




shifts of C4 and C5 could also be easily identified at δC 114.3 and 150.2 ppm, 
respectively, lying within the expected region for an alkene.  
 
Scheme 3.29: Synthesis of protected 4,5-unsaturated analogues 149 and 150. 
This step proceeds via an E1cB mechanism, with the acidic H5 proton of 103 easily 
removed by Et3N as it can be stabilised by conjugation into the carbonyl. Following 
a conformational change to a 1C4 chair, elimination of the C4-acetate affords 
derivative 147, as shown in Scheme 3.30. 
 
Scheme 3.30: Formation of 147 via an E1cB reaction. 
Following elimination of the C4-acetate, sodium borohydride (NaBH4) mediated 




confirmed by NMR, through disappearance of the aldehyde proton at δH 9.29 ppm 
and replacement by a multiplet at δH 4.07 ppm integrating for 2H, corresponding to 
H6 and H6’. The desired reduction product was only isolated in 52% yield, therefore 
Luche reduction conditions were evaluated.139,140 In this procedure, cerium 
trichloride heptahydrate (CeCl3•7H2O) acts as a Lewis acid catalyst to generate 
methoxyborohydride in-situ, outlined in Scheme 3.31. This species is a harder 
reducing agent than NaBH4, therefore would have greater selectivity towards the 
harder 1,2-addition site in accordance to hard soft acid base (HSAB) theory.  
 
Scheme 3.31: Summary of Luche reduction conditions. 
Unfortunately, in both reduction attempts using these conditions, the isolated yields 
were further reduced to 41 and 10%, hence the original conditions were used. 
Finally, allylic alcohol 148 was protected with two different protecting groups: tert-
Butyldimethylsilyl (TBDMS) and benzoyl. Each structure was confirmed by NMR, 
where for 149 five new resonances were identified at δC 25.9, 25.8 and 25.6 ppm (-
SiC(CH3)3), 18.3 ppm (-SiC(CH3)3) and –5.4 ppm (2 × -SiCH3). For 150, a new 




Attempted synthesis of a glycosyl donor 
Next, synthesis of a suitable glycosyl donor was attempted using PhSH in the 
presence of two different Lewis acids (Scheme 3.32). 
 
Scheme 3.32: Attempted synthesis of thioglycoside donors 151 and 152. 
In a first attempted synthesis of thioglycoside 151 from 149, TMSOTf was used but 
1H NMR analysis of the isolated product showed absence of the singlet at δH 0.83 
ppm, confirming an undesired cleavage of the 6-O-TBDMS group. Use of BF3•OEt2 
was also evaluated, where after 1.5 h TLC analysis showed that the starting material 
had been consumed. However, akin to the previous reaction, the major product 
showed no resonance at δH 0.83 ppm indicating an undesired silyl group cleavage.  
Next, glycosylation of PhSH with 150 was performed using BF3•OEt2 and TMSOTf 
activation on small scale (~ 50 mg). Unfortunately, TLC analysis did not show any 
conversion of starting material in either reaction, and this was the only material 
identified by NMR, with no upfield shift of the anomeric proton observed (previously 
δH 6.40 ppm in 150). The experiments were repeated on larger scales (~ 100 mg), 
however no change to the anomeric proton/carbon chemical shifts were observed in 




As thioglycoside synthesis was unsuccessful, both substrates were screened 
against anomeric acetate removal conditions towards the synthesis of a 
trichloroacetimidate donor (Scheme 3.33). In the case of 6-O-TBDMS protected 
derivative 149, the reagent scope was limited due to its acid sensitivity, however 
more conditions could be trialled on 6-O-Bz compound 150. The results of the 
attempted transformations are summarised in Table 3.4. 
 
Scheme 3.33: Attempted synthesis of hemiacetals 153 and 154. 
Substrate Entry Reagent Time (h) Result 
6-O-TBDMS 
149 
1 Hydrazine acetate 24 No conversion 
2 BnNH2 24 No conversion 
6-O-Bz 
150 
3 Hydrazine acetate 24 No conversion 
4 EDA/AcOH 24 No conversion 
5 BnNH2 24 No conversion 
6 Nd(OTf)3 36 No conversion 
 
Table 3.4: Summary of conditions attempted for anomeric acetate removal. 
Hydrazine acetate and EDA/AcOH, both evaluated previously in Chapter 2.1.1, 
failed to remove the anomeric acetate on either substrate (Table 3.4, Entries 1, 3 
and 4). Anomeric acetate removal of 149 and 150 was also unsuccessful using 
BnNH2141, confirmed by NMR analysis (Table 3.4, Entries 2 and 5). Further literature 




acetate removal. Tran et al.142 reported optimum results when using 5% mol 
Nd(OTf)3, however adoption of this procedure did not result in conversion of 150. In 
the second attempt, up to 50 mol% of catalyst was added, however no conversion 
of 150 was observed after 30 h. In a final attempt to induce conversion, 1.0 
equivalent of Nd(OTf)3 was added and heated at 50 °C overnight. Once again, no 
conversion of 153 was observed by TLC and the starting material was recovered 
(Table 3.4, Entry 6). Given the failure to synthesise desired hemiacetal 154 to 
produce a handle for further functionalisation, this route was abandoned. 
As the anomeric acetate could not be cleaved, the strategy was changed to evaluate 
synthesis of a glycosyl bromide, previously employed by Schultz et al.101 Use of 
phosphorus tribromide (PBr3)/H2O in DCM was first attempted on per-O-acetylated 
mannopyranose 14 (Scheme 3.34) to confirm reproducibility of the procedure. 1H 
NMR data of the isolated compound matched reported values, with successful 
formation of the α-anomer confirmed by the small vicinal JH1-H2 of 1.3 Hz.143  
 
Scheme 3.34: Synthesis of glycosyl bromide 155 using PBr3 and H2O. 
The procedure was then performed on 150 (Scheme 3.35), where within 3 h, 
complete conversion of starting material to two new Rf value spots was observed by 
TLC. Crude 1H NMR analysis showed three products in a ratio of 1.0:0.4:0.2. The 
major product was confirmed as an undesired C5-Br product 156 (δH 6.30 ppm). 




δH 2.0-2.5 ppm, consistent with a change in hybridisation from sp2 to sp3 following 
addition of HBr. The minor product was desired glycosyl bromide 157 (δH 6.49 ppm) 
and the remaining material was unreacted 150 (δH 6.40 ppm). 
 
Scheme 3.35: Attempted synthesis of 157 from protected allylic alcohol 150. The 
major product of the reaction was 156. 
The proposed mechanisms for the formation of these products are shown in Scheme 
3.36, where following in-situ generation of HBr, two competing pathways are 
presented. In pathway (a), C5-Br compound 156 is produced following competing 
addition of HBr to the double bond whereas in pathway (b) minor product 157 is 
generated through glycosylation of bromide at the anomeric centre. 
 




Also common for the synthesis of glycosyl bromides, the reaction of 150 with 
HBr/AcOH in DCM at 0 °C was complete within 1 h. NMR analysis showed the same 
resonances observed in the previous attempt using PBr3/H2O, however the ratio of 
C5-Br product 156 to glycosyl bromide 157 was 1.0:0.2. Given that this method 
showed high selectivity for production of 156, these conditions were not repeated. A 
comparison of 1H NMR spectra of both conditions attempted for this transformation 
is shown in Figure 3.12. 
Attempted modifications of the PBr3/H2O procedure to favour formation of 157 were 
unsuccessful. The reaction was performed with half the equivalents of H2O (3.0 
equiv. instead of 6.0 equivalents), then repeated and held at 0 °C for the duration. 
Within 1.5 h, 150 was completely consumed in both instances and NMR analysis of 
the product revealed that the major product was the undesired C5-Br product 156, 
and little improvement to the ratio was observed (1.0:0.3). No further optimisation of 








Figure 3.12: Comparative 400 MHz 1H NMR spectra of attempted syntheses of 
157, showing variable ratios of 150:167:156. 
  
Method 1: PBr3/H2O in DCM 





Next, compound 158 was prepared from allylic alcohol 148 for evaluation against 
the recently optimised MacDonald phosphorylation procedure (Scheme 3.37).  
 
Scheme 3.37: Attempted synthesis of 159.  
Following preparation of the reaction mixture (50 mg scale) in a glove box, the 
Schlenk tube was heated at 60 °C under vacuum and a dark brown melt was 
afforded after 1.5 h. TLC analysis showed partial conversion of 158 to a lower Rf 
value spot. Following work-up and purification by SAX chromatography, analysis by 
31P NMR showed one resonance at δP 2.6 ppm, with a corresponding JH1-P of 8.0 
Hz. It was noted that the 1H spectrum was unusually messy compared to spectra 
obtained for other glycosyl 1-phosphates following SAX chromatography, and only 
the anomeric proton (δH 5.32 ppm) could be assigned. Though appearing promising 
by NMR, subsequent HRMS analysis did not detect any ions correlating to the 
proposed molecular formula, which may indicate limited stability of glycosyl 1-




The procedure was repeated on a larger scale (130 mg) at a reduced temperature 
of 45 °C however formation of the melt was impeded and resulted in a brown/black 
tar after 2 h. Crude NMR data suggested only decomposition of the material, with 
no 31P data successfully obtained. Disappointingly, a final attempt employing the first 
set of reaction conditions (60 °C) also failed to reproduce the first result and no 
further work on this procedure could be completed during the timeframe available.  
Pre-installed anomeric thioglycoside series 
As problems were encountered during installation of a glycosyl donor, the synthetic 
strategy was altered to proceed via a substrate that already contained a pre-installed 
thioglycoside donor, detailed in Scheme 3.38. Tetra-ol 109 was selectively protected 
at the C6-position with a TBDMS group then per-O-acetylated to afford 161 in an 
overall yield of 75% over 2 steps. 
 






The use of fluoride reagents such as tetra-N-butylammonium fluoride (TBAF) is the 
most common methodology for the deprotection of silyl ethers.144 This 
transformation is driven by the formation of a strong Si-F bond, that is on average 
30 kcal/mol stronger than that of Si-O, via an SNSi mechanism. Owing to this, 
cleavage of the 6-O-TBDMS group of 161 was attempted using TBAF, but despite 
use of only 1.2 equivalents at 0 °C, formation of multiple products was observed by 
TLC. Separation of the products was achieved by column chromatography, however 
1H NMR analysis confirmed that undesired acetyl cleavage had occurred, with 
absence of three singlets at δH 2.08, 2.02 and 1.98 ppm observed in the 1H NMR 
spectrum. The reaction was repeated with only 0.5 equivalents of TBAF, however 
the same result was observed. Other methods reported in the literature for the 
removal of silyl ethers included catalytic NIS in MeOH and ceric ammonium nitrate 
(CAN) in MeOH, of which both were attempted.145,146 Unfortunately, neither of these 
methods showed any conversion of 161 by TLC.  
With the aim of having increased stability to TBAF, 163 was also synthesised in 74% 
yield (Scheme 3.39), before being subjected to silyl deprotection with TBAF towards 
the synthesis of 164. However, undesired benzoyl cleavage was also observed with 
this substrate.  
 




During a previous reaction, it was observed that 6-O-TBDMS group cleavage 
occurred in the presence of Lewis acids when attempting to form a thioglycoside. 
These conditions were attempted on 161, and 6-O-TBDMS cleavage was 
successfully induced within 1 h using 0.5 equivalents of BF3•OEt2 at 0 °C. The 
desired alcohol 162 was isolated in 75% yield, scaled up to 3.5 g (Scheme 3.40). 
 
Scheme 3.40: Synthesis of acetyl protected thioglycoside donor 168. 
With the desired thioglycoside donor in hand, 162 was oxidised to the corresponding 
aldehyde 165 using DMP and the C4-acetate was eliminated under basic conditions, 
as described previously. Enal 166 was reduced using NaBH4 and protected with an 
acetate at the C6-position to give protected thioglycoside donor 168 available for 
phosphate addition. The structure was confirmed by 1H NMR analysis, where an 
additional resonance corresponding to the acetate group was identified as a singlet 




With donor 168 in hand, the next stage was attempted glycosylation with DBP to 
afford protected glycosyl 1-phosphate 169, as shown in Scheme 3.41. A summary 
of conditions attempted for this transformation can be found in Table 3.5. 
 
Scheme 3.41: Attempted synthesis of protected glycosyl 1-phosphate 169. 
Entry Activation conditions (equiv.) Scale (mg) Time (h) 
1 NIS (1.5), AgOTf (1.5) 68 2 
2 NIS (1.5), AgOTf (1.5) 230 1 
3 PhIO (1.2), TMSOTf (0.4) 95 1 
4 TTBP (2.5), Ph2SO (1.3), Tf2O (1.3) 95 1.5 
 
Table 3.5: Summary of conditions attempted for the synthesis of 169. 
Synthesis of 169 was initially attempted using NIS/AgOTf activation conditions 
(Table 3.5, Entry 1). TLC analysis appeared to show conversion of 168 to a baseline 
Rf value spot within 2 h at –10 °C, however isolation of this compound proved difficult 
as the compound did not stain well with H2SO4/MeOH and was only weakly UV 
visible. Following column chromatography, two sets of fractions were isolated 
however only 15 mg of material was collected. 1H and 31P NMR analysis of the 
fractions confirmed that multiple products were present, with two resonances 
observed at δP –2.5 and –2.7 ppm in the 31P spectrum.  
This suggested formation of an anomeric mixture, or the possibility of addition of the 




(Table 3.5, Entry 2) but the reaction was sluggish requiring a temperature of 10 °C 
to initiate conversion of 168. After stirring for 4 h, the reaction mixture was quenched 
and purified. Analysis of the material by NMR corresponded to previously obtained 
data, and regrettably it could not be established if addition was occurring at a 
different position as the product(s) formed were unstable, rapidly decomposing to 
form black oils. 
Wakao et al. reported the use of iodosobenzene (PhIO) and TMSOTf as a promoter 
system for the chemoselective activation of thioglycosides in the presence of allyl 
glycosides.147 PhIO 170 was easily prepared by treatment of BAIB with 3M NaOH, 
illustrated in Scheme 3.42. The resultant solid was dried in a desiccator overnight 
over P2O5 to remove H2O.  
 
Scheme 3.42: Preparation of PhIO 170 from BAIB and NaOH (3M). 
To a solution of 168 was added sequentially DBP and freshly dried PhIO 170 (Table 
3.5, Entry 3). After stirring for 1 h, the solution was cooled to –30 °C and TMSOTf 
was added dropwise. After stirring at this temperature for 30 min, TLC analysis 
indicated conversion of 168 to at least two lower Rf value spots. The reaction mixture 
was warmed to –15 °C, and after 1 h the reaction was deemed complete.  
Attempted isolation of the products by chromatography was once again 




still contained at least two products, neither of which corresponded to the starting 
material. However, 31P analysis only showed one resonance at δP –0.9 ppm which 
neither corresponds to dibenzyl phosphate or an anomeric dibenzyl phosphate 
(typically observed between δP –3.0 and –4.0 ppm in previous analogues).   
Finally, conditions reported by Crich et al.148 were attempted. 168 was pre-activated 
with 2,4,6-Tri-tert-butylpyrimidine (TTBP) and diphenyl sulphoxide (Ph2SO) for 1 h, 
cooled to –78 °C and Tf2O added dropwise. DBP was then added and the reaction 
mixture was stirred for 1.5 h. The reaction mixture was quenched and concentrated 
in vacuo before being columned immediately. Once again, 1H NMR analysis 
revealed several products however 31P NMR analysis could not be obtained in this 
attempt and the material quickly decomposed. No further attempts to access 169 
were performed using donor 168. 
Conclusions 
Installation of an endocyclic 4,5-double bond was shown to dramatically alter the 
anomeric reactivity of the analogues investigated. Attempted removal of the 
anomeric acetate and thioglycoside donor synthesis both failed, and anomeric 
reactivity was only observed under strong Brønsted acid conditions. However, the 
desired glycosyl bromide 157 was still only a minor product of this reaction and the 
major product was determined as C5-bromo analogue 159. The reactivity of these 
derivatives was comparable to glycals (1,2-unsaturated sugars) which are excellent 
glycosyl donors, and readily undergo electrophilic addition across the double bond 





Figure 3.13: Reactivity comparison between 4,5- and 1,2-unsaturated sugars. 
Results obtained using the pre-installed thioglycoside series of analogues afforded 
mixtures of products, consistent with the varying methods of reactivity presented by 
the installation of a 4,5-double bond. Unfortunately, characterisation of the products 
formed was impossible as decomposition was observed in all attempts. MacDonald 
phosphorylation was the most promising method towards synthesis of 159, but 
regrettably the results obtained from the first attempt could not be reproduced in the 





3.3 Active site intermediate analogues 
3.3.1 Biological rationale 
The next series of analogues were designed as active site intermediates with the 
potential to be oxidised by GMD, by the mechanism previously described in Chapter 
1.3.2, recapped in Scheme 3.43.  
 
Scheme 3.43: Proposed mechanism of GMD catalysed oxidation of GDP-Man 3 to 
GDP-ManA 4.66 
Members of this category of tools were structurally similar to the native substrate 
and product of GMD. It was hoped that these analogues may provide information 
regarding key binding requirements within the active site, or potentially provide 
interesting kinetic data surrounding the rate of oxidation of these analogues if they 
are accepted as substrates of GMD. If the latter is observed, then these analogues 




Literature precedent and proposed mechanism of action 
The use of amine-containing probes for structure-function investigations is not well 
documented in the literature. However, incorporation of a 1º or 2º amine functionality 
into a sugar-nucleotide probe to afford GDP-6-amino-6-deoxy-mannose 171 and 
GDP-6-deoxy-6-methoxyamino-mannose 172 (Figure 3.14) would be useful to 
explore the mechanism of action. 
 
Figure 3.14: Chemical structures of GDP-Man analogues 171 and 172. 
Evaluation of 171 and 172 as substrates of GMD could provide new information 
regarding this putative oxidation step, where if the analogues were accepted 
formation of imine or oxime intermediates may be possible. The oxidation potentials 
of C-O to C=O and C-N to C=N are different, with C-N to C=N expected to be 
slower.150 Nevertheless, formation of such Schiff bases as intermediates in enzyme 
mechanisms is well documented in the literature, with examples including QueF, a 
nitrile reductase, and N-acetylneuraminate lyase.151–153  
This study would provide useful information about substrate binding in the active site 
of GMD, in addition to the possibility of the analogues acting as inhibitors to reduce 






Scheme 3.44: Proposed mechanism of GMD mediated oxidation of 171 or 172 to 






3.3.2 Synthesis of 6-amino-6-deoxy-α-D-mannopyranosyl phosphate  
The route towards glycosyl 1-phosphate 174 was designed from building block 112, 
as shown in Scheme 3.45. Alcohol 112 was successfully converted to a bromide 
using Appel halogenation conditions (PPh3 and CBr4), which was subsequently 
displaced with NaN3 at elevated temperature (75 °C). Conversion from a bromide to 
an azide could be easily confirmed by 13C NMR, with the C6 carbon shifting 
significantly downfield from δC 33.4 ppm to δC 51.6 ppm. 
 
Scheme 3.45: Synthesis of 174. 
Following this, DBP was glycosylated with C6-azide 176 using NIS/AgOTf activation 
conditions, which proceeded in a good yield of 65%. Presence of the dibenzyl 
phosphate was confirmed by NMR analysis, with a resonance at δP –2.8 ppm 
observed in the 31P NMR spectrum and a JH1-P coupling constant of 6.1 Hz. 
The final step was deprotection of protected glycosyl 1-phosphate 177 by 
hydrogenolysis using Pd/C and Pd(OH)2/C catalysis. The first attempt was 
performed in EtOH/THF (2:1) with 1.0 equivalent of 0.1 M HCl, to minimise 




After stirring for 18 h, TLC analysis (MeCN/H2O, 3:1) indicated conversion of starting 
material to a lower Rf value spot. However, following work-up and HSQC-DEPT 
analysis, the presence of 3 benzyl groups could still be observed. The reaction 
solvent was changed to MeOH/H2O (2:1) and hydrogenolysis continued, however 
no further conversion was observed by TLC. The catalyst and solvent were changed 
once again however the reaction still did reach completion. The 1H NMR spectrum 
was now difficult to interpret due to a messy baseline, indicating that the material 
was beginning to decompose. 
At this time, other members of the research group were experiencing similar issues 
surrounding incomplete hydrogenolysis when using Pd(OH)2/C. Therefore, the 
catalyst was exchanged for a new batch. The reaction was performed akin to the 
first attempt, except for addition of 1.2 equivalents of 0.1 M HCl opposed to 1.0 
equivalent. The reaction mixture was stirred for 15 h, where TLC analysis 
(MeCN/H2O, 3:1) showed conversion of starting material to a baseline Rf value spot. 
Following work-up, NMR analysis indicated full hydrogenolysis had been successful, 
affording 174 as the disodium salt in 90% yield. The anomeric proton at δH 5.42 ppm 
displayed a JH1-P of 5.6 Hz and HRMS analysis found [174–H]– as the major ion at 
m/z 258.0388 compared to the theoretical m/z of 258.0378. This analogue was 





3.3.3 Studies towards the synthesis of 6-deoxy-6-methoxyamino-α-D-
mannopyranosyl phosphate  
The route towards a C6-methoxyamine functionalised analogue was devised from 
112, and the initial route proceeded via formation of a triflate and displacement with 
methoxyamine hydrochloride (MeONH2•HCl) in the presence of pyridine (Scheme 
3.46).   
 
Scheme 3.46: Attempted synthesis of C6-methoxyamine functionalised donor 179 
via displacement of a C6-triflate. 
Reaction of 112 with Tf2O in the presence of pyridine at 0 ºC afforded triflate 178 
which was used crude in immediate reaction with MeONH2•HCl. The reaction 
mixture was stirred for 18 h, whereupon a new Rf value spot could be observed by 
TLC. Crude NMR analysis of the material did not appear promising, with the 
diagnostic -OCH3 singlet corresponding to the methoxyamine functionality absent 
from the spectrum. Purification by column chromatography only lead to the isolation 
of 7 mg of material (from 290 mg), and the resultant NMR spectrum could not be 





Given the success using a tosylate group in previous syntheses, 180 was prepared 
instead for use in the displacement reaction (Scheme 3.47). However, upon stirring 
for 18 h at elevated temperature (up to 60 °C) with MeONH2•HCl, TLC analysis 
showed that no reaction had taken place and only 112 could be identified.  
 
Scheme 3.47: Attempted synthesis C6-methoxyamine functionalised donor 179 via 
displacement of a C6-tosylate. 
Though requiring additional steps, a new route was designed via an oxime, as 
shown in Scheme 3.48. Accessed via Parikh-Doering oxidation, aldehyde 113 was 
reacted with MeONH2•HCl in the presence of Na2CO3 to form oxime 181. The 
resultant 1H NMR spectra was complex with significant overlap between the ring 
protons making assignment challenging, however a diagnostic singlet 
corresponding to the methoxyamine OCH3 could be identified at δH 3.83 ppm.  
 





In 2006, Peri et al. reported the use of NaBH3CN (5.0 equivalents) in glacial AcOH 
for the reduction of a related substrate in their studies towards the synthesis of novel 
Lipid A antagonists.154 Their procedure was initially attempted using 2.5 equivalents 
of NaCNBH3, however slow formation of a new Rf value spot was observed and the 
remaining 2.5 equivalents were added after 3 hours. After 6 h the reaction mixture 
was concentrated in vacuo, and immediately purified by column chromatography to 
afford desired compound 179 in 42% yield. When the reaction was repeated, 5.0 
equivalents was added from the beginning and stirred for a total of 15 h, resulting in 
a yield improvement to 57%. The desired reduction product could be identified by 
NMR, with new H6 and H6’ protons at 3.38 and 3.02 ppm and presence of the 
methoxyamine OCH3 singlet at δH 3.46 ppm (Figure 3.15). The molecular ion 
corresponding to [179+H]+ was identified at m/z 572.2478, in good agreement with 







Figure 3.15: 400 MHz HSQC-DEPT spectrum of 179, showing H6’, H6 (blue) 





(J = 13.3, 2.5 Hz) 
dd  




Next, DBP was glycosylated with donor 179 (Scheme 3.49) in attempted formation 
of protected glycosyl 1-phosphate 182 on small scale (50 mg). Monitoring of the 
reaction by TLC showed no formation of a new Rf value spot and 6 mg of material 
was isolated, for analysis by 1H and 31P NMR. 
 
Scheme 3.49: Attempted synthesis of 182. 
The 1H spectrum was very noisy, and whilst the -OCH3 of the methoxyamine group 
could still be observed as a singlet at δH 3.88 ppm the anomeric doublet of doublets 
could not be identified. Promisingly, the 31P{1H} spectrum showed a resonance in 
the previously observed region for the dibenzyl phosphate moiety in other 
analogues, at δP –2.8 ppm. However, analysis of the sample by HRMS revealed no 
ion corresponding to the proposed molecular formula. 
The reaction was repeated using the same activation conditions. After stirring for 2 
h at 0 °C, TLC analysis suggested partial conversion to a lower Rf value spot. 
Following work up and purification, NMR analysis was directly comparable to the 
previous attempt. The sample was re-purified, however no improvement in 
resolution of the resultant NMR spectra was observed and the data was of 





The procedure was repeated for a third time on a larger scale (112 mg) where, 
following work-up, the material was submitted for crude NMR analysis. In this 
attempt, 31P{1H} data showed only a singlet at δP –2.8 ppm however the anomeric 
doublet of doublets could still not be observed.  
A competing reaction may occur during attempted synthesis of 182, through attack 
of nitrogen at the anomeric centre of the oxocarbenium ion intermediate to form a 
system comparable to that of 1,6-anhydro sugar, illustrated in Scheme 3.50.  
A similar cyclisation product was observed previously by a member the research 
group during the synthesis of other C6-nitrogen containing building blocks. 
 
Scheme 3.50: Proposed competing mechanism of nitrogen cyclisation. 
Before the reaction is repeated, the amine should be protected to evaluate the 
difference on outcome of the glycosylation reaction. Whilst use of a benzyl group 
would permit simultaneous hydrogenolysis with the benzyl ethers, the removal of 
benzyl amine protecting groups can be challenging and it may be more appropriate 







3.4 Evaluating the substrate specificity of GDP-ManPP: chemoenzymatic synthesis 
of modified GDP-Man analogues 
Enzymatic synthesis of GDP-sugars is well established in the literature, 
predominantly utilising GDP-ManPP from S. enterica. This methodology enables 
facile access to these important precursors, with the enzyme generally displaying 
low substrate specificity, providing scope to synthesise modified GDP-Man 
analogues, crucial to this project.  
Four modified glycosyl 1-phosphates synthesised chemically were evaluated as 
substrates of GDP-ManPP. Two additional glycosyl 1-phosphates, 183 and 184 that 
were synthesised by another member of the research group were also screened 
(see Table 3.6). Assays were performed on small quantities of glycosyl 1-phosphate 
(< 5 mg), which were incubated with GDP-ManPP, inorganic pyrophosphatase 
(iPPase) and guanosine 5’-triphosphate (GTP) in Tris-HCl (pH 8.0) buffer containing 
MgCl2 and dithiothreitol (DTT) (Scheme 3.51). Conversion to the corresponding 
sugar-nucleotide could be easily monitored via SAX chromatography, which saw 






Scheme 3.51: General procedure for enzymatic synthesis of sugar-nucleotide 
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0.5 35 < 5 
 
1.7 27 79 
 
1.3 27 0 
 
Table 3.6: Summary of glycosyl 1-phosphate analogues evaluated as substrates of 
GDP-ManPP. 
Three glycosyl 1-phosphates were accepted as substrates by GDP-ManPP, 
permitting isolation of the respective GDP-Man analogues. 6-azido-6-deoxy-
mannopyranosyl phosphate 119 showed 55% conversion to its corresponding GDP-
sugar 91 after 35 h, and GDP-4-deoxy-4-fluoro-mannose 128 and GDP-6-amido-
mannose 173 were also successfully synthesised from 130 and 183, showing 96 
and 79% conversion after 27 h, respectively (Table 3.7). Each sugar-nucleotide was 
characterised by 1H and 31P NMR and HRMS, with the diagnostic δP resonances for 






Category GDP-Man analogue 
























Table 3.7: Summary of GDP-Man analogues synthesised enzymatically using 
GDP-ManPP. 
The NDP-sugars of the three remaining substrates were unsuccessfully synthesised 
using this protocol. The mixture of disulphide products 124 and 125 were incubated 
under the described conditions for 35 h, hoping that the reducing conditions used 
for the assay would permit isolation of GDP-6-deoxy-6-thio-mannose 92. 
Unfortunately, no conversion to a GDP-sugar was observed by SAX, with only GTP 
and GDP observed.  
C6-amino functionalised glycosyl 1-phosphate 174 was screened against GDP-
ManPP, however after incubation for 35 h minimal conversion to GDP-6-amino-6-
deoxy-mannose 171 (< 5%) was observed. As the buffer used is pH = 8.0, the amine 
would be expected to be protonated (pKa = ~ 11.0) hence this species may exist as 




other GDP-sugars) and theoretically alter the retention time of 174 in SAX 
chromatography which may be misleading during purification. Whilst the buffer pH 
cannot be changed, other possible routes to access this sugar-nucleotide could 
proceed via the reduction of GDP-6-azido-6-deoxy-mannose 91 using the 
Staudinger procedure post sugar-nucleotide synthesis.  
Finally, glycosyl 1-phosphate 184 bearing a C6-hydroxamate functionality was 
screened against GDP-ManPP. Regrettably, no conversion to a GDP-sugar could 
be observed by SAX chromatography; instead, only the products of GTP hydrolysis, 
GMP and GDP could be observed.  
3.4.1 Discussion 
Evaluation of GDP-ManPP substrate specificity towards the modified glycosyl 1-
phosphates synthesised in this chapter presented new findings that supplemented 
prior research efforts in this area by the groups of Macmillan and Lowary.76,96 As 
expected from previous literature, C6-azido functionalised glycosyl 1-phosphate 119 
was a moderate substrate of GDP-ManPP, but 6-amido glycosyl 1-phosphate 183 
was demonstrated to be a good substrate of the enzyme. These results supported 
previous findings that the C6-OH is not required for substrate binding.  
Conversely, the C4-OH was suggested to interact with GDP-ManPP, being tightly 
bound within the active site. Replacement of C4-OH with C4-F in analogue 130 was 
well tolerated by GDP-ManPP, and the highest percentage conversion to GDP-




During this study, it was observed that C6-modified glycosyl 1-phosphates bearing 
positive or negative charges under the described assay conditions (pH = 8.0), C6-
amino 174 and C6-hydroxamate 184 respectively, were both poor substrates of 
GDP-ManPP. This supported earlier findings by another member of the research 
group that showed α-D-mannopyranuronic acid 42, which would also be negatively 






Figure 3.16: Summary of substrate specificity of GDP-ManPP.  

















3.5 Conclusions and Future Directions 
This chapter describes efforts towards the synthesis GDP-Man analogues that were 
designed to probe a nucleophilic Cys268 residue in GMD and are categorised as C6-
modified, C4-modified and active site intermediate analogues.  
The first section detailed synthetic routes towards eight modified glycosyl 1-
phosphates, of which four were successful. Installation of new functionalities to C6-
modified and active site intermediate analogues proceeded via a common C6-OH 
building block, protected with acetyl or benzyl groups. Introduction of an azide was 
afforded by displacement of a tosylate towards the synthesis of glycosyl 1-
phosphate 119 compared to displacement of a chloride with KSAc for the synthesis 
of C6-thio functionalised glycosyl 1-phosphate 122. Synthesis of a C6-amino 
containing glycosyl 1-phosphate 174 was accomplished via successive Appel 
halogenation and azide displacement reactions, whereby simultaneous azide 
reduction and benzyl ether hydrogenolysis then afforded the target compound. An 
alternative protecting group strategy was required to access C4-fluoro functionalised 
glycosyl 1-phosphate 130, and the optimum route proceeded via reductive ring 
opening of a C4-C6 benzylidene acetal to reveal the C4-OH for DAST mediated 
fluorination. Incorporation of the anomeric phosphate group was performed using 
two different strategies. Optimisation of the MacDonald phosphorylation procedure 
proved crucial, permitting access to modified glycosyl 1-phosphates 119 and 122, 
bearing C6-azido and C6-thio functionalities, from acetylated precursors in good 
yields. Synthesis of 122 was complicated by the formation of two disulphides 124 




thioglycoside donors were converted to their corresponding glycosyl 1-phosphates 
through reaction with DBP followed by hydrogenolysis, to afford analogues 130 and 
174, bearing C4-fluoro and C6-amino groups respectively.  
Synthesis of the remaining four glycosyl 1-phosphate analogues was unsuccessful. 
During the synthesis of C6-chloro glycosyl 1-phosphate 95, cyclic compound 97 was 
formed as the major product from MacDonald phosphorylation. Access to 95 could 
next be attempted using benzyl protected derivatives, where during hydrogenolysis 
it would be of interest to evaluate if isolation of 95 is possible and whether formation 
of by-product 97 is observed under the non-acidic conditions used for this 
transformation.  
Despite evaluation of multiple strategies, α-D-mannopyranosylurononitrile 
phosphate 108 was not isolated. Acetyl protected C6-nitrile donors showed poor 
anomeric reactivity, comparable to that of uronate donors discussed in Chapter 
2.1.1. The most promising route proceeded using benzylated derivatives that had 
increased anomeric reactivity, but unfortunately the route failed at the final 
hydrogenolysis step, due to undesired reduction of the nitrile moiety. In future 
experiments, alternative conditions for this transformation such as oxidative 
debenzylation (NaBrO3/Na2S2O4) could be attempted.  
Installation of a protected anomeric phosphate to a C6-methoxyamine donor failed 
and synthesis of protected glycosyl 1-phosphate analogue 182 could not be 
completed. In all attempts, a mixture of products was formed, proposed to arise from 
a competing reaction through the unprotected amine which should be suitably 




The final target 159, containing an endocyclic C4,5-alkene, was also not completed 
during this project. Work towards this analogue was both challenging and time-
consuming, with a range of routes attempted. It was observed that analogues 
bearing this functionality behaved in a similar manner to glycals, with anomeric 
reactivity not observed unless using a strong Brønsted acid. Installation of the 
protected phosphate via a pre-installed thioglycoside donor also failed, with only 
mixtures of products formed that were unstable. Access to this target via MacDonald 
phosphorylation appeared to be the most promising route, however during the 
timeframe available the results could not be reproduced, and further work on this 
step should be completed in future.    
The second section described the evaluation of six modified glycosyl 1-phosphates 
as substrates of GDP-ManPP. Three analogues, bearing C4-fluoro, C6-amido and 
C6-azido functionalities, were shown to be excellent to moderate substrates, 
respectively. This chemoenzymatic strategy provided fast access to modified GDP-
Man analogues on milligram scales for biochemical evaluation against GMD. No 
conversion of the remaining three glycosyl 1-phosphates, bearing C6-thio, C6-amino 
and C6-hydroxamate functionalities respectively, to their corresponding GDP-sugar 
was observed.  
Nevertheless, this study provided new information surrounding structure activity 
relationships of GDP-ManPP, where it was shown that turnover of 6-position 
modified glycosyl 1-phosphates bearing positive or negative charges was not 
tolerated by the enzyme. In order to access these analogues in the future, chemical 




Chapter 4: Biochemical evaluation of GDP-Man analogues  
4.0 Introduction and aims 
As discussed in Chapter 3.0, the use of sugar-nucleotide probes to investigate GMD 
mediated oxidation of GDP-Man 3 has not been widely investigated to date. Several 
small molecule inhibitors of GMD have been identified in the literature, the most 
notable being erythromycin A 5 and penicillic acid 6, as mentioned in Chapter 1.3.2. 
However, these compounds are only mM inhibitors (IC50 of 1.2 and 2.4 mM, 
respectively)68 and 6 is not selective for the catalytic Cys268 residue.70 Determination 
of GMD inhibition is most commonly achieved using a spectrophotometric assay that 
monitors NAD(H) production.   
Following chemoenzymatic synthesis of three modified GDP-Man analogues, their 
activities towards GMD were to be investigated using a colorimetric assay 
monitoring NAD(H) formation. Evaluation of the analogues as substrates and/or 
inhibitors of GMD was envisaged to provide insight into substrate specificity and 







4.1.1 Evaluation as a substrate of GMD 
To assess the viability of GDP-6-azido-6-deoxy-mannose 91 as a substrate of GMD, 
a 3-well assay was prepared as follows: negative control, GDP-Man (10 µM) and a 
well containing 91 (50 µM) with GDP-Man 3 (10 µM). After incubation for 45 min, 
data showed analogue 91 had little influence on the oxidation of 3, with conversion 
reaching 89% within this time period. The experiment was repeated, however the 
inhibitor was pre-incubated with GMD on ice for 2 h prior to the addition of 3. This 
made little difference to the rate of NAD(H) formation, with conversion reaching 83% 
within 50 min (Figure 4.1). As this analogue showed only 11-16% inhibition of GDP-
ManA 4 production at 50 µM, no further experiments were performed. GDP-6-azido-
6-deoxy-mannose 91 was shown not to be a substrate of GMD. 
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4.2 GDP-4-deoxy-4-fluoro-mannose  
4.2.1 Evaluation as a substrate of GMD 
The potential of GDP-4-deoxy-4-fluoro-mannose 128 as a substrate of GMD was 
first evaluated by incubation of the analogue (50 µM) with GMD (50 µg/mL) for 60 
min. During this time, no production of NAD(H) was observed. The experiment was 
repeated, but after 40 min the well containing analogue 133 was spiked with GDP-
Man 3 and production of NAD(H) began (Figure 4.2). 
 
Figure 4.2: Incubation of 128 with GMD showing NAD(H) production after spiking 
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This data suggested that analogue 128 is either oxidised by GMD very slowly or is 
not a substrate of GMD and is unable to bind in the active site. This implies that the 
C4-OH group is essential for substrate binding, as replacement by 4-F may remove 
hydrogen bond donor capability and would appear to disrupt this process. Referring 
to the PDB structure of GMD shown in Figure 4.3 (PDB ID: 1MV8, Ligand 
[GDX]2005:A), within the active site it is observed that the C4-OH of 4 appears to 
make up to three hydrogen bond contacts with the carboxylate groups of proximal 
Leu159 and Glu157 residues, suggesting this to be disrupted by analogue 128. 
 
Figure 4.3: GDP-ManA 4 bound in GMD active site showing three hydrogen 
bonding contacts between C4-OH and carboxylate groups of Leu159 and Glu159. 





Unfortunately, analogue 128 could not be used as a competitive inhibitor of GMD 
because it was not oxidised. It has however provided new information surrounding 
substrate binding specificities within the active site of GMD. It would be of interest 
to evaluate other C4-modified sugar-nucleotides against GMD, such as GDP-4-
methoxy-mannose, which was previously synthesised by Lou et al.76 and GDP-4-
deoxy-mannose. Testing of such analogues with varying hydrogen bond donor and 
acceptor capabilities could provide further information into substrate binding within 






4.3.1 Evaluation as an inhibitor of GMD 
GDP-6-amido-6-deoxy-mannose 173 was first evaluated as a substrate of GMD.  
A 3-well assay was prepared as follows: negative control, GDP-Man (10 µM) and a 
well containing 173 (50 µM) with GDP-Man 3 (10 µM) and monitored for 45 min. 
Interestingly, this analogue only showed 14% conversion of 3 at 50 µM (Figure 4.4). 
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Next, the assay was performed in triplicate using 7 different concentrations of 173 
(200-1 µM). The expected relationship between increased conversion and 
decreased inhibitor concentration was clearly observed, as shown in Figure 4.5.  
Figure 4.5: Evaluation of variable concentrations of 173 as an inhibitor of GMD. 
Figure 4.6 shows the average inhibition (%) observed at variable concentrations of 
173. The data suggests that the IC50 value lies between 20 and 100 µM, however 
this could not be determined accurately as a wider range of inhibitor concentrations 

































Figure 4.6: Average inhibition (%) at variable concentrations of 173.  
4.3.2 Evaluating potential hydrolysis of GDP-6-amido-6-deoxy-mannose by GMD 
Finally, we sought to investigate whether GDP-6-amido-mannose 173 was being 
hydrolysed by GMD to form the native product of oxidation, GDP-ManA 4. Evaluation 
of 4 as an inhibitor was performed using the same assay, where incubation with 
GMD for 50 min showed 44% inhibition of NAD(H) production at 50 µM, shown in 
Figure 4.7, lying within a similar range to that observed for analogue 173. This 
observation confirmed GDP-ManA 4 acts as a feedback inhibitor of GMD, where if 
abundant in high concentration, it prevents oxidation of GDP-Man by remaining 



























Figure 4.7: Evaluation of GDP-ManA 4 as a feedback inhibitor of GMD. 
To rule out a feedback inhibition mechanism for analogue 173, two experiments 
were performed, and the resultant mixtures analysed by HRMS, outlined in Scheme 
4.1. Two reactions were prepared containing 173: one control without GMD (Sample 
A) and one with GMD (Sample B). Each mixture was incubated for 3 h on ice, then 
MeOH was added. The reaction containing GMD was vortexed, centrifuged, then 
the supernatant was removed and filtered.  
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For Sample A, the major ion was identified at m/z 619.0797 corresponding to 
[173+H]+. If hydrolysis was occurring, a peak at m/z 620.0797 corresponding to 
GDP-ManA [4+H]+ would be observed, however in Sample B only the m/z 
corresponding to [176+H]+ could be observed. This suggests no hydrolysis, or a very 
minimal amount of hydrolysis of 173 is induced by GMD under these conditions. 
4.3.3 Discussion 
GDP-6-amido-6-deoxy-mannose 173 was identified as a µM inhibitor of GMD, with 
an IC50 value in the range of 20 to 50 µM. HRMS analysis confirmed that no 
hydrolysis of this analogue to the native product GDP-ManA 4 was induced by GMD, 
ruling out 4 acting as a feedback inhibitor via this mechanism. It is thus proposed 
that 173 may act as a competitive inhibitor of GMD, with molecular docking studies 
of 173 in the active site of GMD revealing that the C(O)NH2 may establish two 
hydrogen bonds with a proximal Glu157 residue and the key Cys268 residue (Figure 
4.9), proposed to permit strong binding of this analogue.  
 
Figure 4.9: Molecular docking of 173 in the active site of GMD showing two 















4.4 Conclusions and Future Directions 
In conclusion, three GDP-Man analogues were evaluated as substrates of GMD. 
GDP-6-azido-6-deoxy-mannose 91 was not a substrate of the enzyme, with 
conversion of GDP-Man 3 to GDP-ManA 4 only reduced by 14%. GDP-4-deoxy-4-
fluoro-mannose 128 was also shown not to be a substrate of GMD. This has been 
proposed to originate through disruption of key hydrogen bonding contacts between 
C4-OH and the carboxylate group of neighbouring Leu158 and Glu157 residues, 
suggesting that the C4-OH is required for substrate binding.  
Serendipitously, GDP-6-amido-6-deoxy-mannose 173, which was not originally 
designed as a tool to probe GMD, was demonstrated to be a µM inhibitor of the 
enzyme. The mechanism of inhibition is not yet determined, however feedback 
inhibition through hydrolysis of the analogue to GDP-ManA 4 has been excluded. 
From inspection of molecular docking data, it appears that the amide group of 173 
may be able to form a hydrogen bonding network with a proximal Glu157 residue and 
the key Cys268 residue, proposed to result in strong binding of this analogue within 
the active site of GMD. This suggests a competitive inhibition mechanism may be 
exhibited by 173, and this hypothesis could be strengthened by performing further 
kinetic analysis and obtaining a crystal structure of 173 bound in the GMD active 
site. 
The data collected from biochemical evaluation can be used as a guide for the 
design of new analogues to further supplement understanding of GMD catalysed 
oxidation. More analogues exhibiting structural similarities to the native 




inhibition profile exhibited by 173. Evaluation of GDP-6-hydroxamate-6-deoxy-
mannose 185 is now of interest, and an alternative strategy to access this material 
via chemical sugar-nucleotide synthesis would be beneficial to this investigation. 
Furthermore, the tetrazole group, a commonly employed carboxylic acid bioisostere 
in medicinal chemistry, would be interesting to incorporate into a GDP-Man 
analogue, affording 186 to further explore interactions within the binding pocket of 
GMD. The structures of these proposed analogues are shown in Figure 4.10. 
 
Figure 4.10: Proposed structures of GDP-Man analogues 185 and 186. 
Evaluation of electrophilic GDP-Man analogues, capable of alkylating Cys268, as 
substrates of GMD should be completed next, with a view of identifying new covalent 
inhibitors. Further work to complete the synthesis of electrophilic GDP-Man 
analogues 89 and 90, bearing C6-chloro and C6-nitrile functionalities respectively, 
that were described in Chapter 3 could be supplemented by synthesis of a GDP-
Man analogue featuring a C6-C8 Michael acceptor (Figure 4.11). Preliminary 
molecular docking has shown such homologues to fit in the GMD active site, with a 
distance of 3.39 Å calculated between C6 and Cys268, again comparable to that of 





Figure 4.11: Generic structure of a GDP-Man analogue bearing a C6-C8 Michael 
acceptor. 
When evaluating potential covalent adducts, it will be important to ensure selectivity 
for the active site Cys268 residue, to provide tools with high efficacy. This could be 
achieved by retaining the sugar-nucleotide backbone, which ensures specific 
binding interactions within the active site are retained. Whilst this approach is 
applicable for the preliminary exploration of functionalities capable of inhibiting GMD, 
future work will require synthesis of cell-permeable probes to facilitate monitoring of 
such ligands beyond in vitro studies. Rationalising a cell-permeable GMD probe with 
inhibitor activity would open a pathway to the design of ‘drug-like’ molecules that 






Chapter 5: Overall Conclusions and Future Directions 
In conclusion, two complementary routes to synthesise GDP-ManA, the constituent 
sugar-nucleotide building block for alginate biosynthesis, were evaluated. For the 
chemical synthesis, the final pyrophosphorylation step was optimised to produce 
GDP-ManA in 46% yield using DCI as the activator on multi-milligram scales. In 
contrast, an enzymatic route using GMD permitted facile access to this key sugar-
nucleotide, albeit in lower quantities for use as an analytical standard.  
Studies towards the synthesis of modified GDP-Man analogues for use as structure 
function tools of GMD proceeded with varying success. Following chemical 
synthesis of modified glycosyl 1-phosphates, a total of six analogues were screened 
against GDP-ManPP, of which three were successfully converted to the 
corresponding GDP-Man analogue. Although the remaining three sugar-nucleotide 
analogues could not be accessed via the proposed chemoenzymatic strategy, this 
study supplemented prior studies into GDP-ManPP by providing new insights into 
the substrate specificity of this enzyme. The information obtained can be used to 
guide future synthetic routes towards the remaining GDP-sugar targets described 
and other related analogues. 
Screening of the GDP-Man analogues synthesised against GMD provided important 
new details surrounding substrate specificity of this strategic enzyme. Notably, a 
GDP-Man analogue bearing a C6-amido group was identified as a µM inhibitor. 
Further work to determine the IC50 value and confirm the proposed competitive 
inhibition mechanism are now required, however this finding provides a guide for the 




Chapter 6: Experimental 
6.0 General experimental details 
All reagents and solvents which were available commercially were purchased from 
Acros, Alfa Aesar, Fisher Scientific, Sigma Aldrich or TCI. All reactions in non-
aqueous solvents were conducted in oven dried glassware with a magnetic stirring 
device under an inert atmosphere of nitrogen passed through molecular sieves using 
a vacuum manifold. Solvents were purified by passing through activated alumina 
columns and used directly from a Pure Solv-MD solvent purification system and 
were transferred under nitrogen. Reactions requiring low temperatures used the 
following cooling baths: –78 °C (dry ice/acetone), –30 °C (dry ice/acetone), –15 °C 
(NaCl/ice/water) and 0 °C (ice/water).  
Reactions were followed by thin layer chromatography (TLC) using Merck silica gel 
60F254 analytical plates (aluminium support) and were developed using standard 
visualising agents: short wave UV radiation (245 nm) and 5% sulfuric acid in 
methanol/Δ or orcinol/Δ.  
Purification via flash column chromatography was conducted using silica gel 60 
(0.043-0.063 mm) under positive pressure of compressed air.   
Purification by C18 chromatography was conducted using a Thermoscientific X30 
SPE column (HyperSep C18, 6 mL) eluting with H2O.   
Purification via strong ion exchange (SAX) chromatography was conducted on a 
Bio-Rad Biologic LP system using a Bio-Scale Mini UNOsphere Q (strong anion 
exchange) cartridge (5 mL): flow rate (3.0 mL/min), 0 → 100% 1.0 M NH4HCO3 over 




50 (strong anion exchange) column (5 mL): flow rate (7.0 mL/min), 5 → 250 mM 
NH4HCO3 over 15 min with on-line UV detector to monitor @265nm.   
Infra-red spectra were recorded neat on a Thermo Scientific Nicolet iS10 
spectrometer; selected absorbtion frequencies (νmax) are reported in cm-1.   
Optical activities were recorded on automatic Rudolph Autopol I or Bellingham and 
Stanley ADP430 polarimeters (concentration in g/100mL).   
pH measurements were recorded using a Hanna® pH 20 meter.  
1H NMR spectra were recorded at 600, 400 or 300 MHz, 13C NMR spectra at 150, 
100 or 75 MHz, 19F NMR spectra at 376 MHz and 31P NMR spectra at 161 MHz 
respectively using Bruker AV-III spectrometers. 1H NMR resonances were assigned 
with the aid of gDQCOSY. 13C NMR resonances were assigned with the aid of 
gHSQCAD. Coupling constants are reported in Hertz. Chemical shifts (δ, in ppm) 
are standardised against the deuterated solvent peak. NMR data were analysed 
using Mestrenova software. 1H NMR splitting patterns were assigned as follows: brs 
(broad singlet), s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of 
doublet of doublets), appt (apparent triplet), t (triplet), quartet (q) or m (multiplet 
and/or multiple resonances). Assignment in NMR analysis follows the generic ring 
numbering system shown in Figure 6.1.  
LRMS and HRMS (ESI) were obtained on Agilent 6530 Q-TOF, LQT Orbitrap XL1 
or Waters (Xevo, G2-XS TOF or G2-S ASAP) Micromass LCT spectrometers using 
a methanol mobile phase in positive/negative ionisation modes as appropriate. 





Figure 6.1: Ring numbering system for NMR assignment.  
DFT calculations were performed by Dr. Jóhannes Reynisson as follows: The 
geometry optimisations were performed with Gaussian 16 software155 using 
restricted density functional theory. The B3LYP functional hybrid method was 
employed and the 6-311+G(2df, p) with diffused basis set was used for the geometry 
optimisation and frequency analysis in vacuum. The normal modes revealed no 
imaginary frequencies indicating that they represent minima on the potential energy 
surface.156–158 
Molecular docking was performed by Dr. Ayesha Zafar and Dr. Jóhannes Reynisson 
as follows: The Scigress Ultra version F.J 2.6 program159 was used for the modelling 
of the ligands in the crystal structures of GMD (PDB ID: 1MV8).66 Hydrogen atoms 
were added to the structures and the ligands were built into the binding pocket based 
on GDX, the co-crystallised ligand. The ligands were first structurally optimised 





6.1 General experimental procedures 
A. Glycosylation of thioglycoside using NIS/AgOTf activation 
Thioglycoside (1.0 equiv.) was dissolved in DCM (0.1 M) and stirred with powdered 
4 Å MS for 1 h. DBP (1.5 equiv.) was added and the reaction mixture was stirred for 
a further 30 min before being cooled to –30 °C. NIS (1.5 equiv.) and AgOTf (0.3 
equiv.) were added successively and the reaction was stirred until TLC analysis 
indicated the reaction was complete. The reaction mixture was quenched with Et3N, 
filtered over CeliteTM then diluted with DCM. The organic layer was washed with 
saturated aqueous Na2S2O3 solution (20 mL), saturated aqueous NaHCO3 solution 
(20 mL), H2O (20 mL), brine (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo.  
B. Glycosylation of trichloroacetimidate using TMSOTf activation 
Crude trichloroacetimidate (1.0 equiv.) was dissolved in DCM (0.1 M) and stirred 
with powdered 4 Å MS for 1 h. DBP (1.7 equiv.) was added and the reaction mixture 
was stirred for a further 30 min before being cooled to –10 °C. TMSOTf (0.5 equiv.) 
was added dropwise and the reaction mixture allowed to warm to RT over 1 h with 
stirring until TLC analysis indicated the reaction was complete.  The reaction mixture 
was quenched with Et3N, filtered over CeliteTM then diluted with DCM. The organic 
layer was washed with saturated aqueous NaHCO3 solution (25 mL), H2O (25 mL), 





C. DAST fluorination  
A solution of DAST (8.0 equiv.) in DCM (1 M) was cooled to –78 °C in a TeflonTM 
flask and a solution of C4-OH sugar (1.0 equiv.) in anhydrous DCM (0.1 M) was 
added dropwise. The reaction mixture was warmed to RT and stirred until TLC 
analysis indicated the reaction was complete. The reaction mixture was quenched 
with saturated aqueous NaHCO3 solution (10 mL) under positive pressure of N2 and 
diluted with DCM (25 mL). The organic layer was washed with saturated aqueous 
NaHCO3 solution (20 mL), H2O (2 × 20 mL), brine (20 mL), dried (MgSO4), filtered 
and concentrated in vacuo. 
D. MacDonald phosphorylation 
Per-O-acetylated sugar (1.0 equiv.) was weighed into a pre-dried Schlenk tube and 
dried under high vacuum for 1 h. H3PO4 (5.0 equiv.) was weighed inside a glove box 
or glove bag, transferred to the Schlenk tube and the tube sealed under nitrogen. 
The tube was placed under nitrogen on a double manifold and then heated under 
high vacuum at the given temperature with gentle stirring to form a melt. The reaction 
was monitored by TLC analysis (Pet. ether/EtOAc, 1/2) for formation of a baseline 
(Rf = 0) spot corresponding to the glycosyl 1-phosphate (hemiacetal by-product 
observed at Rf 0.5) until the reaction was complete. The resultant melt was cooled 
to RT, reconstituted in anhydrous THF then added to a stirred solution of 1 M LiOH 
(concentration = 25 mM with respect to starting material) at 0 °C then warmed to RT 
and stirred until saponification was complete by TLC analysis (MeCN/H2O/AcOH, 




filter under vacuum and rinsed with H2O. The filtrate was neutralised through the 
addition of AmberliteTM 120 ion-exchange resin (H+ form) to pH = 7, filtered and 
concentrated in vacuo. The crude residue was then triturated with MeOH, 
centrifuged and the supernatant removed before purification or directly applied to a 
Bio-Scale Mini UNOsphere Q (SAX) cartridge (CV = 5 mL), eluting with 3 CV of H2O 
and 3 CV of 1.0 M NH4HCO3 solution. Fractions containing the glycosyl 1-phosphate 
were collected and lyophilised repeatedly to remove residual NH4HCO3 and deliver 
the target material.  
E. Chemical synthesis of sugar-nucleotides 
Glycosyl 1-phosphate and GMP-morpholidate were exchanged to their bis-
triethylammonium salt forms prior to the reaction and lyophilised. Glycosyl 1-
phosphate (bis-triethylammonium salt, 1.0 equiv.), GMP-morpholidate (bis-
triethylammonium salt, 1.5 equiv.) and activator were each co-evaporated with Tol 
or pyridine (3 × 2 mL) and then dissolved in DMF or pyridine (0.05 M), respectively. 
The reaction mixture was stirred at room temperature and conversion monitored by 
TLC analysis (IPA/NH4OH/H2O, 6/3/1). The reaction mixture was concentrated 
under reduced pressure (water bath temperature not exceeding 30 °C) and dried 
under high vacuum before analysis by crude 1H and 31P NMR to confirm presence 
of an NDP-sugar. 
F. Deprotection of sugar-nucleotides 
The crude reaction mixture was suspended in a mixture of MeOH and H2O (1:1) then 




temperature or until TLC analysis (IPA/NH4OH/H2O, 6/3/1) indicated conversion of 
starting material to a lower Rf value spot. The reaction mixture was concentrated 
under reduced pressure (water bath temperature not exceeding 30 °C) to give a dark 
yellow residue. The resultant residue was dissolved in H2O and if using DCI, passed 
down a Thermo ScientificTM X30 SPE column (HyperSep C18, 6 mL), eluting with 
H2O to remove DCI. The resulting aliquots were purified by SAX chromatography as 
described in the general experimental procedures. 
G. Enzymatic synthesis of sugar-nucleotides using GDP-ManPP 
The assay for enzymatic synthesis of sugar-nucleotides by GDP-ManPP was 
prepared as follows: The assay buffer was Tris-HCl (pH 8.0, 100 µM) containing 
MgCl2 (12.8 mM) and DTT (1.6 mM). The final concentration of assay components 
were as follows: glycosyl 1-phosphate (1.0 equiv., 14.7 µM) and GTP (0.93 equiv., 
15 µM). The enzyme concentrations were as follows: GDP-ManPP (0.1 mg/mL) and 
inorganic pyrophosphatase (iPPase, 2.70 U/mL). The reaction was incubated with 
shaking at ambient temperature until formation of an NDP-sugar was observed by 
SAX. MeOH (2 mL) was added and the mixture was centrifuged (5000 RPM) for 5 
min to remove insoluble protein, passed through a syringe filter (0.4 µM, PTFE) and 








6.2 Enzyme production 
6.2.1 GDP-mannose pyrophosphorylase (GDP-ManPP) 
Expression and purification of GDP-ManPP from S. enterica (the clone was kindly 
donated by T. L. Lowary) was performed by the Field group using the following 
procedure: The transformant was grown according to the literature.161 1 L of 
transformant in LB medium containing appropriate antibiotic (kanamycin, 25 µg/mL) 
was incubated at 37 °C with gentle shaking until an OD600 of about 0.6. 
Heterologous protein expression was induced by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 0.5 mM final concentration, followed by incubation 
at 18 °C overnight at 180 rpm. Afterwards, cells were harvested by centrifugation 
(4000 × g, 4 °C, 20 min) and stored at –80 °C until use. Frozen cells were thawed in 
50 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole supplemented with DNAse 
(10 µg/mL, Sigma) and proteinase inhibitor cocktail (Roche), then lysed by 
sonication in ice. After centrifugation (20,000 x g, 4 °C, 20 min) to remove the cell 
debris, the crude protein solution was purified at 4 °C using an ÄKTA pure FPLC 
system (GE Healthcare). The supernatant was passed through a HisTrapTM HP 
column (5 ml, GE healthcare), pre-equilibrated with buffer A (50 mM Tris-HCl pH 
8.0, 500 mM NaCl, 20 mM imidazole). Unbound proteins were washed with five 
column volumes of buffer A, followed by elution with buffer B (50 mM Tris-HCl pH 8, 
500 mM NaCl, 500 mM imidazole). GDP-ManPP comprising fractions were pulled 
together to give a final 7 mg/mL concentrated solution (concentration determined by 
Bradford assay, Sigma). Concentrated GDP-ManPP was then divided into aliquots 




6.2.2 GDP-mannose dehydrogenase (GMD) 
Expression and purification of GMD from P. aeruginosa (the recombinant plasmid 
pET-3a containing the algD gene encoding for GMD was kindly donated by P. 
Tipton) was performed by the Field group using the following procedure: The 
transformant was grown according to the literature.162 1 L of transformant in LB 
medium containing appropriate antibiotic (carbenicillin, 100 µg/mL) was incubated 
at 37 °C with gentle shaking until an OD600 of about 0.6. Heterologous protein 
expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at 
0.4 mM final concentration, followed by incubation at 37 °C for 4 hours at 180 rpm. 
Afterwards, cells were harvested by centrifugation (4000 × g, 4 °C, 20 min) and 
stored at - 80 °C until use. Frozen cells were thawed in 20 mM HEPES pH 7.5, 150 
mM NaCl supplemented with DNAse (10 µg/mL, Sigma) and proteinase inhibitor 
cocktail (Roche), then lysed by sonication in ice. After centrifugation (20,000 x g, 4 
°C, 20 min), protamine sulfate was added to the supernatant to precipitate nucleic 
acid. After removal of precipitated nucleic acid by centrifugation, the crude protein 
solution was fractionated with ammonium sulfate, with GMD precipitating between 
45 and 60% saturation. Protein pellets were re-dissolved in 20 mM HEPES pH 7.5, 
150 mM NaCl and purified using an ÄKTA pure FPLC system (GE Healthcare) by 
gel filtration chromatography using a Superdex S200 16/600 column (GE 
Healthcare). Proteins were eluted with 20 mM HEPES (pH 7.5) and 150 mM NaCl 
at the flow rate of 1 mL/min. GMD comprising fractions were pulled together to give 




assay, Sigma). Concentrated GMD was then divided into aliquots and stored at –
80°C until required. 
6.3 Determination of GMD activity and assay 
Fluorescence assays were performed in black NUNC 96 plates on a BMG Labtech 
FLUOstar Omega microplate reader equipped with suitable excitation and emission 
filters at 355 and 460 nm, respectively. The fluorescence assay showed an increase 
in fluorescence at 460 nm compared to the negative control, indicating formation of 
NAD(H) hence activity of GMD. Four concentrations of GMD were evaluated: 200, 
100, 50 and 20 µg/mL, with the optimum concentration found to be 50 µg/mL, which 
was adopted for all assays described in this thesis (Figure 6.2). 
 




















Positive Control, NAD(H) Negative Control
GDP-Man, 200 µg/mL GMD GDP-Man, 100 µg/mL GMD




The assay for GMD activity against GDP-Man analogues was prepared as follows: 
The assay buffer was sodium phosphate (pH 7.38, 200 µM) containing MgCl2 (5 µM) 
and DTT (10 µM). The final concentration of assay components were as follows: 
NAD+ (200 µM), GDP-Man 3 (10 µM), GDP-Man analogue (50 µM). The enzyme 





6.4 Experimental details for Chapter 2 
6.4.1 α-D-mannopyranuronic acid derivatives: acetyl protected methyl uronate series 
1,2,3,4-Tetra-O-acetyl-6-O-trityl-β-D-mannopyranose 65  
 
D-mannose 64 (25.8 g, 142 mmol, 1.0 equiv.) and TrCl (40.1 g, 143 mmol, 1.1 equiv.) 
were suspended in pyridine (125 mL) and stirred at 50 °C for 3 h. The solution was 
cooled to 0 °C and Ac2O (75 mL) was added via a dropping funnel over 30 min 
before being warmed to RT. After stirring for 18 h, the reaction mixture was poured 
onto ice (750 mL) and stirred vigorously for 1.5 h to afford a white solid (H2O was 
exchanged twice during this time to remove pyridine). The solid was collected by 
vacuum filtration and washed with ice-cold H2O (250 mL) and dried for 2.5 h. The 
solid was recrystallized from the minimum amount of hot EtOH collected by filtration 
and dried (P2O5) in a vacuum desiccator, affording 65 as a white solid (39.0 g, 66.0 
mmol, 46% β-anomer). These data were in good agreement with literature 
values.163,164 
Rf 0.38 (Hex/EtOAc, 3/1);  
1H NMR (300 MHz, CDCl3) δH 7.47-7.45 (7H, m, Ar-H), 7.30-7.23 (8H, m, Ar-H), 5.87 
(1H, d, J = 1.1 Hz, H1), 5.48 (1H, dd, J = 3.3, 1.1 Hz, H2), 5.38 (1H, appt, J = 9.9 Hz, 
H4), 5.07 (1H, dd, J =  9.9, 3.3 Hz, H3), 3.70-3.63 (1H, m, H5), 3.35 (1H, dd, J = 10.6, 
2.8 Hz, H6’), 3.17 (1H, dd, J = 10.6, 4.5 Hz, H6), 2.25 (3H, s, C(O)CH3), 2.15 (3H, s, 




13C NMR (100 MHz, CDCl3) δC 170.5 (C=O), 170.1 (C=O), 169.4 (C=O), 168.7 
(C=O), 143.9 (Ar-C), 129.0 (Ar-C), 128.0 (Ar-C), 127.3 (Ar-C), 90.8 (C1), 87.0 
(OCPh3) , 75.0 (C5), 71.2 (C3), 68.7 (C2), 66.3 (C4), 62.5 (C6), 21.1 (C(O)CH3), 21.0 
(C(O)CH3), 20.8 (2C, C(O)CH3);  
LRMS m/z (ES+) 613 ([M+Na]+, 100%);  
HRMS m/z (ESI+) [Found: (M+Na)+ 613.2035 C33H34O10Na requires M+Na+, 
613.2044].  
1,2,3,4-Tetra-O-acetyl-β-D-mannopyranose 66  
 
65 (10.2 g, 17.3 mmol, 1.0 equiv.) was dissolved in AcOH (120 mL) at 40 °C with 
stirring. The solution was cooled to 15 °C and HBr/AcOH (33% w/w in acetic acid, 5 
mL, 20 mmol, 1.2 equiv.) was added dropwise, inducing a yellow precipitate. After 
10 s, the solution was filtered through CeliteTM onto H2O (250 mL) and the solid 
washed with AcOH (10 mL) under vacuum. HBr/AcOH was quenched with saturated 
aqueous NaHCO3 solution (250 mL) forming an opaque white suspension which was 
extracted with CHCl3 (2 × 200 mL). The organic layer was washed with saturated 
aqueous NaHCO3 solution (100 mL), H2O (100 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The resultant residue was dissolved in the minimum amount 
of hot CHCl3 and induced to crystallise with Et2O. The crystals were collected by 
filtration and dried in vacuo, affording 66 as a white solid (3.6 g, 10 mmol, 60%). 




Rf 0.33 (Hex/EtOAc, 1/1);   
1H NMR (300 MHz, CDCl3) δH 5.88 (1H, d, J = 1.2 Hz, H1), 5.50 (1H, dd, J = 3.2, 1.2 
Hz, H2), 5.27 (1H, appt, J = 9.9 Hz, H4), 5.18 (1H, dd, J = 9.9, 3.2 Hz, H3), 3.82-3.58 
(3H, m, H5, H6, H6’), 2.22 (3H, s, C(O)CH3), 2.11 (3H, s, C(O)CH3), 2.10 (3H, s, 
C(O)CH3), 2.02 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.6 (C=O), 170.4 (C=O), 170.0 (C=O), 168.7 
(C=O), 90.7 (C1), 75.7 (C5), 70.8 (C3), 68.5 (C2), 65.9 (C4), 61.4 (C6), 20.9 (C(O)CH3), 
20.9 (C(O)CH3), 20.8 (C(O)CH3), 20.7 (C(O)CH3);  
LRMS m/z (ES+) 366 ([M+NH4]+, 100%);  
HRMS m/z (ES+) [Found: (M+NH4)+ 366.1397 C14H20O10NH4 requires M+NH4+, 
366.1395].  
1,2,3,4-Tetra-O-acetyl-β-D-mannopyranosiduronic acid 67  
 
To a vigorously stirred solution of 66 (1.5 g, 4.3 mmol, 1.0 equiv.) in DCM/H2O (2:1, 
30 mL) was added TEMPO (0.3 g, 2.2 mmol, 0.5 equiv.) and BAIB (6.9 g, 22 mmol, 
5.0 equiv.). After 5 h, the reaction was quenched with 10% aqueous Na2S2O3 
solution (30 mL), the organic layer removed and the aqueous layer acidified to pH 
2-3 using 1M HCl. The aqueous layer was extracted with EtOAc (2 × 30 mL), dried 
(MgSO4), filtered and concentrated in vacuo affording 67 as a white solid (1.2 g, 3.3 




Rf 0.81 (DCM/MeOH, 9/1);  
[α]26𝐷 	 −20.0 (c = 0.50, MeOH); 
1H NMR (300 MHz, CDCl3) δH 5.96 (1H, d, J = 1.5 Hz, H1), 5.50 (1H, dd, J = 3.2, 1.5 
Hz, H2), 5.48 (1H, appt, J = 9.2 Hz, H4), 5.21 (1H, dd, J = 9.2, 3.2 Hz, H3), 4.2 (1H, 
d, J = 8.9 Hz, H5), 2.21 (3H, s, C(O)CH3), 2.13 (3H, s, C(O)CH3), 2.10 (3H, s, 
C(O)CH3), 2.04 (3H, s, C(O)CH3); 
13C NMR (100 MHz, CDCl3) δC 169.9 (C=O, uronic acid), 169.7 (C=O), 169.5 (C=O), 
169.4 (C=O), 168.2 (C=O), 89.4 (C1), 72.3 (C5), 69.3 (C3), 66.9 (C2), 65.9 (C4), 20.4 
(C(O)CH3), 20.4 (C(O)CH3), 20.3 (C(O)CH3), 20.2 (C(O)CH3);  
LRMS m/z (ES−) 361 ([M−H]−, 100%);  
HRMS m/z (ES−) [Found: (M−H)− 361.0767 C14H17O11 requires M−H−, 361.0776].  
Methyl 1,2,3,4-tetra-O-acetyl-β-D-mannopyranosyluronate 68 
 
To a solution of 67 (0.60 g, 1.7 mmol, 1.0 equiv.) in DMF (8 mL) was added methyl 
iodide (250 µL, 4.02 mmol, 2.4 equiv.) and K2CO3 (0.16 g, 1.1 mmol, 1.5 equiv.). 
After stirring for 72 h, the reaction was quenched with MeOH (5 mL), extracted with 
EtOAc (25 mL) and washed with H2O (15 mL) and brine (15 mL). The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo. The resultant yellow solid 




Rf 0.23 (Hex/EtOAc, 3/1);  
[α]26𝐷 	 −16.0 (c = 0.50, CHCl3); 
1H NMR (300 MHz, CDCl3) δH 5.91 (1H, d, J = 1.3 Hz, H1), 5.50 (1H, dd, J = 3.5 Hz, 
1.2, H2), 5.42 (1H, appt, J = 9.4 Hz, H4), 5.19 (1H, dd, J = 9.6, 3.2 Hz, H3), 4.15 (1H, 
d, J = 9.4 Hz, H5), 3.74 (3H, s, C(O)OCH3), 2.21 (3H, s, C(O)CH3), 2.12 (3H, s, 
C(O)CH3), 2.07 (3H, s, C(O)CH3), 2.03 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.6 (C=O, uronate), 170.0 (C=O), 170.0 (C=O), 
168.8 (C=O), 167.2 (C=O), 90.1 (C1), 73.6 (C5), 70.0 (C3), 67.8 (C2), 66.7 (C4), 53.3 
(C(O)OCH3), 21.1 (C(O)CH3), 21.1 (C(O)CH3), 21.0 (C(O)CH3), 20.9 (C(O)CH3);  
LRMS m/z (ES+) 394 ([M+NH4]+, 100%);  
HRMS m/z (ES+) [Found: (M+NH4)+ 394.1337 C15H20O11NH4 requires M+NH4+, 
394.1344]. 
Methyl 2,3,4-tri-O-acetyl-α/β-D-mannopyranosyluronate 71  
 
To a solution of 68 (100 mg, 0.3 mmol, 1.0 equiv.) in DMF (2 mL) was added 
hydrazine acetate (38 mg, 0.41 mmol, 1.5 equiv.). After stirring for 3 h, the solvent 
was removed in vacuo and the residue reconstituted in EtOAc (10 mL) and washed 
with H2O (10 mL) and brine (10 mL). The organic layer was dried (MgSO4), filtered 




with Hex/EtOAc (3/1, 1/1) afforded 71 as a colourless oil (58 mg, 0.17 mmol, 64%, 
95% α-anomer).  
Rf 0.47 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 5.45 (1H, d, J = 3.2 Hz, H3), 5.41 (1H, appt, J = 8.9 
Hz, H4), 5.34 (1H, d, J = 2.5 Hz, H1), 5.26-5.25 (1H, m, H2), 4.58 (1H, d, J = 8.9 Hz, 
H5), 3.77 (3H, s, C(O)OCH3), 2.15 (3H, s, C(O)CH3), 2.07 (3H, s, C(O)CH3), 2.02 
(3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.2 (C=O, uronate), 169.7 (C=O), 168.6 (C=O), 
162.8 (C=O), 92.1 (C1), 69.7 (C2), 69.6 (C5), 68.3 (C3), 67.2 (C4), 54.7 (C(O)OCH3), 
20.9 (C(O)CH3), 20.7 (C(O)CH3), 20.6 (C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 352.1246 C13H18O10NH4 requires M+NH4+, 
352.1283]. 
Dibenzyl methyl 2,3,4-tri-O-acetyl-α-D-mannopyranosyluronate phosphate 73 
 
To a solution of 71 (550 mg, 1.7 mmol, 1.0 equiv.) and oven dried anhydrous K2CO3 
(360 mg, 2.6 mmol, 1.6 equiv.) in DCM (5.5 mL) was added trichloroacetonitrile (0.37 
mL, 4.62 mmol, 2.8 equiv.). After stirring for 18 h, the solution was filtered over 
CeliteTM, washed with DCM (15 mL) and concentrated in vacuo to afford 72 as a 




DBP (770 mg, 2.8 mmol, 1.7 equiv.) and TMSOTf (0.15 mL, 0.81 mmol, 0.5 equiv.) 
in DCM (15 mL). Reaction time: 1 h. Purification by silica gel column 
chromatography, eluting with Tol/acetone (10/1, 7/1, 3/1) afforded 73 as a colourless 
oil (369 mg, 0.62 mmol, 38%). These data were in good agreement with literature 
values.105 
Rf 0.30 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 7.35-7.34 (8H, m, Ar-H), 7.19-7.17 (2H, m, Ar-H), 5.70 
(1H, dd, JH1-P = 6.4 Hz, JH1-H2 = 2.0 Hz, H1), 5.41-5.31 (2H, m, H3, H4), 5.24 (1H, d, 
J = 2.0 Hz, H2), 5.10-5-08 (4H, m, CH2Ph), 4.39 (1H, d, J = 8.8 Hz, H5), 3.69 (3H, s, 
C(O)OCH3), 2.13 (3H, s, C(O)CH3), 2.05 (3H, s, C(O)CH3), 2.01 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 169.6 (C=O, uronate), 169.5 (C=O), 169.5 (C=O), 
167.2 (C=O), 129.1 (Ar-C), 128.7 (Ar-C), 128.7 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 
94.7 (C1), 70.8 (C5), 70.1 (CH2Ph), 69.9 (CH2Ph), 68.2 (C2), 67.6 (C3), 66.4 (C4), 
52.8 (C(O)OCH3), 21.5 (C(O)CH3), 20.7 (C(O)CH3), 20.6 (C(O)CH3);  
31P NMR (161 MHz, CDCl3) δP –3.2 (1P, d,  JH1-P = 6.4 Hz);  
HRMS m/z (ASAP) [Found: (M+H) 595.1586, C27H31O13P requires M+H+, 595.1586].  
Methyl 2,3,4-tri-O-acetyl-α-D-mannopyranosyluronate phosphate   





A suspension of 73 (200 mg, 0.3 mmol, 1.0 equiv.) and 10% Pd/C (0.2 eq. per benzyl 
group) in MeOH (5 mL) was stirred vigorously under an atmosphere of H2 for 5 h. 
The reaction mixture was filtered over CeliteTM, washed with MeOH (20 mL), the 
filtrate treated with Et3N (95 µL, 0.68 mmol, 2.0 equiv.) and concentrated in vacuo 
to afford 60 as a white solid (148 mg, 0.24 mmol, 71%). Data previously reported for 
the bis-tetrabutylammonium salt.105 
Rf 0.45 (EtOAc/MeOH/H2O, 5/3/1);  
[α]26𝐷 	 +16.1 (c = 0.30, MeOH); 
1H NMR (400 MHz, CDCl3) δH 5.62 (1H, d, JH1-P = 7.0 Hz, H1), 5.47 (1H, d, J = 9.9 
Hz, H3), 5.37-5.30 (2H, m, H2, H4), 4.70 (1H, d, J = 10.0 Hz, H5), 3.70 (3H, s, 
C(O)OCH3), 2.93 (12H, q, J = 6.6 Hz, [CH3CH2]3NH+), 2.13 (3H, s, C(O)CH3), 2.03 
(3H, s, C(O)CH3), 1.96 (3H, s, C(O)CH3), 1.25 (18H, t, J = 6.9 Hz, [CH3CH2]3NH+);  
13C NMR (100 MHz, CDCl3) δC 169.9 (2C, C=O), 169.6 (C=O), 168.6 (C=O), 93.6 
(C1), 69.6 (C2), 69.5 (C5), 68.6 (C3), 67.1 (C4), 52.5 (C(O)OCH3), 45.6 
([CH3CH2]3NH+), 20.9 (C(O)CH3), 20.7 (C(O)CH3), 20.6 (C(O)CH3), 9.2 
([CH3CH2]3NH+); 
31P NMR (161 MHz, CDCl3) δP –0.9 (1P, d, JH1-P = 7.0 Hz);  





α-D-mannopyranuronic acid (disodium salt) 42 
 
To a solution of 60 (130 mg, 0.21 mmol, 1.0 equiv.) in MeOH/H2O (2:1, 3 mL/1.5 
mL) was added Et3N (3 mL). The solution was stirred for 18 h then concentrated in 
vacuo (water bath temperature did not exceed 30 °C). Purification by ion-exchange 
chromatography (Dowex® 50W-X8 resin, Na+ form) followed by repeated 
lyophilisation afforded 42 as a cream solid (53 mg, 0.19 mmol, 90%).  
Rf 0.33 (MeCN/H2O with 3 drops NH4OH, 2/1);  
[α]26𝐷 	 +22.2 (c = 0.45, H2O); 
1H NMR (400 MHz, D2O) δH 5.28 (1H, d, JH1-P = 8.6 Hz, H1), 4.02 (1H, d, J = 10.0 
Hz, H5), 3.89-3.83 (2H, m, H2, H3), 3.75-3.65 (1H, m, H4);  
13C NMR (100 MHz, D2O) δC 177.4 (C=O), 95.2 (C1), 72.9 (C4), 71.0 (C2), 70.0 (C3), 
69.0 (C5); 
31P NMR (161 MHz, D2O) δP 1.4 (1P, d, JH1-P = 8.6 Hz); 






6.4.2 α-D-mannopyranuronic acid derivatives: acetyl protected benzyl uronate series 
 
Benzyl 1,2,3,4-tetra-O-acetyl-β-D-mannopyranosyluronate 74  
 
To a solution of 66 (0.43 g, 1.2 mmol, 1.0 equiv.) in DMF (6 mL) was added BnBr 
(0.34 mL, 2.9 mmol, 2.4 equiv.) and K2CO3 (0.25 g, 1.8 mmol, 1.5 equiv.). After 
stirring for 24 h, the solvent was removed in vacuo and the residue reconstituted in 
EtOAc (25 mL), washed with H2O (25 mL) and brine (25 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting in Hex/EtOAc (3/1, 1/1) afforded 74 as a white solid (481 
mg, 1.06 mmol, 88%). These data were in good agreement with literature values.165   
Rf 0.85 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 7.36 (5H, m Ar-H), 5.92 (1H, brs, H1), 5.48 (1H, d, J 
= 2.7 Hz, H2), 5.42 (1H, appt, J = 9.4 Hz, H4), 5.19 (1H, d, J = 3.4 Hz, H3), 5.15 (2H, 
d, J = 8.9 Hz, CH2Ph), 4.19 (1H, d, J = 9.4 Hz, H5), 2.20 (3H, s, C(O)CH3), 2.10 (3H, 
s, C(O)CH3), 1.99 (3H, s, C(O)CH3), 1.79 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.2 (C=O, uronate), 169.6 (C=O), 169.5 (C=O), 
168.4 (C=O), 166.3 (C=O), 134.7 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 128.6 (Ar-C), 
89.9 (C1), 73.3 (C5), 69.7 (C4), 67.9 (CH2Ph), 67.5 (C2), 66.4 (C4), 20.7 (C(O)CH3), 
20.7 (C(O)CH3), 20.5 (C(O)CH3), 20.4 (C(O)CH3);  




HRMS m/z (ES+) [Found: (M+Na)+ 475.1211 C21H24O11Na requires M+Na+, 
475.1217].  
Benzyl 2,3,4-tri-O-acetyl-α/β-D-mannopyranosyluronate 75  
 
To a solution of 74 (100 mg, 0.22 mmol, 1.0 equiv.) in DMF was added hydrazine 
acetate (24 mg, 0.36 mmol, 1.2 equiv.). After stirring for 4 h, the solvent was 
removed in vacuo and the residue reconstituted in EtOAc (10 mL), washed with H2O 
(10 mL) and brine (10 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. Purification by silica gel column chromatography eluting with 
Hex/EtOAc (3/1, 1/1) afforded 75 as a colourless oil (74 mg, 0.18 mmol, 82%). These 
data were in good agreement with literature values.165   
Rf 0.66 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 7.36 (5H, s, Ar-H), 5.45 (1H, dd, J = 9.5, 3.0 Hz, H3), 
5.41 (1H, appt, J = 9.1 Hz, H4), 5.31 (1H, brs, H1), 5.24 (1H, s, H2), 5.17 (1H, s, 
CH2Ph), 5.11 (1H, s, CH2Ph), 4.62 (1H, d, J = 9.0 Hz, H5). 2.14 (3H, s, C(O)CH3), 
1.97 (3H, s, C(O)CH3), 1.78 (3H, s, C(O)CH3); 
13C NMR (100 MHz, CDCl3) δC 170.3 (C=O, uronate), 169.8 (C=O), 168.3 (C=O), 
162.9 (C=O), 128.7 (Ar-C), 128.6 (Ar-C), 92.1 (C1), 69.9 (C2), 69.4 (C5), 68.5 (C3), 









D-mannose 64 (1.5 g, 8.3 mmol, 1.0 equiv.) and TrCl (2.39 g, 8.58 mmol, 1.03 equiv.) 
were suspended in pyridine (12 mL) and stirred at 50 °C for 3 h. The solution was 
cooled to 0 °C, then BzCl (4.85 mL, 41.7 mmol, 5.0 equiv.) was added via a dropping 
funnel over 30 min before being warmed to RT then to 50 °C to aid solubility. After 
stirring for 18 h, the reaction mixture was poured onto H2O/ice (75 mL), extracted 
with EtOAc (100 mL), washed with H2O (3 × 75 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by Reveleris® automated silica gel column 
chromatography, eluting in Pet. Ether/EtOAc (4/1, 3/1) afforded 78 (5.8:1 α/β 
mixture) as a yellow oil (6.47 g, 7.71 mmol, 93%).  
Rf 0.31 (Hex/EtOAc, 3/1);  
1H NMR (400 MHz, CDCl3) δH α-anomer 8.26-8.08 (10H, m, Ar-H), 7.99-7.85 (6H, 
m, Ar-H), 7.76 (3H, d, J = 8.4, 2.5 Hz, Ar-H), 7.70-7.62 (4H, m, Ar-H), 7.59-7.04 
(17H, m, Ar-H), 6.70 (1H, d, J = 1.4 Hz, H1), 6.37 (1H, appt, J = 10.1 Hz, H4), 4.64-
4.48 (1H, m, H2), 4.30 (1H, dd, J = 10.1, 2.7 Hz, H3), 3.56-3.50 (2H, m, H6, H6’), 3.20 
(1H, dd, J = 10.7, 3.5 Hz, H5);  
13C NMR (100 MHz, CDCl3) δC α-anomer 165.9 (C=O), 165.5 (C=O), 165.0 (C=O), 
164.0 (C=O), 143.7 (2C, Ar-C), 134.0 (Ar-C), 133.8 (Ar-C), 133.4 (Ar-C), 133.2 (Ar-




(2C, Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.1 (Ar-C), 127.8 (Ar-C), 
127.4 (Ar-C), 127.0 (Ar-C), 91.8 (C1), 72.3 (C3), 67.1 (C2), 66.2 (C4), 63.2 (C6), 61.6 
(C5);  
HRMS m/z (ES+) [Found: (M+Na)+ 861.2697 C53H42O10 requires M+Na+, 861.2676]. 
1,2,3,4-Tetra-O-benzoyl-α/β-D-mannopyranose 79 
 
To a solution of 78 (2.0 g, 2.4 mmol, 1.0 equiv.) in DCM: MeOH (1:1, 7 mL each) 
was added p-TsOH monohydrate (0.49 g, 0.52 mmol, 1.0 equiv.). After stirring at RT 
for 18 h, the reaction mixture was quenched with Et3N until pH = 7 then concentrated 
in vacuo. Purification by silica gel column chromatography, eluting in Pet. 
Ether/EtOAc (4/1, 3/1, 2/1, 1/1) afforded 79 (4:1 α/β mixture) as a colourless oil (0.82 
g, 1.5 mmol, 61%).  
Rf 0.01 (Pet. Ether/EtOAc, 2/1);  
1H NMR (400 MHz, CDCl3) δH α-anomer 8.22-8.08 (6H, m, Ar-H), 8.02-7.90 (3H, m, 
Ar-H), 7.88-7.82 (2H, m, Ar-H), 7.71-7.31 (16H, m, Ar-H), 6.62 (1H, d, J = 2.1 Hz, 
H1), 6.12 (1H, dd, J = 10.2, 3.4 Hz, H3), 6.01 (1H, appt, J = 10.2 Hz, H4), 5.88 (1H, 
dd, J = 3.3, 2.1 Hz, H2), 4.24 (1H, ddd, J = 10.0, 3.6, 2.3 Hz, H5), 3.85 (1H, dd, J = 
12.9, 2.2 Hz, H6’), 3.80 (1H, dd, J = 12.9, 3.9 Hz, H6);  
13C NMR (100 MHz, CDCl3) δC α-anomer 166.3 (C=O), 165.8 (C=O), 165.4 (C=O), 




130.2 (Ar-C), 130.1 (Ar-C), 129.9 (Ar-C), 128.9 (2C, Ar-C), 128.7 (2C, Ar-C), 128.6 
(Ar-C), 128.5 (Ar-C), 91.5 (C1), 73.5 (C5), 69.7 (C2 or C3), 69.6 (C2 or C3), 66.6 (C4), 
61.3 (C6);  
HRMS m/z (ES+) [Found: (M+NH4)+ 614.2032 C34H28O10NH4 requires M+NH4+, 
614.2065]. 
1,2,3,4-Tetra-O-benzoyl-α/β-D-mannopyranosiduronic acid 80 
 
To a vigorously stirred solution of 79 (240 mg, 0.4 mmol, 1.0 equiv.) in DCM/H2O 
(2:1, 4.2 mL) was added successively TEMPO (13 mg, 80 µmol, 0.2 equiv.) and 
BAIB (322 mg, 1.0 mmol, 2.5 equiv.). After 5 h, the reaction mixture was quenched 
with 10% aqueous Na2S3O3 solution (10 mL) and the organic layer was separated. 
The aqueous layer was acidified to pH 2 through the addition of 1M HCl, then 
extracted with EtOAc (50 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The two organic layers were combined for purification by silica gel column 
chromatography, eluting in Pet. Ether/EtOAc with 2% v/v AcOH, affording 80 (3:1 
α/β mixture) as a colourless oil (100 mg, 0.16 mmol, 41%).  
Rf 0.10 (Pet. Ether/EtOAc, 1/2 with 2% v/v AcOH);  
1H NMR (400 MHz, CDCl3) δH 8.12-8.06 (2H, m, Ar-H), 8.05-7.99 (2H, m, Ar-H), 
7.92-7.88 (2H, m, Ar-H), 7.55 (2H, td, J = 7.4, 3.3 Hz, Ar-H), 7.49-7.37 (6H, m, Ar-




6.60 (1H, d, J = 2.0 Hz, H1), 5.86 (1H, dd, J = 9.3, 3.3 Hz, H3), 5.80-5.76 (1H, m, H2), 
4.60 (1H, appt, J = 9.3 Hz, H4), 4.53 (1H, d, J = 9.4 Hz, H5);  
13C NMR (100 MHz, CDCl3) δC 171.8 (C=O, uronic acid), 166.1 (2C, 2 × C=O), 165.3 
(C=O), 164.2 (C=O), 137.9 (Ar-C), 134.3 (Ar-C), 133.8 (Ar-C), 133.6 (Ar-C), 130.2 
(Ar-C), 130.0 (Ar-C), 129.9 (Ar-C), 129.1 (Ar-C), 129.0 (Ar-C), 128.8 (2C, Ar-C), 
128.7 (Ar-C), 128.5, (Ar-C), 128.4 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 125.3 (Ar-C), 
91.1 (C1), 72.9 (C5), 70.9 (C3), 68.9 (C2), 67.0 (C4);  
HRMS m/z (ES−) [Found: (M−H)− 609.1405 C34H26O11 requires M−H−, 609.1402]. 
Methyl 1,2,3,4-tetra-O-benzoyl-α/β-D-mannopyranosyluronate 81 
 
To a solution of 80 (0.22 g, 0.36 mmol, 1.0 equiv.) in DMF (3.6 mL) was added MeI 
(53 µL, 0.86 mmol, 2.4 equiv.) and K2CO3 (77 mg, 0.54 mmol, 1.5 equiv.). After 12 
h, the reaction mixture was quenched with MeOH (3 mL) then extracted with EtOAc 
(50 mL), washed with H2O (2 × 30 mL) and brine (30 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo Purification by silica gel column 
chromatography, eluting in Pet. Ether/EtOAc (4/1) afforded 81 (6:1 α/β mixture) as 
a colourless oil (95 mg, 0.15 mmol, 42%).  
Rf 0.72 (Pet. Ether/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 8.19-8.15 (2H, m, Ar-H), 8.09 (2H, dd, J = 6.4, 2.1 




6.81 (1H, d, J = 3.4 Hz, H1), 6.10-6.02 (2H, m, H3, H4), 5.89 (1H, dd, J = 6.5, 3.4 Hz, 
H2), 4.79 (1H, d J = 7.7 Hz, H5), 3.68 (3H, s, C(O)OCH3);  
13C NMR (100 MHz, CDCl3) δC 167.9 (C=O, uronate), 166.0 (C=O), 65.8 (C=O), 
165.72 (C=O), 164.24 (C=O), 134.6 (Ar-C), 134.2 (Ar-C), 134.1 (2C, Ar-C), 130.7 
(Ar-C), 130.5 (Ar-C), 130.3 (2C, Ar-C), 129.2 (Ar-C), 129.1 (2C, Ar-C), 129.0 (2C, 
Ar-C), 128.9 (Ar-C), 91.1 (C1), 72.6 (C5), 69.5 (C3 or C4), 69.2 (C3 or C4), 68.2 (C2), 
53.4 (C(O)OCH3). 
Benzyl 1,2,3,4-tetra-O-benzoyl-α/β-D-mannopyranosyluronate 82 
 
To a solution of 80 (0.33 g, 0.54 mmol, 1.0 equiv.) in DMF (5.4 mL) was added BnBr 
(0.32 mL, 1.3 mmol, 2.4 equiv.) and K2CO3 (0.11 g, 0.81 mmol, 1.5 equiv.). After 18 
h, the solvent was removed in vacuo and the resultant residue extracted with EtOAc 
(50 mL), washed with H2O (2 × 30 mL) and brine (30 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting in Pet. Ether/EtOAc (4/1) afforded 82 (3:1 α/β mixture) as 
a white solid (0.19 g, 0.27 mmol, 50%).  
Rf 0.82 (Pet. Ether/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 8.18-8.06 (5H, m, Ar-H), 7.96-7.84 (6H, m, Ar-H), 
7.57-7.43 (5H, m, Ar-H), 7.40-7.28 (5H, m, Ar-H), 7.24-7.11 (4H, m, Ar-H), 6.79 (1H, 




5.89 (1H, appt, J = 3.0 Hz, H2), 5.20 (1H, d, J = 12.1 Hz, CH2Ph), 4.97 (1H, d, J = 
12.1 Hz, CH2Ph), 4.81 (1H, d, J = 8.1 Hz, H5);  
13C NMR (100 MHz, CDCl3) δC 167.1 (C=O, uronate), 165.5 (C=O), 165.4 (C=O), 
165.3 (C=O), 163.9 (C=O), 134.5 (Ar-C), 134.2 (Ar-C), 1339 (Ar-C), 133.7 (Ar-C), 
130.3 (Ar-C), 130.2 (Ar-C), 130.1 (Ar-C), 130.0 (Ar-C), 128.9 (Ar-C), 128.8 (Ar-C), 
128.7 (Ar-C), 128.56 (Ar-C), 90.9 (C1), 72.4 (C5), 69.3 (C2, C3 or C4), 68.9 (C2, C3 or 
C4), 68.2 (CH2Ph), 67.8 (C2, C3 or C4); 
HRMS m/z (ESI+) [Found: (M+Na)+ 723.1843 C41H32O11 requires M+Na+, 723.1843].  
Benzyl ethyl 2,3,4-tri-O-benzoyl-α-D-1-thio-mannopyranosyluronate 85 
 
To a solution of 82 (1.19 g, 1.52 mmol, 1.0 equiv.) in DCE (15.2 mL) at RT was 
added dropwise EtSH (0.18 mL, 2.6 mmol, 1.7 equiv.) and BF3•Oet2 (0.38 mL, 3.0 
mmol, 2.0 equiv.). The reaction mixture was heated to 50 °C for 24 h, then the 
reaction mixture was cooled to RT and quenched with saturated aqueous NaHCO3 
solution (15 mL) and diluted with DCM (100 mL). The organic layer was washed with 
saturated aqueous NaHCO3 solution (50 mL), H2O (75 mL), brine (75 mL) then dried 
(MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting with Pet. Ether/EtOAc (6/1) afforded 85 as a yellow oil (0.40 
g, 0.62 mmol, 41%).  




[α]26𝐷 	 −17.5 (c = 0.25, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 8.18-8.04 (3H, m, Ar-H), 7.98-7.92 (2H, m, Ar-H), 
7.90-7.80 (2H, m, Ar-H), 7.68-7.41 (8H, m, Ar-H), 7.40-7.27 (5H, m, Ar-H), 7.24-7.09 
(5H, m, Ar-H), 6.03 (1H, appt, J = 8.8 Hz, H4), 5.82 (1H, dd, J = 8.8, 3.3 Hz, H3), 5.77 
(1H, appt, J = 3.3 Hz, H2), 5.71 (1H, d, J = 2.6 Hz, H1), 5.21 (1H, d, J = 12.2 Hz, 
CH2Ph), 5.04 (1H, d, J = 8.3 Hz, H5), 4.96 (1H, 12.2 Hz, CH2Ph), 2.78 (2H, q, J = 
8.0 Hz, -SCH2CH3), 1.36 (3H, t, J = 8.0 Hz, -SCH2CH3);  
13C NMR (100 MHz, CDCl3) δC 167.9 (C=O, uronate), 165.6 (C=O), 165.4 (C=O), 
165.3 (C=O), 136.2 (Ar-C), 134.6 , 134.3 (Ar-C), 134.0 (Ar-C), 133.9 (Ar-C), 133.7 
(Ar-C), 133.6 (Ar-C), 130.4 (Ar-C), 130.3 (Ar-C), 130.1 (Ar-C), 130.0 (Ar-C), 129.9 
(Ar-C), 129.3 (Ar-C), 129.0 (2C, Ar-C), 128.9 (Ar-C), 128.7 (Ar-C), 128.6 (2C, Ar-C), 
128.5 (2C, Ar-C), 81.9 (C1), 71.0 (C2), 69.8 (C5), 68.5 (C3), 68.4 (C4), 67.9 (CH2Ph), 
25.7 (-SCH2CH3), 15.0 (-SCH2CH3);  
HRMS m/z (ESI+) [Found: (M+Na)+ 663.1628 C36H32O9S requires M+Na+, 
663.1665].  
Tri-O-benzyl 2,3,4-tri-O-benzoyl-α-D-mannopyranosyluronate phosphate 86 
 
Prepared as per Procedure A using thioglycoside 85 (90 mg, 0.14 mmol, 1.0 equiv.), 




(11 mg, 42 µmol, 0.3 equiv.). Reaction time: 1.5 h. Purification by silica gel column 
chromatography, eluting with Pet. Ether/EtOAc (4/1, 3/1) afforded 86 as a colourless 
oil (35 mg, 41 µmol, 29%). 
Rf 0.51 (Pet. Ether/EtOAc, 2/1); 
[α]26𝐷 	 −76.7 (c = 1.25, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 8.12 (7H, m, Ar-H), 7.65-7.28 (21H, m, Ar-H), 7.21-
7.06 (4H, m, Ar-H), 6.02 (1H, dd, JH1-P = 7.3 Hz, JH1-H2 = 3.1 Hz, H1), 5.97 (1H, appt, 
J = 9.4 Hz, H4), 5.87 (1H, dd, J = 9.4, 2.7 Hz, H3), 5.66 (1H, appt, J = 2.7 Hz, H2), 
5.16-5.09 (5H, m, CH2Ph), 4.96 (1H, d, J = 12.1 Hz, CH2Ph), 4.74 (1H, d, J = 9.4 
Hz, H5);  
13C NMR (100 MHz, CDCl3) δC 170.0 (C=O, uronate), 165.3 (C=O), 165.2 (2 × C=O), 
135.5 (Ar-C), 135.4 (2C, Ar-C), 135.3 (Ar-C), 134.5 (Ar-C), 133.9 (Ar-C), 133.6 (2C, 
Ar-C), 130.2 (Ar-C), 130.0 (Ar-C), 129.9 (2C, Ar-C), 128.9 (2C, Ar-C), 128.8 (2C, Ar-
C), 128.6 (Ar-C), 128.5 (2C, Ar-C), 128.4 (Ar-C), 128.3 (Ar-C), 95.0 (C1), 71.4 (C5), 
70.3 (CH2Ph), 69.4 (C2), 68.7 (C3), 68.1 (2C, CH2Ph), 67.4 (C4);  
31P NMR (161 MHz, CDCl3 δP –3.1 (1P, d, JH1-P = 7.3 Hz);  










Method 1 (Khorana): Dowex® 50W-X8 resin (H+ form, 17 × 700 mm column) was 
exchanged to its morpholine form by passing a 10% aqueous morpholine solution 
through the column (200 mL). Exchange was indicated through a basic pH of the 
eluate (pH 10.87). Guanosine 5’-monophosphate disodium salt 88 (407 mg, 1.0 
mmol, 1.0 equiv.) in H2O (50 mL) was applied to the column and eluates containing 
sodium morpholine-GMP were concentrated in vacuo to a final volume of 10 mL. 
Morpholine (210 µL, 2.4 mmol, 2.4 equiv.) and tBuOH (10 mL) were added and the 
solution was heated to 100 °C at reflux, whilst a solution of DCC (825 mg, 4.0 mmol, 
4.0 equiv.) in t-BuOH (15 mL) was added dropwise over 2 h. The solution was heated 
at reflux for a further 3 h, where TLC analysis) showed two spots (Rf = 0.52 + 0.93), 
and the Rf value of 87 is reported as 0.45.113  The yellow solution cooled to RT and 
was left for 72 h whereupon a white crystalline by-product (dicyclohexylurea) had 
formed. The suspension was filtered and concentrated in vacuo to half its original 
volume and extracted with Et2O (2 × 20 mL). The combined organic layers were 
washed with H2O (120 mL) and the aqueous phase was purified by Sephadex® G-




Fractions containing 87 were visualised, collected and concentrated in vacuo. The 
residue was dissolved in MeOH (10 mL),4-morpholine-N,N’-dicyclo- 
hexylcarboxamidine (600 mg, 2.0 mmol, 2.0 equiv.) was added then the solution 
concentrated in vacuo. The residue was dissolved in MeOH (5 mL) and Et2O (25 
mL) was added to form a white precipitate. The liquid was decanted and the 
precipitate was washed with Et2O (2 × 10 mL), re-dissolved in H2O and lyophilized 
to afford guanosine 5’-phosphoromorpholidate (N,N’-dicylohexylcarboamidinium 
salt) 87 as a white solid (198 mg, 0.27 mmol, 27%). Rf 0.52 (IPA/NH4OH/H2O, 7/1/2); 
31P (161 MHz, D2O) δP – 7.4 (1P, s). 
Method B (Mukaiyama): Sodium morpholine-GMP was prepared as per the above 
procedure. To a solution of morpholine-GMP in DMSO (10 mL) was added 
morpholine (0.58 mL, 6.6 mmol, 5.4 equiv.) to form an opaque white solution. After 
stirring for 5 min at RT, dipyridyl disulphide (0.89 g, 4.1 mmol, 3.3 equiv.) was added 
slowly to the solution followed by Ph3P (1.06 g, 4.1 mmol, 3.3 equiv.). The resultant 
bright yellow solution was stirred for 4 h at RT and a solution of NaI (0.1 M in 
acetone) was then added until a precipitate formed. This was collected by filtration, 
dissolved in H2O and purified by Sephadex® G-25 column chromatography, eluting 
with a gradient of TEAB (0.005 → 0.5 M). Fractions containing 87 were visualised, 
collected and concentrated in vacuo. Repeated lyophilisation afforded guanosine 5’-
phosphoromorpholidate (sodium salt) 87 as a white solid (161 mg, 0.37 mmol, 30%).  
Rf 0.52 (IPA/NH4OH/H2O, 7/1/2);  




1H NMR (400 MHz, D2O) δH 7.93 (1H, s, H8), 5.79 (1H, d, J = 5.0 Hz, H1’), 4.67 (1H, 
t, J = 5.1 Hz, H2’), , 4.41 (1H, t, J = 4.8 Hz, H3’), 4.20 (1H, brs, H4’), 3.95-3.88 (2H, 
m, H5’a, H5’b), 3.47 (4H, t, J = 4.5 Hz, CH2 morpholine), 2.85-2.82 (4H, m, CH2 
morpholine);  
13C{31P} NMR (101 MHz, D2O) δC 159.5 (guanine C), 154.5 (guanine C), 151.68 
(guanine C), 137.25 (C8), 116.4 (guanine C), 87.3 (C1’), 83.7 (C4’), 83.7 (C1’), 73.7 
(C2’), 70.4 (C3’), 66.9 (CH2 morpholine), 64.1 (C5’), 44.7 (CH2 morpholine);  
31P{1H} (161 MHz, D2O) δP –7.5 (1P, s); 
HRMS m/z (ES-) [Found: (M−H)− 431.1080 C14H21N6O8P requires M-H−, 431.1079]. 
Guanosine diphosphate-mannuronic acid (bis-ammonium salt) 4  
 
Chemical Synthesis: Prepared as per Procedure E using 59 (22 mg, 53 µmol, 1.0 
equiv.), GMP-morpholidate 97 (36 mg, 84 µmol, 1.5 equiv.) and DCI (6 mg, 53 µmol, 
1.0 equiv.) in pyridine (1 mL). Reaction time: 120 h. Deprotected as per Procedure 
F. Purification by C18 chromatography and strong-anion exchange chromatography 




ammonium salt, 15 mg, 24 µmol, 46%). These data were in good agreement with 
literature values.105 
Enzymatic Synthesis: GDP-mannose 3 (1.6 mg, 2.5 µmol, 1.0 equiv.) and NAD+ (3.5 
mg, 5.25 µmol, 2.1 equiv.) were dissolved in buffer (0.9 mL, 200 mM sodium 
phosphate, pH 7.4, 1 mM DTT, 0.5 mM MgCl2) and GMD (0.8 mg/mL) was added. 
Final reaction volume: 1 mL. The mixture was incubated at room temperature with 
gentle shaking. After 21 h, the enzymatic transformation was stopped by addition of 
MeOH (1 mL) and the mixture was vortexed and centrifuged (5000 RPM). The 
supernatant was filtered through a syringe disc filter (0.45 µm, PTFE) and purified 
by strong-anion exchange chromatography as described in as described in the 
general experimental details to afford 4 as a white solid (bis-ammonium salt, 1.17 
mg, 1.9 µmol, 70%). These data were in good agreement with literature values.105 Rf 
0.19 (isopropyl alcohol/NH4OH/water, 6/3/1);  
1H NMR (400 MHz, D2O) δH 7.96 (1H, s, H8’’), 5.79 (1H, d, J = 6.1 Hz, H1,), 5.39 (1H, 
dd, JH1-P = 8.0, JH1-H2 = 1.7 Hz, H1), 4.64 (1H, hidden, H2,), 4.35 (1H, dd, J = 4.8, 3.3 
Hz, H3,), 4.34-4.29 (1H, m, H4,), 4.18 (2H, dd, J = 5.2, 3.5 Hz, H5’b), 3.95 (1H, d, J 
=10.0 Hz, H5’a), 3.88 (1H, dd, J = 2.2, 3.3 Hz, H2), 3.78 (1H, dd, J = 9.6, 3.3 Hz, H3), 
3.64 (1H, t, J = 9.7 Hz, H4); 
31P{1H} NMR (101 MHz, D2O) δP −11.2 (1P, s), −13.7 (1P, s); 





6.5 Experimental details for Chapter 3 
6.5.1 Optimisation of MacDonald Phosphorylation 
 
α-D-galactopyranosyl phosphate 94 
 
Prepared as per Procedure D using 93 (300 mg, 0.77 mmol, 1.0 equiv.) and H3PO4 
(377 mg, 3.85 mmol, 5.0 equiv.) at 50 °C. Reaction time: 4 h. 94 was afforded as a 
white solid (152 mg, 0.52 mmol, 67%). These data were in good agreement with 
literature values.166 
1H NMR (400 MHz, D2O) δH 5.31 (1H, dd, JH1-P = 7.3 Hz, JH1-H2 = 3.6 Hz, H1), 4.01 
(1H, dd, J = 7.0, 4.9 Hz, H5), 3.82 (1H, d, J = 2.7 Hz, H4), 3.74 (1H, dd, J = 10.2, 3.4 
Hz, H3), 3.57 (3H, m, H2, H6, H6’);  
13C NMR (101 MHz, D2O) δC 94.1 (C1), 71.0 (C5), 69.6 (C3), 69.0 (C4), 68.7 (C2), 
61.4 (C6);  





α-D-mannopyranosyl phosphate 44 
 
Prepared as per Procedure D using 14 (250 mg, 0.64 mmol, 1.0 equiv.) and H3PO4 
(313 mg, 3.20 mmol, 5.0 equiv.) at 45 °C. Reaction time: 4 h. 44 was afforded as a 
white solid (91 mg, 0.35 mmol, 55%). These data were in good agreement with 
literature values.98 
Rf 0.40 (MeCN/H2O and 3 drops NH4OH, 2/1); 
[α]26𝐷 	 +22.2 (c = 0.45, H2O); 
1H (400 MHz, D2O) δH 5.23 (1H, d, JH1-P = 8.5 Hz, H1), 3.87-3.74 (4H, m, H2, H3, H5, 
H6), 3.66-3.59 (1H, m, H6’) 3.50 (1H, appt, J = 9.6 Hz, H4);  
13C (100 MHz, D2O) δC 95.0 (C1), 73.0, 71.2 (C2), 70.2, 67.2 (C4), 61.3 (C6);  
31P (161 MHz, D2O) δP 2.0 (1P, d, JH1-P = 8.5 Hz);  











To a solution of 66 (0.50 g, 1.4 mmol, 1.0 equiv.) and Ph3P (0.64 g, 2.5 mmol, 1.7 
equiv.) in DCM (14 mL) was added dropwise CCl4 (0.24 mL, 2.5 mmol, 1.7 equiv.). 
The reaction mixture was heated at 40 °C with stirring for 9 h, before being cooled 
to RT, poured onto H2O (30 mL) and diluted with DCM (35 mL). The organic layer 
was washed with H2O (2 × 30 mL), brine (30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by silica gel column chromatography, eluting with 
Pet. ether/EtOAc (4/1, 3/1, 1/1) afforded 96 as a white foam (0.32 g, 0.82 mmol, 
61%).  
Rf 0.78 (Pet. ether/EtOAc, 1/1);  
[α]26𝐷 	 −13.3 (c = 0.75, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 5.87 (1H, d, J = 1.2 Hz, H1), 5.44 (1H, dd, J = 3.3, 1.2 
Hz, H2), 5.26 (1H, appt, J = 9.8 Hz, H4), 5.12 (1H, dd, J = 9.8, 3.3 Hz, H3), 3.84-3.78 
(1H, m, H5), 3.64 (1H, dd, J = 12.2, 2.9 Hz, H6’), 3.57 (1H, dd, J = 12.2, 5.8 Hz, H6), 
2.16 (3H, s, C(O)CH3), 2.07 (3H, s, C(O)CH3), 2.04 (3H, s, C(O)CH3), 1.96 (3H, s, 
C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.2 (C=O), 169.8 (C=O), 169.6 (C=O), 168.4 
(C=O), 90.3 (C1), 74.7 (C5), 70.5 (C3), 68.2 (C2), 66.9 (C4), 42.9 (C6), 20.8 (C(O)CH3), 




HRMS m/z (ESI+) [Found: (M+Na)+ 389.0633 C14H19ClO9 requires M+Na+, 
389.0616]. 
O1,O6-Hydroxyphosphoryl-D-mannopyranose (bis-ammonium salt) 97 
 
Prepared as per Procedure D using 96 (150 mg, 0.41 mmol, 1.0 equiv.) and H2PO4 
(200 mg, 2.1 mmol, 5.0 equiv.). Reaction time: 3 h. 97 was afforded as a white solid 
(15 mg, 71 µmol, 17%). 
Rf 0.30 (MeCN/H2O + 3 drops AcOH); 
1H NMR (400 MHz, D2O) δH 5.29 (1H, appt, JH1-P = 6.8 Hz, H1), 4.39 (1H, s, H5), 4.30 
(1H, dd, J = 5.9, 2.4 Hz, H4), 4.21 (2H, dd, J = 13.6, 8.5 Hz, H3, H6), 4.05 (1H, dd, J 
= 10.8, 2.5 Hz, H6’), 3.85 (1H, d, JH2-P = 6.5 Hz, H2); 
13C NMR (100 MHz, D2O) δC 96.6 (d, JC1-P = 3.2 Hz, C1), 77.0 (C3), 75.4 (C5), 70.2 
(d, JC2-P = 4.4 Hz C2), 70.1 (C4), 69.0 (C6); 
 31P{1H} NMR (161 MHz, D2O) δP 2.0 (1P, s); 





6.5.3 α-D-mannopyranosylurononitrile derivatives  
 
1,2,3,4-Tetra-O-acetyl-β-D-manno-hexodialdo-1,5-pyranoside 103  
 
To a solution of 66 (1.5 g, 4.3 mmol, 1.0 equiv.) in DCM (16 mL) was added DMP 
(2.18 g, 5.2 mmol, 1.2 equiv.). After stirring for 6 h, the reaction mixture was diluted 
with DCM (50 mL) and washed with saturated aqueous Na2S2O3 (50 mL), saturated 
aqueous NaHCO3 solution (50 mL) and H2O (50 mL). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to afford 103 as a white solid which was 
used without any further purification (1.25 g, 3.61 mmol, 84%).  
 Rf 0.37 (Hex/EtOAc, 1/3);  
1H NMR (400 MHz, CDCl3) δH 9.64 (1H, s, CHO), 6.07 (1H, d, J = 2.0 Hz, H1), 5.48 
(1H, dd, J = 3.3, 2.0 Hz, H2), 5.44 (1H, appt, J = 8.0 Hz, H4), 5.20 (1H, dd, J = 8.0 
Hz, 3.3 Hz, H3), 4.07 (1H, d, J = 8.0 Hz, H5), 2.17 (3H, s, C(O)CH3), 2.14 (3H, s, 
C(O)CH3), 2.10 (3H, s, C(O)CH3), 2.03 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 195.6 (CHO), 169.9 (C=O), 169.6 (C=O), 169.6 
(C=O), 168.5 (C=O), 89.6 (C1), 77.7 (C5), 68.7 (C3), 66.8 (C4), 65.4 (C2), 20.8 





1,2,3,4-Tetra-O-acetyl-β-D-mannopyranosyl 6-oxime 104  
 
To a solution of 103 (0.50 g, 1.4 mmol, 1.0 equiv.) in THF (14 mL) was added 
dropwise a solution of NH2OH.HCl (0.10 g, 1.4 mmol 1.0 equiv.) in H2O (2.90 mL). 
After cooling to 0 °C, a solution of Na2CO3 (0.18 g, 1.7 mmol 1.2 equiv.) in H2O (1.73 
mL) was added dropwise at 0 °C before being slowly warmed to RT. After stirring 
for 18 h, the reaction mixture was poured onto H2O (100 mL) and extracted EtOAc 
(3 × 75 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by silica 
gel column chromatography, eluting in Hex/EtOAc (1/2) afforded 104 as a colourless 
oil (0.26 g, 0.73 mmol, 51%).  
Rf 0.74 (Hex/EtOAc, 1/2);  
[α]26𝐷 	−17.4 (c = 1.25, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.39 (1H, d, J = 6.7 Hz, HC=N), 5.93 (1H, d, J = 1.2 
Hz, H1), 5.51 (1H, dd, J = 3.2, 1.2 Hz, H2), 5.33 (1H, d, J = 9.9 Hz, H5), 5.19 (1H, dd, 
J = 9.9, 3.2 Hz, H3), 4.20 (1H, appt, J = 9.9 Hz, H4), 2.22 (3H, s, C(O)CH3), 2.11 (3H, 
s, C(O)CH3), 2.04 (3H, s, C(O)CH3), 2.02 (3H, s, C(O)CH3);  
13C NMR (101 MHz, CDCl3) δC 170.4 (C=O), 169.9 (C=O), 169.8 (C=O) 168.3 
(C=O), 146.4 (C=N), 90.2 (C1), 73.1 (C5), 70.1 (C3), 68.1 (C2), 66.6 (C4), 20.7 (2C, 




HRMS m/z (ES+) [Found: (M+NH4)+ 379.1363 C14H19NO10 requires M+NH4+, 
379.1392].  
1,2,3,4-Tetra-O-acetyl-β-D-mannopyranosylurononitrile 105  
 
To a solution of 104 (500 mg, 1.38 mmol, 1.0 equiv.) in MeCN (34 mL) was added 
POCl3 (0.13 mL, 1.4 mmol, 1.0 equiv.). After 5 min the solution was heated to 65 °C 
and after stirring for 5 h, the reaction mixture was cooled to RT and quenched with 
saturated aqueous NaHCO3 solution (20 mL). The reaction mixture was extracted 
with EtOAc (50 mL), washed with H2O (2 × 30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by silica gel column chromatography, eluting with 
Hex/EtOAc (1/1) afforded 105 as a colourless oil (170 mg, 0.51 mmol, 37%).  
Rf 0.9 (Hex/EtOAc, 1/2);  
[α]26𝐷 	−49.6 (c = 1.65, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 6.10 (1H, d, J = 2.9 Hz, H1), 5.40 (1H, appt, J = 3.1 
Hz, H2), 5.34 (1H, appt, J = 9.0 Hz, H4), 5.24 (1H, dd, J = 6.3, 3.3 Hz, H3), 4.63 (1H, 
d, J = 6.0 Hz, H5), 2.20 (3H, s, C(O)CH3), 2.17 (3H, s, C(O)CH3), 2.15 (6H, s, 
C(O)CH3);  
13C NMR (101 MHz, CDCl3) δC 169.7 (C=O), 169.6 (C=O), 168.9 (C=O), 168.8 
(C=O), 114.7 (C≡N), 88.7 (C1), 67.6 (C4), 66.9 (C3), 65.1 (C2), 61.0 (C5), 20.64 (2C, 




HRMS m/z (ES+) [Found: (M+NH4)+ 361.1252 C14H17NO9 requires M+NH4+, 
361.1286]; 
vmax/cm-1 2240 (C≡N stretching), 1748 (C=O stretching), 1204 (C-O stretching). 
1,2,3,4,6-Penta-O-acetyl-α/β-D-mannopyranose 14 
 
D-mannose 64 (5.0 g, 28 mmol, 1.0 equiv.) was suspended in Ac2O (27.0 mL, 290 
mmol, 10.3 equiv.) and cooled to 0 °C before H2SO4 (2 drops) was added. The 
reaction mixture was warmed to RT over 1 h, before being diluted with H2O/ice (100 
mL) and extracted with EtOAc (100 mL). The organic layer was washed with 
saturated aqueous NaHCO3 solution (2 × 100 mL), H2O (2 × 100 mL) dried (MgSO4), 
filtered and concentrated in vacuo. Repeated co-evaporation to remove residual 
AcOH afforded 14 (3.6:1 α/β) as a colourless oil (10.1 g, 26 mmol, 93%). These data 
were in good agreement with literature values.167 
Rf 0.58 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH (α-anomer) 6.09 (1H, d, J = 2.1 Hz, H1), 5.36-5.35 
(2H, m, H3, H4), 5.27 (1H, d, J = 2.1 Hz, H2), 4.34-4.27 (1H, m, H6), 4.17-4.03 (2H, 
m, H5, H6’), 2.19 (3H, s, C(O)CH3), 2.18 (3H, s, C(O)CH3), 2.10 (3H, s, C(O)CH3), 




13C NMR (100 MHz, CDCl3) δC (α-anomer) 170.6 (C=O), 169.9 (C=O), 169.7 (C=O), 
168.0 (C=O), 166.4 (C=O), 90.63 (C1), 70.6 (C5), 68.8 (C3), 68.4 (C2), 65.6 (C4), 62.1 
(C6), 20.8 (C(O)CH3), 20.7 (2C, C(O)CH3), 20.6 (2C, C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 408.1496 C16H22O11 requires M+NH4+, 
408.1500]. 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranose 15 
 
To a solution of 14 (5.0 g, 12 mmol, 1.0 equiv.) in DCM (10 mL) was added PhSH 
(1.96 mL, 19 mmol, 1.5 equiv.) and BF3•OEt2 (7.58 ml, 61 mmol, 4.8 equiv.) 
dropwise. After 48 h, the reaction mixture was diluted with DCM (20 mL), washed 
with saturated aqueous NaHCO3 solution (3 × 30 mL), 5% aqueous NaOH solution 
(3 × 30 mL), H2O (3 × 30 mL) and brine (30 mL). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. Recrystallisation from the minimum 
amount of absolute EtOH afforded 15 as a yellow solid (3.66 g, 8.3 mmol, 65%). 
These data were in good agreement with literature values.167 
Rf 0.73 (Hex/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 7.50-7.48 (2H, m, Ar-H), 7.35-7.30 (3H, m, Ar-H), 
5.51-5.50 (2H, m, H1, H3), 5.34-5.33 (2H, m, H2, H4), 4.58-4.52 (1H, m, H5), 4.31 
(1H, dd, J = 12.2, 5.9 Hz, H6), 4.11 (1H, dd, J = 12.2, 2.4 Hz, H6’), 2.16 (3H, s, 




13C NMR (100 MHz, CDCl3) δC 170.5 (C=O), 169.9 (C=O), 169.8 (C=O), 169.7 
(C=O), 134.5 (Ar-C), 132.7 (Ar-C), 132.1 (Ar-C), 129.2 (Ar-C), 128.1 (Ar-C), 85.7 
(C1), 70.9 (C3), 69.6 (C5), 69.4 (C2), 66.4 (C4), 62.5 (C6), 20.8 (C(O)CH3), 20.7 
(C(O)CH3), 20.7 (C(O)CH3), 20.6 (C(O)CH3).  
HRMS m/z (ES+) [Found: (M+NH4)+ 458.1475 C20H24O9S requires M+NH4+, 
458.1479]. 
Phenyl 1-thio-α-D-mannopyranoside 109 
 
To a solution of 15 (1.0 g, 2.3 mmol, 1.0 equiv.) in MeOH (10 mL) was added 
dropwise a solution of NaOMe in MeOH (1M, 2 mL total). After stirring for 2 h, the 
reaction mixture was neutralised through addition of AmberliteTM 120 ion-exchange 
resin (H+ form) pH = 7, filtered and concentrated in vacuo. Drying over P2O5 in a 
vacuum desiccator afforded 109 as a white foam which was used without any further 
purification (0.54 g, 2.0 mmol, 87%). These data were in good agreement with 
literature values.168 
Rf 0.05 (Hex/EtOAc, 1/2);  
1H NMR (400 MHz, DMSO-D6) δH 7.52-7.48 (2H, m, Ar-H), 7.35-7.24 (3H, m, Ar-H), 
5.34 (1H, d, J = 1.4 Hz, H1), 5.14 (1H, d, J = 4.2 Hz, C2-OH), 4.89 (1H, d, J = 5.4 Hz, 




(1H, m, H2), 3.76 (1H, dd, J = 10.8, 4.2 Hz, H5), 3.66 (1H, ddd, J = 11.8, 5.7, 2.1 Hz, 
H6’), 3.55-3.43 (3H, m, H3, H4, H6);  
13C NMR (100 MHz, DMSO-d6) δC 135.4 (Ar-C), 131.5 (Ar-C), 129.5 (Ar-C), 127.5 
(Ar-C), 89.4 (C1), 75.9 (C5), 72.4 (C2), 72.0 (C3), 67.5 (C4), 61.4 (C6).  
HRMS m/z (ES+) [Found: (M+NH4)+ 290.1061 C12H16O5S requires M+NH4+, 
290.1062]. 
Phenyl 6-O-trityl mannopyranoside 110 
 
To a solution of 109 (13.5 g, 49 mmol, 1.0 equiv.) in pyridine (245 mL) was added 
TrCl (15.0 g, 53 mmol, 1.1 equiv.). The reaction mixture was heated to 50 °C and 
stirred for 18 h, before the reaction mixture was cooled to RT then concentrated in 
vacuo. The resultant orange oil was co-evaporated with toluene (2 × 30 mL) then 
purified by Reveleris® automated silica gel flash column chromatography, eluting 
with Pet. ether/EtOAc (8/2) to afford 110 as a yellow oil (20.0 g, 39 mmol, 79%). 
These data were in good agreement with literature values.118 
Rf 0.4 (Pet. Ether/EtOAc, 1/1);  
1H NMR (400 MHz, MeOD-d4) δH 7.71-7.67 (2H, m, Ar-H), 7.48-7.42 (5H, m, Ar-H), 
7.29-7.18 (13H, m, Ar-H), 5.54 (1H, d, J = 1.2 Hz, H1), 4.39-4.33 (1H, m, H5), 4.12-
4.02 (1H, m, H2), 3.68 (1H, dd, J = 9.3, 3.3 Hz, H3), 3.56 (1H, appt, J = 9.6 Hz, H4), 




13C NMR (100 MHz, MeOD-d4) δC 145.5 (Ar-C), 136.2 (Ar-C), 132.6 (Ar-C), 130.1 
(Ar-C), 130.0 (Ar-C), 128.7 (Ar-C), 128.3 (Ar-C), 128.0 (Ar-C), 89.9 (C1), 74.8 (C5), 
73.5 (C2), 73.4 (C3), 69.4 (C4), 65.4 (C6);  
HRMS m/z (ESI+) [Found: (M+Na)+ 537.1733 C31H30O5S requires M+Na+, 
537.1712].  
Phenyl 2,3,4-tri-O-benzyl-6-O-trityl mannopyranoside 111 
 
NaH (60% in mineral oil, 3.74 g, 156 mmol, 6.0 equiv.) was washed with hexane (3 
× 10 mL), decanted, dried under high vacuum for 10 min and dissolved in DMF (35 
mL). To this solution was added dropwise at 0 °C a solution of 110 (13.5 g, 26 mmol, 
1.0 equiv.) in DMF (135 mL) over 30 min. The reaction mixture was stirred for 30 
min before BnBr (15.44 mL, 130 mmol, 5.0 equiv.) was added dropwise at 0 °C 
before warming to RT. After stirring for 18 h, the reaction mixture was quenched with 
MeOH (40 mL) then concentrated in vacuo. Purification by Reveleris® automated 
silica gel flash column chromatography, eluting with Pet. ether/EtOAc (8/2) afforded 
111 as a yellow oil (14.2 g, 23 mmol, 89%). These data were in good agreement 
with literature values.118 
Rf 0.79 (Pet. ether/EtOAc, 3/1);  
1H NMR (400 MHz, CDCl3) δH 144.2 (Ar-C), 138.4 (Ar-C), 138.2 (Ar-C), 135.1 (Ar-




C), 128.3 (Ar-C), 128.0 (Ar-C), 127.9 (3C, Ar-C), 127.7 (2C, Ar-C), 127.7 (Ar-C), 
127.2 (Ar-C), 127.0 (Ar-C), 5.68 (1H, d, J = 1.4 Hz, H1), 4.76-4.61 (6H, m, CH2Ph), 
4.31-4.25 (1H, m, H5), 4.15-4.07 (1H, m, H4), 4.02 (1H, dd, J = 3.0, 1.7 Hz, H2), 3.83 
(1H, dd, J = 9.3, 3.1 Hz, H3), 3.54 (1H, dd, J = 10.0, 1.8 Hz, H6’), 3.31, 1H, dd, J = 
10.0, 4.8 Hz, H6);  
13C NMR (100 MHz, CDCl3) δC 144.2 (Ar-C), 138.4 (Ar-C), 138.2 (Ar-C), 135.2(Ar-
C), 135.1 (Ar-C), 131.2 (Ar-C), 129.1 (Ar-C), 129.0 (Ar-C), 128.6(Ar-C), 128.5 (Ar-
C), 128.4 (Ar-C), 128.3 (Ar-C), 128.0 (Ar-C), 127.9 (3C, Ar-C), 127. (3C, Ar-C), 127.2 
(Ar-C), 127.0 (Ar-C), 85.5 (C1), 80.4 (C3), 77.3 (C4), 75.4 (C2), 75.2 (CH2Ph), 72.9 
(C5), 72.5 (CH2Ph), 72.2 (CH2Ph), 63.0 (C6);  
HRMS m/z (ESI+) [Found: (M+Na)+ 807.3154 C52H48O5S requires M+Na+, 
807.3120].  
Phenyl 2,3,4-tri-O-benzyl mannopyranoside 112 
 
To a solution of 111 (14.0 g, 18 mmol, 1.0 equiv.) in dichloromethane and methanol 
(180 mL total, 1:1) was added p-TsOH monohydrate (1.73 g, 9 mmol, 0.5 equiv.) at 
RT. The reaction mixture was stirred for 4 h, quenched with Et3N until pH = 7 and 
concentrated in vacuo. The resultant yellow residue was purified by Reveleris® 




(9/1, 3/1), to afford 112 as a yellow oil (7.82 g, 14 mmol, 79%). These data were in 
good agreement with literature values.118 
Rf 0.46 (Pet. ether/EtOAc, 3/1);  
1H NMR (400 MHz, CDCl3) δH 7.44-7.28 (20H, m, Ar-H), 5.54 (1H, d, J = 1.5 Hz, H1), 
4.99 (1H, d, J = 10.9 Hz, CH2Ph), 4.72-4.62 (5H, CH2Ph), 4.18-4.13 (2H, m, H5), 
4.08 (1H, appt, J = 9.4 Hz, H4), 4.03 (1H, dd, J = 3.0, 1.8 Hz, H2), 3.92 (1H, dd, J = 
9.1, 3.0 Hz, H3), 3.87-3.81 (2H, m, H6, H6’);  
13C NMR (100 MHz, CDCl3) δC 138.4 (Ar-C), 138.2 (Ar-C), 137.9 (Ar-C), 134.0 (Ar-
C), 132.0 (Ar-C), 129.2 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.0 (Ar-C), 127.9 (3C, 
Ar-C), 127. 8 (Ar-C), 86.1 (C1), 80.2 (C3), 76.5 (C2), 75.4 (CH2Ph), 74.9 (C4), 73.4 
(C5), 72.4 (CH2Ph), 72.3 (CH2Ph), 62.3 (C6);  
HRMS m/z (ESI+) [Found: (M+Na)+ 565.2035 C33H34O5S requires M+Na+, 
565.2025].  
Phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-manno-hexodialdo-1,5-pyranoside 113 
 
To a solution of 112 (2.0 g, 3.7 mmol, 1.0 equiv.) in DMSO (37 mL) was added 
successively Et3N (1.53 mL, 11.0 mmol, 3.0 equiv.) and SO3•pyridine (1.75 g, 11.0 
mmol, 3.0 equiv.). After stirring for 3 h, the reaction mixture was extracted with 
EtOAc (100 mL) and washed with H2O (3 × 50 mL) and brine (3 × 50 mL). The 




as a yellow oil which was used without any further purification (1.8 g, 3.3 mmol, 
89%). These data were in good agreement with literature values.118 
Rf 0.24 (Hex/EtOAc, 2/1);  
1H NMR (400 MHz, CDCl3) δH 9.73 (1H, s, CHO), 7.34-7.27 (20H, m, Ar-H), 5.61 
(1H, d, J = 4.1 Hz, H1), 4.66 (2H, d, J = 11.7 Hz, CH2Ph), 4.58-4.48 (5H, m, CH2Ph, 
H5), 4.16-4.10 (1H, m, H4), 3.94-3.92 (1H, m, H2), 3.87 (1H, dd, J = 7.6, 2.9 Hz, H3); 
13C NMR (100 MHz, CDCl3) δC 197.6 (CHO), 137.7 (Ar-C), 137.6 (4C, Ar-C), 129.1 
(Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (3C, Ar-C), 
127.6 (Ar-C), 84.9 (C1), 80.4 (C3), 76.2 (C2), 75.3 (CH2Ph), 74.1 (C4), 73.8 (C5), 72.8 
(CH2Ph), 72.3 (CH2Ph). 
Phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranosyl oxime 114 
 
To a solution of 113 (1.0 g, 1.9 mmol, 1.0 equiv.) in THF (18.5 mL) was added 
dropwise solution of hydroxylamine hydrochloride (0.13 g, 1.9 mmol, 1.0 equiv.) in 
H2O (3.7 mL). The solution was cooled to 0 °C before a solution of Na2CO3 (0.24 g, 
2.2 mmol, 1.2 equiv.) in H2O (2.22 mL) was added dropwise. The solution was stirred 
for 30 min at 0 °C before being warmed to RT. After stirring for 18 h, the reaction 
mixture was poured onto H2O (50 mL) then extracted with EtOAc (50 mL), washed 




vacuo. Purification by silica gel column chromatography, eluting in Pet. ether/EtOAc 
(5/1) afforded 114 as a yellow oil (0.56 g, 1.0 mmol, 56%).  
Rf 0.52 (Hex/EtOAc, 3/1);  
[α]26𝐷  +42.3 (c = 4.10, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.65 (1H, brs, HC=N), 7.46 (1H, d, J = 6.5 Hz, Ar-H), 
7.40-7.23 (19H, m, Ar-H), 5.49 (1H, d, J = 1.6 Hz, H1), 4.85 (1H, m, CH2Ph), 4.76-
4.71 (1H, m, H3), 4.70-4.58 (5H, m, CH2Ph), 4.03-3.97 (2H, m, H2, H4), 3.88-3.85 
(1H, m, H5);  
13C NMR (100 MHz, CDCl3) δC 148.5 (C=N), 138.1 (Ar-C), 138.0 (Ar-C), 137.7 (Ar-
C), 133.9 (Ar-C), 131.7 (Ar-C), 129.1 (Ar-C), 128.4 (2C, Ar-C), 128.2 (Ar-C), 128.0 
(Ar-C), 127.8 (2C, Ar-C), 127.6 (Ar-C), 86.1 (C1), 79.5 (C5), 76.4 (C2 or C4), 76.3 (C2 
or C4), 75.1 (CH2Ph), 72.4 (CH2Ph), 72.3 (CH2Ph), 70.7 (C3);  
HRMS m/z (ES+) [Found: (M+H)+ 556.2166 C33H33NO5S requires M+H+, 556.2158]. 
Phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranosylurononitrile 115 
 
To a solution of 114 (0.14 g, 0.25 mmol, 1.0 equiv.) in MeCN (10 mL) was added 
dropwise POCl3 (38 µL, 0.25 mmol, 1.0 equiv.). The solution was stirred for 5 min at 
RT, before being heated to 65 °C. After stirring for 5 h, the reaction mixture was 




extracted with EtOAc (30 mL). The organic layer was washed with H2O (2 × 30 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting with Pet. ether/EtOAc (4/1) afforded 115 as a colourless oil 
(59 mg, 0.11 mmol, 44%).  
Rf 0.77 (Pet. ether/EtOAc, 3/1);  
[α]26𝐷 	+67.7 (c = 0.95, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.39-7.26 (20H, m, Ar-H), 5.49 (1H, d, J = 2.2 Hz H1), 
4.91-4.87 (3H, m, H5, CH2Ph), 4.69-4.62 (4H, m, CH2Ph), 4.20 (1H, appt, J = 9.1 Hz, 
H4), 3.94 (1H, appt, J = 2.6 Hz, H2), 3.74-3.67 (1H, dd, J = 9.1, 2.9 Hz, H3);  
13C NMR (100 MHz, CDCl3) δC 137.6 (Ar-C), 137.4 (Ar-C), 137.2 (Ar-C), 132.8 (Ar-
C), 131.5 (Ar-C), 129.4 (Ar-C), 128.6 (2C, Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.1 
(3C, Ar-C), 127.9 (Ar-C), 117.1 (C≡N), 86.2 (C1), 78.4 (C3), 76.1 (C4), 75.8 (2C, C2, 
CH2Ph) 72.7 (CH2Ph), 72.6 (CH2Ph), 62.2 (C5);  
HRMS m/z (ES+) [Found: (M+H)+ 538.2055 C33H31NO4S requires M+H+, 538.2053]. 
Dibenzyl phenyl 2,3,4-tri-O-benzyl-α-D-mannopyranosylurononitrile phosphate 116 
 
Prepared as per Procedure A using thioglycoside 115 (76 mg, 0.14 mmol, 1.0 
equiv.), DBP (58 mg, 0.21 mmol, 1.5 equiv.), NIS (47 mg, 0.21 mmol, 1.5 equiv.) 




Purification by silica gel column chromatography, eluting with Pet. ether/EtOAc (3/1) 
afforded 116 as a colourless oil (55 mg, 78 µmol, 56%).  
Rf 0.27 (Pet. ether/EtOAc, 3/1); 
[α]26𝐷 	+10.8 (c = 3.25, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.39-7.27 (25H, m, Ar-H), 5.40 (1H, dd, JH1-P = 8.0 
Hz, JH1-H2 = 1.9 Hz, H1), 5.12 (2H, dd, J = 6.4, 4.8 Hz, CH2Ph), 5.01 (2H, m, CH2Ph), 
4.75 (2H, m, CH2Ph), 4.65-4.56 (4H, m, CH2Ph), 4.26 (1H, d, J = 7.2 Hz, H5), 4.10 
(1H, appt, J = 7.4 Hz, H4), 3.79 (1H, dd, J = 2.8, 1.9 Hz, H2), 3.55 (1H, dd, J = 7.4, 
2.8 Hz, H3);  
13C{31P} NMR (100 MHz, CDCl3) δC 137.7 (Ar-C), 137.5 (Ar-C), 136.8 (Ar-C), 135.7 
(Ar-C), 135.6 (Ar-C), 132.6 (Ar-C), 130.1 (Ar-C), 129.5 (Ar-C), 128.7 (Ar-C), 128.6 
(Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.8 
(Ar-C), 116.11 (C≡N), 95.9 (C1), 77.4 (C3), 75.3 (C4), 75.0 (CH2Ph), 73.3 (C2), 72.7 
(CH2Ph), 69.9 (CH2Ph), 69.8 (CH2Ph), 69.7 (CH2Ph), 63.1 (C5);  
31P NMR (161 MHz, CDCl3) δP –3.1 (1P, d, JH1-P = 8.0 Hz); 









To a solution of 66 (0.40 g, 1.2 mmol, 1.0 equiv.) and Ph3P (0.51 g, 2.0 mmol, 1.7 
equiv.) in DCM (8 mL) at 0 °C was added dropwise a solution of CBr4 (0.65 g, 2.0 
mmol, 1.7 equiv.) in DCM (3 mL) before warming to RT. After 5 h, the reaction 
mixture was poured onto H2O (20 mL), diluted with DCM (20 mL), washed with H2O 
(20 mL), brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Purification by silica gel column chromatography, eluting with Pet. Ether/EtOAc (4/1, 
3/1, 1/1) afforded 98 as a white solid (0.35 g, 0.85 mmol, 74%). Data previously 
reported for the α-anomer.169 
Rf 0.77 (Pet. Ether/EtOAc, 1/1);  
[α]26𝐷 	 −14.6 (c = 0.55, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 5.89 (1H, d, J = 1.2 Hz, H1), 5.47 (1H, dd, J = 3.2, 1.2 
Hz, H2), 5.27 (1H, appt, J = 9.7 Hz, H4), 5.13 (1H, ddd, J = 9.7, 3.2, 1.2 Hz, H3), 3.82 
(1H, ddd, J = 9.4, 6.3, 3.0 Hz, H5), 3.50 (1H, dd, J = 11.4, 3.0 Hz, H6’), 3.42 (1H, dd, 
J = 11.4, 6.3 Hz, H6), 2.20 (3H, s, C(O)CH3), 2.10 (3H, s, C(O)CH3), 2.07 (3H, s, 
C(O)CH3), 1.99 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.3 (C=O), 169.9 (C=O), 169.7 (C=O), 168.5 
(C=O), 90.4 (C1), 74.5 (C5), 70.6 (C3), 68.3 (C2), 68.1 (C4), 30.3 (C6), 20.9 (2C, 








To a solution of 98 (0.25 g, 0.72 mmol, 1.0 equiv.) in pyridine (4.8 mL) was added 
pTsCl (0.47 g, 2.5 mmol, 3.4 equiv.). After stirring for 7 h, the reaction mixture was 
poured onto H2O (10 mL) and diluted with CHCl3 (30 mL). The organic layer was 
washed with saturated aqueous NaHCO3 solution (2 × 20 mL), H2O (2 × 20 mL), 
brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. Drying under high 
vacuum afforded 121 as a colourless syrup (0.34 g, 0.67 mmol, 93%). Data 
previously reported for the α-anomer.169  
Rf 0.82 (Pet. Ether/EtOAc, 1/2);  
[α]26𝐷 	−6.7 (c = 1.65, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 7.78-7.74 (2H, m, Ar-H), 7.33 (2H, d, J = 8.0 Hz, Ar-
H), 7.30-7.27 (1H, m, Ar-H), 5.79 (1H, d, J = 1.2 Hz, H1), 5.42 1H, dd, J = 3.2, 1.2 
Hz, H2), 5.20 (1H, appt, J = 9.8 Hz, H4), 5.08 (1H, J = 9.8, 3.2 Hz, H3), 4.13 (2H, d, 
J = 4.3 Hz, H6, H6’), 3.79 (1H, dd, J = 9.6, 4.3 Hz, H5), 2.43 (3H, s, -OphCH3), 2.16 





13C NMR (100 MHz, CDCl3) δC 170.3 (C=O), 169.9 (C=O), 169.7 (C=O), 168.3 
(C=O), 149.9 (Ar-C), 145.2 (Ar-C), 136.1 (Ar-C), 132.6 (Ar-C), 130.0 (Ar-C), 128.2 
(Ar-C), 90.3 (C1), 70.9 (C5), 70.5 (C4), 68.1 (C3), 67.6 (C2), 65.8 (C6), 21.8 (-
OphCH3), 20.8 (C(O)CH3), 20.7 (2C, C(O)CH3), 20.6 (C(O)CH3);  




To a solution of 121 (0.20 g, 0.39 mmol, 1.0 equiv.) in DMF (3.9 mL) was added 
successively 15-crown-5 ether (0.23 mL, 1.20 mmol, 3.0 equiv.) and NaN3 (78 mg, 
1.20 mmol, 3.0 equiv.). The reaction mixture was heated to 60 °C and after stirring 
for 24 h, the reaction mixture was cooled to RT, poured onto H2O (20 mL) and 
extracted with EtOAc (25 mL). The organic layer was washed with 10% aqueous 
Na2S2O3 solution (20 mL), H2O (20 mL), brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by silica gel column chromatography, eluting with 
Tol/EtOAc (5/1, 4/1) afforded 120 as a colourless oil (31 mg, 83 µmol, 32%). Data 
previously reported for the α-anomer.169 
Rf 0.33 (Tol/acetone, 4/1) 




1H NMR (400 MHz, CDCl3) δH 5.86 (1H, d, J = 1.2 Hz, H1), 5.47 (1H, dd, J = 3.2, 1.2 
Hz, H2), 5.25 (1H, appt, J = 10.0 Hz, H4), 5.11 (1H, dd, J = 10.0, 3.2 Hz, H3), 3.78-
3.72 (1H, m, H5), 3.38 (2H, dd, J = 13.4, 4.5 Hz, H6, H6’), 2.21 (3H, s, C(O)CH3), 2.09 
(3H, s, C(O)CH3), 2.05 (3H, s, C(O)CH3), 1.99 (3H, s, C(O)CH3); 
13C NMR (100 MHz, CDCl3) δC 170.3 (C=O), 169.9 (C=O), 169.8 (C=O), 168.5 
(C=O), 90.3 (C1), 74.5 (C5), 70.7 (C3), 68.2 (C2), 66.5 (C4), 50.8 (C6), 20.9 (C(O)CH3), 
20.8 (2C, C(O)CH3), 20.6 (C(O)CH3); 
HRMS m/z (ESI+) [Found: (M+Na)+ 396.1039 C14H19N3O9 requires M+Na+, 
396.1019]. 
6-Azido-6-deoxy-α-D-mannopyranosyl phosphate (bis-ammonium salt) 119 
 
Prepared as per Procedure D using 120 (100 mg, 0.27 mmol, 1.0 equiv.) and H3PO4 
(127 mg, 1.30 mmol, 5.0 equiv.). Reaction time: 4 h. 119 was afforded as a white 
solid (48 mg, 0.17 mmol, 65%). Data previously reported for the bis-
triethylammonium salt.96  
Rf 0.28 (MeCN/H2O, 3/1 plus 3 drops AcOH); 
[α]26𝐷 	 +3.6 (c = 0.71, H2O); 
1H NMR (400 MHz, D2O) δH 5.07 (1H, dd, JH1-P = 8.4 Hz, JH1-H2 = 1.9 Hz, H1), 3.72-




13C NMR (101 MHz, D2O) δC 94.9 (C1), 72.4, 71.1, 69.7, 67.2 (C3), 51.0 (C6); 
31P NMR (162 MHz, D2O) δP 1.4 (1P, d, JH1-P = 8.4 Hz);  
HRMS m/z (ESI-) [Found: (M-H)- 284.0288, C6H11N3O8P requires M−H−, 284.0284].  
6.5.5 6-Deoxy-6-thio-α-D-mannopyranose derivatives 
1,2,3,4-Tetra-O-acetyl-6-S-acetyl-6-deoxy-β-D-mannopyranose 123 
 
To a solution of 96 (58 mg, 0.16 mmol, 1.0 equiv.) in DMF (1.6 mL) was added KSAc 
(54 mg, 0.48 mmol, 3.0 equiv.). The reaction mixture was heated to 75 °C and stirred 
for 24 h, cooled to RT then poured onto H2O (10 mL) and extracted with EtOAc (20 
mL). The organic layer was washed with saturated aqueous NaHCO3 solution (15 
mL), H2O (15 mL), brine (15 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Purification by silica gel column chromatography, eluting with Pet. Ether/EtOAc (2/1) 
afforded 123 as an orange oil (55 mg, 0.14 mmol, 88%).  
Rf 0.38 (Pet. Ether/EtOAc, 2/1); 
[α]26𝐷 	 	−7.3 (c = 1.45, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 5.80 (1H, d, J = 1.2 Hz, H1), 5.45-5.43 (1H, dd, J = 
3.2, 1.1 Hz, H2), 5.18 (1H, appt, J = 9.8, H4), 5.07 (1H, dd, J = 9.8, 3.2 Hz, H3), 3.68 
(1H, ddd, J = 9.8, 7.5, 2.7 Hz, H5), 3.28, 1H, dd, J = 14.3, 2.5 Hz, H6’), 3.03 (1H, dd, 
J = 14.3, 7.4 Hz, H6), 2.32 (3H, s, SC(O)CH3), 2.19 (3H, s, C(O)CH3), 2.10 (3H, s, 




13C NMR (100 MHz, CDCl3) δC 194.9 (SC=O), 170.3 (C=O), 170.1 (C=O), 169.9 
(C=O), 168.4 (C=O), 90.5 (C1), 74.7 (C5), 70.7 (C3), 68.4 (C2), 67.8 (C4), 30.5 
(SC(O)CH3), 30.2 (C6), 20.9 (2C, C(O)CH3), 20.8 (C(O)CH3), 20.6 (C(O)CH3);  
HRMS m/z (ESI+) [Found: (M+NH4)+ 424.1284 C16H22O10S requires M+NH4+, 
424.1317]. 
6-Deoxy-6-thio-α-D-mannopyranosyl phosphate disulphide (tetra-ammonium salt) 
124 and 6-Deoxy-6-thio-α-D-mannopyranosyl phosphate mixed disulphide (bis-
ammonium salt) 125 
 
Prepared as per Procedure D using 123 (100 mg, 0.25 mmol, 1.0 equiv.) and H3PO4 
(240 mg, 2.50 mmol, 5.0 equiv.). Reaction time: 4 h. A mixture of 124 and 125 were 
afforded as white solids (5 mg, 18 µmol, 7%).  
Rf 0.15 (MeCN/H2O, 3/1 plus 3 drops AcOH); 
1H NMR (400 MHz, D2O) δH 5.34 (1H, d, JH1-P = 8.1 Hz, disulphide 124)), 5.16 
(0.40H, d, J = 1.3 Hz, mixed disulphide 125), ratio: 2.5:1;  
31P{1H} NMR (162 MHz, D2O) δP 0.9 (0.40P, s, mixed disulphide 125), 0.4 (1P, s, 




HRMS m/z (ESI-) Disulphide 124: [Found: (M−H)- 548.9910, C12H23O16P2S2 requires 
M-H-, 548.9908]. Mixed disulphide 125: [Found: (M−H)− 469.0239 C12H22O13PS2 
requires M-H-, 469.0240]. 
6.5.6 4-Deoxy-4-fluoro-α-D-mannopyranose derivatives 
 
Phenyl 4,6-O-benzylidene-1-thio-α-D-mannopyranoside 131  
 
To a solution of 109 (13.5 g, 49 mmol, 1.0 equiv.) in DMF (150 mL) was added 
successively at 0 °C BDMA (7.5 mL, 50 mmol, 1.02 equiv.) and HBF4•OEt2 (6.9 mL, 
51 mmol, 1.03 equiv.) before warming to RT. After stirring for 18 h, the reaction 
mixture was quenched with Et3N until pH = 7 then concentrated in vacuo. The 
resultant yellow residue was recrystallized from absolute EtOH to afford 131 as a 
white solid (11.0 g, 30 mmol, 62%). These data were in good agreement with 
literature values.168 
Rf 0.79 (Pet. ether/EtOAc, 1/2);  
1H NMR (400 MHz, DMSO-d6) δH 7.51-7.29 (12H, m, Ar-H), 5.63 (1H, s, 
benzylidene-H), 5.55 (1H, d, J = 4.1 Hz, C2-OH), 5.47 (1H, d, J = 0.9 Hz, H1), 5.22 
(1H, d, J = 6.0 Hz, C3-OH), 4.10-4.03 (1H, m, H5, H6), 4.01 (1H, s, H2), 3.94 (1H, 
appt, J = 9.3 Hz, H4), 3.81-3.73 (2H, m, H3, H6’);  
13C NMR (100 MHz, DMSO-d6) δC 137.8 (Ar-C), 133.7 (Ar-C), 131.3 (2C, Ar-C), 
129.3 (2C, Ar-C), 128.9 (Ar-C), 128.0 (2C, Ar-C), 127.5 (Ar-C), 126.4 (2C, Ar-C), 




HRMS m/z (ESI+) [Found: (M+Na)+ 383.0948 C19H20O5S requires M+Na+, 
383.0929].  
Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-α-D-mannopyranoside 132 
 
NaH (60% in mineral oil, 0.20 g, 8.2 mmol, 2.7 equiv.) was washed with hexane (3 
× 20 mL) and decanted, dried under high vacuum and dissolved in DMF (2.5 mL). A 
solution of 131 (1.09 g, 3.0 mmol, 1.0 equiv.) in DMF (15 mL) was added dropwise 
to the suspension of NaH at 0 °C over 15 min. BnBr (0.97 mL, 8.2 mmol, 2.7 equiv.) 
was then added dropwise over 15 min, before the reaction mixture was warmed to 
RT. After stirring for 18 h, the reaction mixture was quenched with MeOH (40 mL), 
concentrated in vacuo and the residue reconstituted in DCM (100 mL). The organic 
layer was washed with H2O (2 × 50 mL), brine (2 × 50 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Purification by silica gel column chromatography, eluting 
with Pet. ether/EtOAc (4/1) afforded 132 as a white solid (1.35 g, 2.5 mmol, 82%). 
These data were in good agreement with literature values.170  
Rf 0.90 (Pet. ether/EtOAc, 2/1); 
1H NMR (400 MHz, CDCl3) δH 7.54 (2H, dd, J = 7.6, 1.9 Hz, Ar-H), 7.41-7.35 (18H, 
m, Ar-H), 5.67 (1H, s, benzylidene-H), 5.53 (1H, d, J = 1.4 Hz, H1), 4.85 (1H, d, J = 
12.2 Hz, CH2Ph), 4.74 (1H, s, CH2Ph), 4.68 (1H, d, J = 12.2 Hz, CH2Ph), 4.37-4.22 
(3H, m, H4, H5, H6), 4.07 (1H, dd, J = 3.2, 1.4 Hz, H2), 3.99 (1H, dd, J = 9.5, 3.2 Hz, 




13C NMR (100 MHz, CDCl3) δC 138.5 (Ar-C), 138.4 (Ar-C), 137.8 (Ar-C), 137.7 (Ar-
C), 133.9 (Ar-C), 132.6 (Ar-C), 131.8 (Ar-C), 129.3 (2C, Ar-C), 129.0 (Ar-C), 128.6 
(Ar-C), 128.5 (2C, Ar-C), 128.4 (Ar-C), 128.3 (2C, Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 
127.8 (2C, Ar-C), 126.4 (Ar-C), 126.2 (2C, Ar-C), 101.6 (benzylidene-C), 87.3 (C1), 
79.2 (C4), 78.2 (C2), 76.4 (C3), 73.2 (CH2Ph), 72.3 (CH2Ph), 68.6 (C6), 65.6 (C5);  
HRMS m/z (ESI+) [Found: (M+Na)+ 563.1896 C33H32O5S requires M+Na+, 
563.1868].  
Phenyl 2,3-di-O-benzyl-1-thio-α-D-mannopyranoside 133 
 
To a solution of 132 (2.8 g, 5.2 mmol, 1.0 equiv.) in MeOH (21 mL) was added p-
TsOH (0.2 g, 1.0 mmol, 0.2 equiv.). The reaction mixture was heated at reflux (85 
°C) for 2 h, cooled to RT, quenched with Et3N (2 mL) and concentrated in vacuo. 
The residue was reconstituted in DCM (80 mL), washed with saturated aqueous 
NaHCO3 solution (2 x 50 mL), H2O (2 x 50 mL), brine (50 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Purification by Reveleris® automated silica gel flash 
column chromatography (liquid injection onto column), eluting with Hex/EtOAc (1/0, 
7/3, 1/1, 0/1) afforded 133 as a white solid (1.7 g, 3.8 mmol, 72%). These data were 
in good agreement with literature values.171  




1H NMR (300 MHz, CDCl3) δH 7.43-7.20 (15 H, m, Ar-H), 5.51 (1 H, d, J = 1.2 Hz, 
H1), 4.60 (1 H, d, J = 12.2 Hz, CH2Ph), 4.50 (2 H, s, CH2Ph), 4.49 (1 H, d, J = 12.1 
Hz, CH2Ph), 4.18-4.10 (1 H, m, H4), 4.09-4.02 (1 H, m, H5), 3.92 (1 H, dd, J = 2.9, 
1.5 Hz, H2), 3.80 (2 H, m, H6, H6’), 3.67 (1 H, dd, J = 9.2, 3.0 Hz, H3), 3.59 (1 H, d, J 
= 3.2 Hz, C4-OH), 2.86 (1 H, t, J = 5.7 Hz, C6-OH);  
13C NMR (75 MHz, CDCl3) δC 138.0 (Ar-C), 137.8 (Ar-C), 134.2, (Ar-C) 131.9 (Ar-
C), 129.2 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-
C), 127.9 (Ar-C), 127.7 (Ar-C), 86.1 (C1), 79.6 (C3), 75.9 (C2), 73.8 (C5), 72.3 
(CH2Ph), 72.1 (CH2Ph), 67.0 (C4), 62.3 (C6);  
LRMS (ES+) m/z 470 [(M+NH4)+, 100%];  
HRMS (ES+) m/z [Found: (M+NH4)+ 470.1993 C26H28O5S requires M+NH4+, 
470.1996].  
Phenyl 6-O-benzoyl-2,3-di-O-benzyl-1-thio-α-D-mannopyranoside 134 
 
To a solution of 133 (1.0 g, 2.2 mmol, 1.0 equiv.) in pyridine (12 mL) at 0 °C was 
added successively DMAP (0.13 g, 1.1 mmol, 0.5 equiv.) and BzCl (0.31 mL, 2.7 
mmol, 1.2 equiv.). The reaction mixture was warmed to RT and after stirring for 24 
h was extracted with DCM (40 mL). The organic layer was washed with 0.5 M HCl 
(40 mL), saturated aqueous NaHCO3 solution (40 mL), H2O (40 mL), brine (40 mL), 




chromatography, eluting with Hex/EtOAc (5/1, 3/1) afforded 134 as a colourless oil 
(1.08 g, 1.9 mmol, 88%).  
Rf 0.93 (Hex/EtOAc, 1/1);  
[α]26𝐷 	 +8.9 (c = 4.05, CHCl3); 
1H (400 MHz, CDCl3) δH 8.01-7.98 (1H, m, Ar-H), 7.55-7.17 (20H, m, Ar-H), 5.65 
(1H, d, J = 1.4 Hz, H1), 4.71 (6H, m, H6, H6’, CH2Ph), 4.43 (1H, d, J = 9.6 Hz, H5), 
4.15 (1H, appt, J = 9.6 Hz, H4), 4.04 (1H, dd, J = 3.0, 1.4 Hz, H2), 3.73 (1H, dd, J = 
9.6, 3.0 Hz, H3);  
13C (100 MHz, CDCl3) δC 166.7 (C=O), 137.8 (Ar-C), 134.1 (Ar-C), 133.0 (Ar-C), 
131.6 (Ar-C), 130.1 (Ar-C), 129.9 (Ar-C), 129.1 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 
128.3 (Ar-C), 128.1 (Ar-C), 128.1 (Ar-C), 127.8 (Ar-C), 127.8 (Ar-C), 127.6 (Ar-C), 
85.7 (C1), 79.6 (C3), 75.7 (C2), 72.0 (CH2Ph), 71.9 (CH2Ph), 71.8 (C5), 66.9 (C4), 
64.2 (C6);  







138 and Phenyl 6-O-benzoyl-2,3-di-O-benzyl-4-deoxy-4-fluoro-1-thio-α-D-
idopyranoside 139 
 
Prepared as per Procedure C using thioglycoside 134 (240 mg, 0.43 mmol, 1.0 
equiv.) in DCM (3 mL) and DAST (0.45 mL, 3.4 mmol, 8.0 equiv.) in DCM (2.25 mL). 
Reaction time: 18 h. Purification by silica gel column chromatography, eluting in 
Hex/EtOAc (9/1, 7/1) afforded a mixture of regioisomers 138 and 139 (59 mg, 0.11 
mmol, 26%).  
Rf 0.7 (Hex/EtOAc, 3/1);  
19F NMR{1H} (376 MHz, CDCl3) δF –197.0 (1F, s);  





Prepared as per Procedure A using crude thioglycosides 138/139 (56 mg, 0.1 mmol, 




and AgOTf (8 mg, 31 µmol, 0.3 equiv.) in DCM (2 mL). Reaction time: 18 h. 
Purification by silica gel column chromatography, eluting in Hex/EtOAc (3/1, 2/1) 
afforded 140 as a colourless oil (14 mg, 19 µmol, 19%).  
Rf 0.23 (Hex/EtOAc, 3/1);  
[α]26𝐷 	 +6.6 (c = 0.95, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.99-7.95 (2H, m, Ar-H), 7.51-7.47 (1H, m, Ar-H), 
7.38-7.27 (22H, m, Ar-H), 5.68-5.64 (1H, m, H1), 5.04-4.97 (4H, m, CH2Ph), 5.01 
(1H, ddd, JH4-F = 52.0 Hz, JH4-H5 = 9.6 Hz, JH4-H3 = 9.3 Hz, H4), 4.67 (2H, d, J = 11.6 
Hz, CH2Ph), 4.56 (2H, dd, J = 11.9, 6.4 Hz, CH2Ph), 4.49 (1H, dd, J = 10.4, 1.9 Hz, 
H6’), 4.40 (1H, ddd, J = 12.3, 4.1, 1.3 Hz, H6), 4.06-3.99 (1H, m, H5), 3.85 (1H, ddd, 
JH3-F = 12.6, JH3-H4 = 9.3, JH3-H2 = 3.2 Hz, H3), 3.72 (1H, dd, J = 5.1, 2.8 Hz, H2);  
13C NMR (100 MHz, CDCl3) δC 166.2 (C=O), 137.9 (Ar-C), 137.6 (Ar-C), 135.5 (Ar-
C), 135.4 (Ar-C), 133.0 (Ar-C), 129.7 (Ar-C), 128.8 (Ar-C), 128.7 (2C, Ar-C), 128.4 
(2C, Ar-C), 128.3 (Ar-C), 128.1 (2C, Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 
95.9 (C1), 88.7 (d, JC4-F = 179 Hz, C4), 76.0 (C3), 75.9 (C2), 73.3 (CH2Ph), 72.9 
(CH2Ph), 70.5 (C5), 69.8 (CH2Ph), 69.7 (CH2Ph), 62.5 (C6);  
19F{1H} NMR (376 MHz, CDCl3) δF –202.9 (1F, s);  
31P{1H} NMR (161 MHz, CDCl3) δP –2.9 (1P, s);  





Phenyl 2,3,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 142 
 
A solution of 132 (0.26 g, 0.48 mmol, 1.0 equiv.) in DCM (4.8 mL) was cooled to 0 
°C. Me2EtSiH (0.16 mL, 1.20 mmol, 2.5 equiv.) was added dropwise and stirred for 
10 min, before BF3•OEt2 (59 µL, 0.48 mmol, 1.0 equiv.) was added dropwise. After 
stirring for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 
solution (5 mL) and diluted with DCM (50 mL). The organic layer was washed with 
saturated aqueous NaHCO3 solution (25 mL), H2O (25 mL), brine (25 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting with Tol/acetone (8/1, 6/1, 5/1) afforded 142 as a colourless 
oil (0.13 g, 0.24 mmol, 50%). These data were in good agreement with literature 
values.172  
Rf 0.52 (Pet. ether/EtOAc, 3/1);  
1H NMR (400 MHz, CDCl3) δH 7.48-7.43 (2H, m, Ar-H), 7.37-7.19 (18H, m, Ar-H), 
5.60 (1H, d, J = 1.4 Hz, H1), 4.68 (1H, d, J = 12.1 Hz, CH2Ph), 4.62-4.47 (5H, m, 
CH2Ph), 4.28 (1H, ddd, J = 9.1, 5.3, 3.5 Hz, H5), 4.12 (1H, appt, J = 9.4 Hz, H4), 4.00 
(1H, dd, J = 3.1, 1.4 Hz, H2), 3.85-3.76 (2H, m, H6, H6’), 3.68 (1H, dd, J = 9.4, 3.1 
Hz, H3);  
13C NMR (100 MHz, CDCl3) δC 138.4 (Ar-C), 137.9 (2C, Ar-C), 134.4 (Ar-C), 131.8 




127.9 (Ar-C), 127.7 (Ar-C), 127.6 (2C, Ar-C), 85.9 (C1), 79.7 (C3), 77.2 (C2), 75.7 
(CH2Ph), 73.5 (CH2Ph), 72.5 (C5), 72.0 (CH2Ph), 70.2 (C6), 67.9 (C4);  
HRMS m/z (ES+) [Found: (M+NH4)+ 560.2499 C33H34O5S requires M+NH4+, 
560.2510].  
Phenyl 2,3,6-tri-O-benzyl-4-deoxy-4-fluoro-1-thio-α-D-mannopyranoside 143 and 
Phenyl 2,3,6-tri-O-benzyl-4-deoxy-4-fluoro-1-thio-α-D-idopyranoside 144 
 
Prepared as per Procedure C using thioglycoside 142 (70 mg, 0.13 mmol, 1.0 equiv.) 
in DCM (1.3 mL) and DAST (0.13 mL, 1.0 mmol, 8.0 equiv.) in DCM (1 mL). Reaction 
time: 16 h. Purification by silica gel column chromatography, eluting with Tol/acetone 
(9/1) afforded a mixture of regioisomers 143 and 144 (33 mg, 59 µmol, 45%).  
Rf 0.86 (Pet. Ether/EtOAc, 3/1); 
19F NMR{1H} (376 MHz, CDCl3) δF –201.8 (1F, s);  






Dibenzyl 2,3,6-tri-O-benzyl-4-deoxy-4-fluoro-α-D-mannopyranosyl phosphate 145 
 
Prepared as per Procedure A using crude thioglycosides 143/144 (100 mg, 0.18 
mmol, 1.0 equiv.), DBP (75 mg, 0.27 mmol, 1.5 equiv.), NIS (61 mg, 0.27 mmol, 1.5 
equiv.) and AgOTf (14 mg, 54 µmol, 0.3 equiv.) in DCM (2 mL). Reaction time: 2.5 
h. Purification by silica gel column chromatography, eluting with Pet. Ether/EtOAc 
(5/1, 3/1, 1/1) afforded 145 as a yellow oil (52 mg, 73 µmol, 41%).  
Rf 0.17 (Pet. Ether/EtOAc, 3/1);  
[α]26𝐷 	 +0.7 (c = 0.25, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.35-7.21 (25H, m, Ar-H), 5.71-5.67 (1H, m, H1), 5.00-
4.93 (4H, m, CH2Ph), 4.89 (1H, ddd, JH4-F = 52.0 Hz, JH4-H5 = 10.0 Hz, JH4-H3 = 9.3 
Hz), 4.66-4.59 (4H, m, CH2Ph), 4.58-4.46 (2H, CH2Ph), 3.94 (1H, dtd, J = 9.8, 5.2, 
1.9 Hz, H5), 3.81 (1H, ddd, JH3-F = 12.7 Hz, JH3-H4 = 9.3 Hz, JH3-H2 = 3.2 Hz, H3), 3.69 
(1H, dt, J = 5.4, 2.5 Hz, H2), 3.67-3.58 (2H, m, H6, H6’);    
13C NMR (100 MHz, CDCl3) δC 138.1 (2C, Ar-C), 137.6 (Ar-C), 135.6 (Ar-C), 128.8 
(2C, Ar-C), 128.7 (Ar-C), 128.4 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 
127.8 (Ar-C), 127.7 (2C, Ar-C), 96.1 (C1), 87.8 (d, JC4-F = 179 Hz, C4), 76.2 (C3), 75.5 





19F NMR (376 MHz, CDCl3) δF –202.5 (1F, dd, JH4-F = 52.0 Hz, JH3-F = 12.7 Hz);  
31P{1H} NMR (161 MHz, CDCl3) δP –2.8 (1P, s);  
HRMS m/z (ESI+) [Found: (M+Na)+ 719.2152 C40H40O7S2 requires M+Na+, 
719.2113].  
4-Deoxy-4-fluoro-α-D-mannopyranosyl phosphate (bis-ammonium salt) 130 
 
A suspension of 145 (48 mg, 67 µmol, 1.0 equiv.) and Pd/C (10% loading, 11 mg, 
10 µmol, 0.03 equiv. per benzyl group) and Pd(OH)2/C (20% loading, 7 mg, 10 µmol, 
0.03 equiv. per benzyl group) in EtOH//THF (2:1, 0.9:0.45 mL) with 5% aqueous 
NaHCO3 solution (250 µL) was stirred vigorously under an atmosphere of H2 for 20 
h. The reaction mixture was filtered over CeliteTM, washed with MeOH/H2O (2:1, 15 
mL) and MeOH/H2O (1:1, 20 mL) then concentrated in vacuo. The residue was 
reconstituted in H2O and purified by strong anion exchange chromatography, eluting 
with H2O (3 column volumes, 15 mL) and 1M NH4HCO3 (3 column volumes, 15 mL). 
This afforded 130 as a white solid (bis-ammonium salt, 15 mg, 57 µmol, 85%).  
Rf 0.38 (MeCN/H2O, 3/1 with 3 drops AcOH);  
[α]26𝐷 	 +20.8 (c = 0.45, H2O); 
1H NMR (400 MHz, D2O) δH 5.41 (1H, brs, H1), 4.60 (1H, dd, JH4-F = 52.0 Hz, JH4-H3 




13C NMR (100 MHz, D2O) δC 95.7 (C1), 87.9 (d, JC4-F = 176.0 Hz, C4), 70.9 (d, JC3-F 
= 24.4 Hz, C3), 68.4 (C2 or C5), 68.2 (C2 or C5), 60.11 (C6);  
19F NMR (376 MHz, D2O) δF –205.3 (1F, dd, JF-H4 = 52.0 Hz, JF-H3 = 13.3 Hz); 
 31P{1H} NMR (161 MHz, D2O) δP –2.2 (1P, s);  
HRMS m/z (ES−) [Found: (M−H)− 261.0182 C6H12FO8P requires M−H−, 261.0181]. 




To a solution of 103 (1.0 g, 2.9 mmol, 1.0 equiv.) in DCM (28 mL) was added Et3N 
(0.48 mL, 3.5 mmol, 1.2 equiv.) dropwise. After stirring for 2 h the reaction mixture 
was diluted with DCM (50 mL) and washed with 1M HCl (50 mL), saturated aqueous 
NaHCO3 solution (50 mL), H2O (50 mL) and brine. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting in Hex/EtOAc (1/2) afforded 147 as a yellow oil (0.52 g, 1.8 
mmol, 63%).  
Rf 0.45 (Hex/EtOAc, 1/3);  
[α]26𝐷  +39.5 (c = 0.55, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 9.29 (1H, s, CHO), 6.48 (1H, dd, J = 2.1 Hz, 1.1 Hz, 




= 4.2 Hz, 2.1 Hz, H3), 2.15 (3H, s, C(O)CH3), 2.13 (3H, s, C(O)CH3), 2.12 (3H, s, 
C(O)CH3); 
13C NMR (100 MHz, CDCl3) δC 184.9 (CHO), 170.0 (C=O), 169.7 (C=O), 168.6 
(C=O), 150.2 (C5), 114.3 (C4), 88.4 (C1), 65.0 (C3), 62.1 (C2), 20.7 (C(O)CH3), 20.6 
(C(O)CH3), 20.5 (C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 304.1039 C12H14O8 requires M+NH4+, 
304.1072]. 
1,2,3-Tri-O-acetyl-4-deoxy-β-D-manno-hex-4-eno-1,5-pyranoside 148  
 
To a solution of 147 (1.29 g, 4.5 mmol, 1.0 equiv.) in THF (45 mL) at 0 °C was added 
NaBH4 (0.20 g, 5.4 mmol, 1.2 equiv.) before warming to RT. After 2 h, the reaction 
mixture was quenched with saturated aqueous NH4Cl solution (30 mL), extracted 
with EtOAc (40 mL) and washed with H2O (50mL) and brine (50 mL). The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. Purification by silica 
gel column chromatography, eluting in Hex/EtOAc (1/2) afforded 148 as a colourless 
oil (0.89 g, 3.1 mmol, 68%).  
Rf 0.63 (Hex/EtOAc, 1/3);  




1H NMR (400 MHz, CDCl3) δH 6.36 (1H, d, J = 2.6 Hz, H1), 5.55 (1H, appt, J = 4.9 
Hz, H3), 5.34 (1H, dd, J = 4.9, 2.6 Hz, H2), 5.13 (1H, d, J = 4.9 Hz, H4), 4.07 (2H, 
brs, H6, H6’), 2.16 (3H, s, C(O)CH3), 2.10 (3H, s, C(O)CH3), 2.09 (3H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.6 (C=O), 169.9 (C=O), 169.5 (C=O), 154.2 (C5), 
95.0 (C4), 87.9 (C1), 65.9 (C2), 61.7 (C3 or C6), 61.6 (C3 or C6), 20.9 (2C, C(O)CH3), 
20.6 (C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 306.1197 C12H16O8 requires M+NH4+, 
306.1228]. 
1,2,3-Tri-O-acetyl-4-deoxy-6-O-tert-butyldimethylsilyl-β-D-manno-hex-4-eno-1,5-
pyranoside 149  
 
To a solution of 148 (135 mg, 0.47 mmol, 1.0 equiv.) in MeCN (5 mL) was added 
DMAP (29 mg, 0.24 mmol, 0.5 equiv.). The solution was cooled to 0 °C then 
imidazole (35 mg, 0.52 mmol, 1.1 equiv.) and TBDMSCl (107 mg, 0.71 mmol, 1.5 
equiv.) were added successively before warming to RT. After stirring for 3 h, the 
reaction mixture was extracted with EtOAc (40 mL) and washed with H2O (2 × 30 
mL), brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification 
by silica gel column chromatography, eluting in Hex/EtOAc (1/1) afforded 149 as a 
yellow oil (103 mg, 0.26 mmol, 54%).  




[α]26𝐷  +5.1 (c = 2.35, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 6.26 (1H, d, J = 2.7 Hz, H1), 5.49 (1H, td, J = 5.1, 1.2 
Hz, H3), 5.25 (1H, dd, J = 5.1, 2.7 Hz, H2), 5.05 (1H, dt, J = 5.1, 1.3 Hz, H4), 3.98 
(2H, brs, H6, H6’), 2.07 (3H, s, C(O)CH3), 2.01 (6H, s, C(O)CH3), 0.85-0.81 (15H, m, 
2 × -SiCH3, 3 × -SiC(CH3)3);   
13C NMR (100 MHz, CDCl3) δC 170.5 (C=O), 169.7 (C=O), 169.4 (C=O), 154.6 (C5), 
93.6 (C4), 87.6 (C1), 66.0 (C2), 61.5 (C3), 61.5 (C6), 25.9 (-SiC(CH3)3), 25.8 (-
SiC(CH3)3), 25.6 (-SiC(CH3)3), 20.9 (2C, C(O)CH3), 20.6 (C(O)CH3); 18.3 (-
SiC(CH3)3), –5.4  (2C, 2 × -SiCH3); 




To a solution of 148 (0.20 g, 0.7 mmol, 1.0 equiv.) in DCM (6.9 mL) was added 
DMAP (43 mg, 0.35 mmol, 0.5 equiv.). The solution was cooled to 0 °C then pyridine 
(62 µL, 0.76 mmol, 1.1 equiv.) and BzCl (0.12 mL, 1.0 mmol, 1.5 equiv.) were added 
successively before warming to RT. After stirring for 15 h, the reaction mixture was 
diluted with DCM (50 mL) and washed with 0.5 M HCl (30 mL), saturated aqueous 
NaHCO3 solution (2 × 30 mL), H2O (30 mL) and brine (30 mL). The organic layer 




column chromatography, eluting in Hex/EtOAc (1/1) afforded 150 as a colourless oil 
(0.19 g, 0.49 mmol, 71%).  
Rf 0.8 (Hex/EtOAc, 1/2); 
[α]26𝐷 	 +5.0 (c = 4.05, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 8.05 (2H, d, J = 7.5 Hz, Ar-H), 7.59 (1H, t, J = 7.5 Hz, 
Ar-H), 7.46 (2H, t, J = 7.5 Hz, Ar-H), 6.40 (1H, brs, H1), 5.59-5.57 (1H, m, H3), 5.39-
5.35 (1H, m, H2), 5.22 (1H, d, J = 4.6 Hz, H4), 4.77 (2H, brs, H6, H6’), 2.14 (3H, s, 
C(O)CH3), 2.09 (6H, s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.4 (C=O), 169.7 (C=O), 169.2 (C=O), 165.7 
(C=O), 150.2 (C5), 133.4 (Ar-C), 129.8 (Ar-C), 129.5 (Ar-C), 128.5 (Ar-C), 97.5 (C4), 
87.8 (C1), 65.7 (C2), 62.4 (C6), 61.4 (C3), 20.8 (2C, C(O)CH3), 20.6 (C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 410.1472 C19H20O9 requires M+NH4+, 
410.1490]. 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl bromide 155 
 
To a solution of 14 (0.50 g, 1.3 mmol, 1.0 equiv.) in DCM (4 mL) at 0 °C was added 
successively PBr3 (0.20 mL, 2.2 mmol, 1.7 equiv.) and H2O (0.14 mL, 7.7 mmol, 6.0 
equiv.). After 15 min, the reaction mixture was warmed to RT and after stirring for 3 




mL) and extracted with DCM (50 mL). The organic layer was washed with H2O (2 × 
40 mL), brine (40 mL), dried (MgSO4), filtered and concentrated in vacuo to afford 
155 as a yellow oil (0.44 g, 1.1 mmol, 84%). These data were in good agreement 
with literature values.173 
Rf 0.51 (Pet. ether/EtOAc, 2/1);  
1H NMR (400 MHz, CDCl3) δH 6.28 (1H, d, J = 1.3 Hz, H1), 5.70 (1H, dd, J = 10.2, 
3.4 Hz, H3) 5.43 (1H, dd, J = 3.4, 1.3 Hz, H2), 5.36 (1H, appt, J = 10.2 Hz, H4), 4.32 
(1H, dd, J = 12.5, 4.9 Hz, H6), 4.24-4.18 (1H, m, H5), 4.12 (1H, dd, J = 12.5, 2.2 Hz, 
H6’), 2.17 (3H, s, C(O)CH3), 2.10 (3H, s, C(O)CH3), 2.06 (3H, s, C(O)CH3), 2.00 (3H, 
s, C(O)CH3);  
13C NMR (100 MHz, CDCl3) δC 170.9 (C=O), 170.1 (C=O), 169.9 (2C, 2 × C=O), 
83.4 (C1), 73.1 (C5), 72.5 (C2), 68.3 (C3), 65.6 (C4), 61.8 (C6), 21.1 (C(O)CH3), 21.0 
(2C, C(O)CH3), 20.9 (C(O)CH3).  
1,2,3,6-Tetra-O-acetyl-4-deoxy-β-D-manno-hex-eno-1,5-pyranoside 158 
 
To a solution of 148 (90 mg, 0.31 mmol, 1.0 equiv.) in DCM (3.1 mL) was added 
successively DMAP (18 mg, 0.16 mmol, 0.5 equiv.), pyridine (38 µL, 0.47 mmol, 1.5 
equiv.) and Ac2O (60 µL, 0.62 mmol, 2.0 equiv.). After stirring for 3 h, the reaction 
mixture was diluted with DCM (25 mL), washed with 1M HCl (20 mL), saturated 
aqueous NaHCO3 solution (20 mL), H2O (20 mL), brine (20 mL), dried (MgSO4), 




eluting with Pet. ether/EtOAc (3/1, 1/1) afforded 158 as a colourless oil (62 mg, 0.19 
mmol, 61%).  
Rf 0.61 (Pet. ether/EtOAc, 1/1);  
[α]26𝐷 	 +19.9 (c = 1.80, CHCl3); 
1H (400 MHz, CDCl3) δH 6.27 (1H, dd, J = 2.6, 1.0 Hz, H1), 5.48-5.44 (1H, dd, J = 
5.0, 1.0 Hz, H3), 5.24 (1H, dd, J = 5.1, 2.6 Hz, H2), 5.04 (1H, d, J = 4.8 Hz, H4), 4.42 
(2H, brs, H6, H6’), 2.06 (3H, s, C(O)CH3), 2.01 (3H, s, C(O)CH3), 2.00 (3H, s, 
C(O)CH3), 1.99 (3H, s, C(O)CH3);  
13C (100 MHz, CDCl3) δC 170.3 (C=O), 170.0 (C=O), 169.6 (C=O), 169.1 (C=O), 
149.9 (C5), 97.5 (C4), 87.7 (C1), 65.5 (C2), 62.0 (C6), 61.3 (C3), 20.7 (2C, (C(O)CH3), 
20.6 (C(O)CH3), 20.4 (C(O)CH3); 
HRMS m/z (ESI+) [Found: (M+NH4)+ 348.1299 C14H18O9 requires M+NH4+, 
348.1334].  
Phenyl 6-O-tert-butyldimethylsilyl-1-thio-α-D-mannopyranose 160 
 
To a solution of 109 (1.16 g, 4.3 mmol, 1.0 equiv.) in MeCN (21 mL) was added 
successively DMAP (0.26 g, 2.1 mmol, 0.5 equiv.), imidazole (0.32 g, 4.7 mmol, 1.1 
equiv.) and TBDMSCl (0.96 g, 6.4 mmol, 1.5 equiv.). After stirring for 2 h, the solvent 




silica gel column chromatography, eluting in Pet. ether/EtOAc (1/1, 1/2) to afford 160 
as a white solid (1.44 g, 3.7 mmol, 87%). These data were in good agreement with 
literature values.174 
Rf 0.26 (Pet. ether/EtOAc, 1/1);  
1H NMR (400 MHz, CDCl3) δH 7.43-7.39 (2H, m, Ar-H), 7.26-7.17 (3H, m, Ar-H), 5.48 
(1H, d, J = 1.1 Hz, H1), 4.16 (1H, brs, H2), 4.08 (1H, dd, J = 5.4, 3.5 Hz, H4), 3.87-
3.79 (3H, m, H3, H6, H6’), 3.72 (1H, s, H5), 3.58 (1H, d, J = 3.4 Hz, C3-OH), 3.28 (1H, 
d, J = 4.2 Hz, C2-OH), 0.84 (9H, s, 3 × -SiC(CH3)3), 0.04 (6H, s, 2 × -SiCH3); 
13C NMR (100 MHz, CDCl3) δC 134.2 (Ar-C), 131.6 (Ar-C), 129.2 (Ar-C), 127.5 (Ar-
C), 87.9 (C1), 72.3 (C5), 72.0 (C2), 71.7 (C4), 70.9 (C3), 64.8 (C6), 26.0 (3C, 3 × -
SiC(CH3)3), 18.4 (-SiC(CH3)3), –5.3  (2C, 2 × -SiCH3); 




To a solution of 160 (1.36 g, 3.5 mmol, 1.0 equiv.) in DCM (35 mL) was added 
successively pyridine (0.85 mL, 10 mmol, 3.0 equiv.), Ac2O (1.32 mL, 14.0 mmol, 
4.0 equiv.) and DMAP (0.21 g, 1.8 mmol, 0.5 equiv.). After stirring for 3 h, the 
reaction mixture was diluted with DCM (100 mL) then washed with H2O (2 × 50 mL), 




silica gel column chromatography, eluting in Pet. ether/EtOAc (3/1) afforded 161 as 
a colourless oil (1.54 g, 3.0 mmol, 86%).  
Rf 0.79 (Pet. ether/EtOAc, 1/1);  
[α]26𝐷  +91.2 (c = 3.50, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.49-7.45 (2H, m, Ar-H), 7.29-7.22 (2H, m, Ar-H), 5.43 
(2H, m, H2, H1), 5.31 (1H, appt, J = 9.8 Hz, H4), 5.26 (1H, dd, J = 9.8, 3.0 Hz, H3), 
4.31 (1H, ddd, J = 9.2, 5.2, 2.4 Hz, H5), 3.70 (2H, ddd, J = 14.0, 11.5, 3.9 Hz, H6, 
H6’), 2.08 (3H, s, C(O)CH3), 2.02 (3H, s, C(O)CH3), 1.98 (3H, s, C(O)CH3), 0.87-0.84 
(9H, m, 3 × -SiC(CH3)3), 0.00 (6H, s, 2 × -SiCH3);  
13C (100 MHz, CDCl3) δC 170.2 (2C, C=O), 169.8 (C=O), 133.4 (Ar-C), 132.2 (Ar-C), 
129.2 (Ar-C), 128.0 (Ar-C), 85.9 (C1), 72.6 (C3), 71.4 (C2), 69.9 (C3), 66.8 (C4), 62.5 
(C6), 26.0 (3C, 3 × -SiC(CH3)3), 21.0 (C(O)CH3), 20.9 (C(O)CH3), 20.8 (C(O)CH3), 
18.5 (-SiC(CH3)3), –5.3 (2C, 2 × -SiCH3); 




To a solution of 160 (0.74 g, 1.9 mmol, 1.0 equiv.) in DCM (12.5 mL) was added 




equiv.) and BzCl (1.11 mL, 9.6 mmol, 5.0 equiv.). After stirring for 7 h, the reaction 
mixture was diluted with DCM (70 mL), washed with H2O (2 × 30 mL), brine (2 × 30 
mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by silica gel 
column chromatography, eluting with Pet. ether/EtOAc (8/1) afforded 163 as a 
colourless oil (0.99 g, 1.4 mmol, 74%). These data were in good agreement with 
literature values.175  
Rf 0.93 (Pet. ether/EtOAc, 2/1);  
1H NMR (400 MHz, CDCl3) δH 8.09 (2H, dd, J = 5.2, 3.2 Hz, Ar-H), 8.02-7.97 (2H, 
m, Ar-H), 7.91-7.85 (2H, m, Ar-H), 6.07 (1H, appt, J = 10.1 Hz, H4), 5.94 (1H, dd, J 
= 3.2, 1.6 Hz, H2), 5.81 (1H, dd, J = 10.1, 3.2 Hz, H3), 5.76 (1H, d, J = 1.6 Hz, H1), 
4.68 (1H, ddd, J = 10.0, 4.7, 2.2 Hz, H5), 3.90 (2H, ddd, J = 13.8, 11.5, 3.5 Hz, H6, 
H6’), 0.90-0.86 (9H, m, 3 × -SiC(CH3)3), 0.02-0.00 (6H, m, 2 × -SiCH3); 
13C NMR (100 MHz, CDCl3) δC 165.9 (C=O), 165.8 (C=O), 165.6 (C=O), 133.8 (Ar-
C), 133.7 (Ar-C), 133.6 (Ar-C), 133.5 (Ar-C), 130.3 (Ar-C), 130.1 (2C, Ar-C), 129.7 
(Ar-C), 129.5 (Ar-C), 129.4 (Ar-C), 128.9 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 128.3 
(Ar-C), 86.4 (C1), 73.1 (C5), 72.5 (C2), 71.2 (C3), 67.2 (C4), 62.6 (C6), 26.2 (3C, 3 × -





Phenyl 2,3,4-tri-O-acetyl-1-thio-α-D-mannopyranoside 162 
 
To a solution of 161 (0.50 g, 0.98 mmol, 1.0 equiv.) in DCM (9.8 mL) at 0 °C was 
added BF3•OEt2 (61 µL, 0.49 mmol, 0.5 equiv.). After stirring for 2.5 h, the reaction 
mixture was quenched with saturated aqueous NaHCO3 solution (10 mL) then 
diluted with DCM (50 mL). The organic layer was washed with H2O (30 mL), brine 
(30 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by silica gel 
column chromatography, eluting with Tol/acetone (7/1) afforded 162 as a colourless 
oil (0.29 g, 0.73 mmol, 74%). These data were in good agreement with literature 
values.176,177 
Rf 0.24 (Pet. ether/EtOAc, 2/1);  
[α]26𝐷 	+87.5 (c = 2.00, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.46 (2H, dt, J = 4.6, 2.6 Hz, Ar-H), 7.34-7.27 (3H, m, 
Ar-H), 5.50 (1H, dd, J = 3.2, 1.5 Hz, H2), 5.49 (1H, d, J = 1.4 Hz, H1), 5.37 (1H, dd, 
J = 10.1, 3.2 Hz, H3), 5.30 (1H, appt, J = 9.9 Hz, H4), 4.28 (1H, dd, J = 9.9, 1.3 Hz, 
H5) 3.71-3.59 (2H, m, H6, H6’), 2.13 (3H, s, C(O)CH3), 2.09 (3H, s, C(O)CH3), 2.02 
(3H, s, C(O)CH3); 
13C NMR (100 MHz, CDCl3) δC 170.9 (C=O), 170.1 (C=O), 169.9 (C=O), 132.7 (Ar-




71.9 (C5), 71.1 (C3), 69.3 (C2), 66.6 (C4), 61.3 (C6), 21.0 (C(O)CH3), 20.8 (C(O)CH3), 
20.7 (C(O)CH3);  
HRMS m/z (ES+) [Found: (M+Na)+ 421.0936 C18H22O8S requires M+Na+, 421.0933]. 
Phenyl 2,3,4-tri-O-acetyl-1-thio-α-D-manno-hexodialdo-1,5-pyranoside 165 
 
To a solution of 162 (0.26 g, 0.65 mmol, 1.0 equiv.) in DCM (6.5 mL) was added 
DMP (0.33 g, 0.78 mmol, 1.2 equiv.). After stirring for 6 h, the reaction mixture was 
quenched with 10% aqueous Na2S2O3 solution (10 mL) then diluted with DCM (50 
mL). The organic layer was washed with 10% aqueous Na2S2O3 solution (25 mL), 
saturated aqueous NaHCO3 solution (25 mL), H2O (25 mL), brine (25 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Drying under high vacuum afforded 
165 as a white solid (0.24 g, 0.60 mmol, 92%) which was used without any further 
purification.  
Rf 0.07 (Pet. ether/EtOAc, 2/1);  
1H NMR (400 MHz, CDCl3) δH 9.59 (1H, s, CHO), 7.55-7.44 (3H, m, Ar-H), 7.34-7.28 
(2H, m, Ar-H), 5.54 (1H, d, J = 2.7 Hz, H1), 5.47 (1H, appt, J = 2.7 Hz, H2), 5.44 (1H, 
appt, J = 9.3 Hz, H4), 5.35-5.31 (1H, m, H3) 4.62 (1H, d, J = 9.2 Hz, H5), 2.13 (3H, s, 




13C NMR (100 MHz, CDCl3) δC 196.0 (CHO), 169.9 (2C, C=O), 169.7 (C=O), 133.3 
(Ar-C), 132.2 (Ar-C), 132.1 (Ar-C), 129.5 (Ar-C), 128.4 (Ar-C), 85.5 (C1), 74.9 (C5), 




To a solution of 165 (0.24 g, 0.60 mmol, 1.0 equiv.) in DCM (6 mL) was added Et3N 
(0.10 mL, 0.72 mmol, 1.2 equiv.). After stirring for 3 h, the reaction mixture was 
diluted with DCM (50 mL), washed with H2O (2 × 25 mL), brine (25 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by silica gel column 
chromatography, eluting with Pet. ether/EtOAc (2/1, 1/1) afforded 166 as a yellow 
oil (0.11 g, 0.33 mmol, 55%).  
Rf 0.80 (Pet. ether/EtOAc, 1/1);  
[α]26𝐷 	+221.9 (c = 4.70, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 9.28 (1H, s, CHO), 7.55-7.51 (2H, m, Ar-H), 7.36-7.32 
(3H, m, Ar-H), 5.89 (1H, dd, J = 2.9 Hz, 1.5 Hz, H4), 5.81 (1H, dd, J = 4.4, 2.9 Hz, 
H3), 5.63 (1H, d, J = 3.8 Hz, H1), 5.49 (1H, appt, J = 4.0 Hz, H2), 2.11 (3H, s, 




13C NMR (100 MHz, CDCl3) δC 185.5 (CHO), 169.9 (C=O), 169.8 (C=O), 150.1 (C5), 
133.4 (Ar-C), 131.2 (Ar-C), 129.5 (Ar-C), 129.2 (Ar-C), 129.0 (Ar-C), 128.3 (Ar-C), 
116.3 (C4), 84.9 (C1), 65.7 (C2), 63.1 (C3), 20.8 (2C, C(O)CH3);  
HRMS m/z (ES+) [Found: (M+NH4)+ 354.1018 C16H16O6S requires M+NH4+, 
354.1051]. 
Phenyl 2,3-di-O-acetyl-4-deoxy-1-thio-α-D-manno-hex-4-eno-1,5-pyranoside 167 
 
To a solution of 166 (172 mg, 0.51 mmol, 1.0 equiv.) in THF (5.1 mL) was added at 
0 °C NaBH4 (23 mg, 0.61 mmol, 1.2 equiv.). After stirring for 1.5 h, the reaction 
mixture was quenched with saturated aqueous NH4Cl solution (5 mL), extracted with 
EtOAc (30 mL), washed with H2O (2 × 25 mL), brine (25 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Purification by silica gel column chromatography, eluting 
with Pet. ether/EtOAc (2/1, 1/1, 1/2) afforded 167 as a colourless oil (90 mg, 0.27 
mmol, 52%).  
Rf 0.30 (Pet. ether/EtOAc, 2/1);  
[α]26𝐷 	+180.7 (c = 2.40, CHCl3); 
1H (400 MHz, CDCl3) δH 7.52-7.48 (2H, m, Ar-H), 7.33-7.29 (3H, m, Ar-H), 5.54 (1H, 
ddd, J = 4.3, 2.6, 0.9 Hz, H3), 5.45 (1H, d, J = 7.3 Hz, H1), 5.17 (1H, dd, J = 8.0, 4.0 
Hz, H2), 5.01-4.99 (1H, d, J = 4.0 Hz, H4), 4.04 (2H, d, J = 4.6 Hz, H6, H6’); 2.08 (3H, 




13C (100 MHz, CDCl3) δC 170.4 (C=O), 169.7 (C=O), 155.5 (C5), 133.2 (Ar-C), 131.4 
(Ar-C), 129.2 (Ar-C), 128.6 (Ar-C), 94.8 (C4), 83.0 (C1), 66.7 (C2), 63.4 (C3), 61.9 
(C6), 21.0 (C(O)CH3), 20.8 (C(O)CH3); 
HRMS m/z (ES+) [Found: (M+Na)+ 351.0735 C16H18O6S requires M+Na+, 351.0721]. 
Phenyl 2,3,6-tri-O-acetyl-4-deoxy-1-thio-α-D-manno-hex-4-eno-1,5-pyranoside 168 
 
To a solution of 167 (90 mg, 0.27 mmol, 1.0 equiv.) in DCM (2.7 mL) was added 
successively DMAP (16 mg, 0.14 mmol, 0.5 equiv.), pyridine (33 µL, 0.41 mmol, 1.5 
equiv.) and Ac2O (51 µL, 0.54 mmol, 2.0 equiv.). After stirring for 2 h, the reaction 
mixture was diluted with DCM (30 mL), washed with 1M HCl (20 mL), saturated 
aqueous NaHCO3 solution (20 mL), H2O (20 mL), brine (20 mL), dried (MgSO4), 
filtered and concentrated in vacuo. Purification by silica gel column chromatography, 
eluting with Pet. ether/EtOAc (2/1, 1/1) afforded 168 as a colourless oil (73 mg, 0.19 
mmol, 71%).  
Rf 0.52 (Pet. ether/EtOAc, 2/1); 
[α]26𝐷 	+247.2 (c = 1.40, CHCl3); 
1H (400 MHz, CDCl3) δH 7.53 (2H, m, Ar-H), 7.33-7.30 (3H, m, Ar-H), 5.55 (1H, appt, 
J = 4.3 Hz, H3), 5.46 (1H, d, J = 6.7 Hz, H1), 5.21 (1H, dd, J = 6.7, 4.3 Hz, H2), 5.04-
5.01 (1H, m, H4), 4.51 (2H, d, J = 5.8 Hz, H6, H6’), 2.09 (3H, s, C(O)CH3), 2.07 (3H, 




13C (100 MHz, CDCl3) δC 170.6 (C=O), 170.5 (C=O), 170.0 (C=O), 151.3 (C5), 133.6 
(Ar-C), 131.8 (Ar-C), 129.5 (Ar-C), 129.0 (Ar-C), 98.0 (C4), 83.6 (C1), 66.7 (C2), 63.5 
(C3), 62.9 (C6), 21.3 (C(O)CH3), 21.2 (2C, C(O)CH3);  
HRMS m/z (ES+) [Found: (M+Na)+ 403.0845 C18H20O7S requires M+Na+, 403.0828]. 
Iodosobenzene 170 
 
A freshly prepared solution of 3M NaOH (24 mL) was added dropwise to a beaker 
equipped with stirring bar containing BAIB (5.0 g, 15.5 mmol) at 0 °C. The solution 
was stirred vigorously and agitated with a spatula to break up solid lumps then after 
15 min removed from the ice bath and warmed to RT. After 45 mins, 20 mL of water 
was added to the vigorously stirring solution and the crude solid was collected in a 
sinter funnel. This procedure was repeated once again then the solid was dried. The 
dry yellow solid was triturated with chloroform (20 mL) then collected in a sinter 
funnel and left to dry under vacuum for 3 h, then dried overnight in a desiccator over 









To a solution of 112 (500 mg, 0.92 mmol, 1.0 equiv.) in DCM (9 mL) at 0 °C was 
added successively Ph3P (410 mg, 1.56 mmol, 1.7 equiv.) and CBr4 (520 mg, 1.56 
mmol, 1.7 equiv.) before warming to RT. After stirring for 16 h, the reaction mixture 
was poured onto H2O (30 mL) and diluted with DCM (30 mL). The organic layer was 
washed with H2O (2 × 30 mL), brine (30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by silica gel column chromatography, eluting with 
Pet. ether/EtOAc (6/1) afforded 175 as a yellow oil (420 mg, 0.69 mmol, 75%).  
Rf 0.90 (Pet. ether/EtOAc, 3/1);  
[α]26𝐷 	 +51.4 (c = 0.70, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 7.48-7.45 (2H, m, Ar-H), 7.40-7.27 (18H, m, Ar-H), 
5.59 (1H, d, J = 1.5 Hz, H1), 5.01 (1H, d, J = 10.9 Hz, CH2Ph), 4.76-4.60 (5H, m, 
CH2Ph), 4.31-4.25 (1H, m, H5), 4.06-4.00 (2H, m, H2, H4), 3.87 (1H, dd, J = 9.3, 3.0 
Hz, H3), 3.69-3.66 (2H, m, H6, H6’);  
13C NMR (100 MHz, CDCl3) δC 138.3 (Ar-C), 138.1 (Ar-C), 137.9 (Ar-C), 134.2 (Ar-
C), 131.8 (Ar-C), 129.2 (Ar-C), 128.6 (2C, Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.0 
(3C, Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 86.0 (C1), 80.1 (C3), 76.9 (C4), 76.3 (C2), 75.6 








To a solution of 175 (0.36 g, 0.59 mmol, 1.0 equiv.) in DMF (4 mL) was added NaN3 
(77 mg, 1.2 mmol, 2.0 equiv.). The reaction mixture was heated to 75 °C and stirred 
for 18 h, before being cooled to RT, poured onto H2O (15 mL) and extracted with 
EtOAc (30 mL). The organic layer was washed saturated aqueous Na2S2O3 solution 
(20 mL), H2O (20 mL), brine (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo. Purification by silica gel column chromatography, eluting with Tol/EtOAc 
(12/1, 9/1, 6/1) afforded 176 as a yellow oil (214 mg, 0.38 mmol, 64%).  
Rf 0.74 (Tol/EtOAc, 6/1);  
[α]26𝐷 	 +35.5 (c = 0.45, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 7.46-7.28 (20H, m, Ar-H), 5.58 (1H, d, J = 1.6 Hz, H1), 
5.00 (1H, d, J = 11.0 Hz, CH2Ph), 4.77-4.68 (2H, m, CH2Ph), 4.69-4.62 (3H, m, 
CH2Ph), 4.29-4.23 (1H, m, H5), 4.03 (1H, dd, J = 2.9, 1.6 Hz, H2), 3.99 (1H, appt, J 
= 9.4 Hz, H4), 3.88 (1H, dd, J = 9.4, 2.9 Hz, H3), 3.48 (2H, m, H6, H6’);  
13C NMR (100 MHz, CDCl3) δC 138.3 (Ar-C), 138.1 (Ar-C), 137.9 (Ar-C), 134.1 (Ar-




(2C, Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 85.8 (C1), 80.1 (C3), 76.3 (C2), 75.6 (CH2Ph), 
75.5 (C4), 72.7 (C5), 72.2 (2C, CH2Ph), 51.6 (C6);  
HRMS m/z (ESI+) [Found: (M+Na)+ 590.2113 C33H33N3O4S requires M+Na+, 
590.2090]; 
vmax/cm-1 2097 (N=N=N stretching). 
Dibenzyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-α-D-mannopyranosyl phosphate 177 
 
Prepared as per Procedure A using thioglycoside 176 (196 mg, 0.26 mmol, 1.0 
equiv.), DBP (108 mg, 0.39 mmol, 1.5 equiv.), NIS (88 mg, 0.39 mmol, 1.5 equiv.) 
and AgOTf (20 mg, 78 µmol, 0.3 equiv.) in DCM (2.6 mL). Reaction time: 45 min. 
Purification by silica gel column chromatography, eluting with Pet. ether/EtOAc (5/1, 
3/1, 2/1) afforded 177 as a yellow oil (124 mg, 0.16 mmol, 65%).  
Rf 0.44 (Tol/EtOAc, 6/1);  
[α]26𝐷 	 +53.6 (c = 0.2, CHCl3);  
1H NMR (400 MHz, CDCl3) δH 7.34-7.28 (23H, m, Ar-H), 7.26-7.24 (2H, m, Ar-H), 
5.70 (1H, dd, JH1-P = 6.1 Hz, JH1-H2 = 1.9 Hz, H1), 5.08-4.89 (5H, m, CH2Ph), 4.63 
(2H, s, CH2Ph), 4.56 (1H, d, J = 11.0 Hz, CH2Ph), 4.48 (2H, s, CH2Ph), 3.95 (1H, 
appt, J = 9.5 Hz, H4), 3.83 (1H, ddd, J = 9.5, 4.5, 2.7 Hz, H5), 3.78 (1H, dd, J = 9.5, 




13C{31P} NMR (100 MHz, CDCl3) δC 138.1 (Ar-C), 138.0 (Ar-C), 137.7 (Ar-C), 135.6 
(2C), 135.5 (2C, Ar-C), 128.7 (3C, Ar-C), 128.4 (3C, Ar-C), 128.1 (Ar-C), 128.0 (Ar-
C), 127.9 (2C, Ar-C), 127.8 (2C, Ar-C), 127.7 (Ar-C), 96.0 (C1), 78.6 (C3), 75.3 
(CH2Ph), 74.3 (C4), 74.2 (C2), 73.3 (C5), 72.8 (CH2Ph), 72.1 (CH2Ph), 69.6 (CH2Ph), 
69.5 (CH2Ph), 51.0 (C6); 
31P NMR (161 MHz, CDCl3) δP –2.8 (1P, d, JH1-P = 6.1 Hz);   
HRMS m/z (ESI+) [Found: (M+Na)+ 758.2647 C41H42N3O8P requires M+Na+, 
758.2608].  
6-Amino-6-deoxy-α-D-mannopyranosyl phosphate (disodium salt) 174 
 
A suspension of 177 (48 mg, 65 µmol, 1.0 equiv.), Pd/C (10% loading, 11 mg, 11 
µmol, 0.03 equiv. per benzyl) and Pd(OH)2/C (20% loading, 8 mg, 11 µmol, 0.03 
equiv. per benzyl) in EtOH/THF (2:1, 0.05 M, 0.9/0.4 mL) and 0.1M HCl (0.76 mL, 
76 µmol, 1.18 equiv.) was stirred vigorously under an atmosphere of H2 for 18 h. 
The reaction mixture was filtered over CeliteTM and washed with MeOH/water (2:1 
then 1:1, 20 mL total) then passed through Dowex® 50W-X8 resin (Na+ form) before 
being concentrated under reduced pressure. The resultant residue was re-





Rf 0.07 (MeCN/H2O, 3/1 plus 3 drops AcOH); 
[α]26𝐷 	 +24.0 (c = 0.46, H2O);  
1H NMR (400 MHz, D2O) δH 5.42 (1H, d, JH1-P = 5.6 Hz, H1), 3.99 (2H, brs, H2, H3), 
3.89 (1H, d, J = 8.3 Hz, H5), 3.58 (1H, appt, J = 9.5 Hz, H4), 3.46 (1H, d, J = 12.9 
Hz, H6), 3.19-3.06 (1H, m, H6’); 
13C NMR (100 MHz, D2O) δC 95.8 (C1), 70.3 (C2 or C3), 70.2 (C2 or C3), 69.2 (C4), 
68.1 (C5), 40.5 (C6); 
31P NMR (161 MHz, D2O) δP –2.0 (1P, d, JH1-P = 5.6 Hz); 
HRMS m/z (ESI-) [Found: (M-H)- 258.0388 C6H13NO8P requires M−H−, 258.0378].  




To a solution of 112 (0.25 g, 0.46 mmol, 1.0 equiv.) in pyridine (3 mL) was added 
pTsCl (0.26 g, 1.4 mmol, 3.0 equiv.). After stirring for 7 h, the reaction mixture was 
poured onto H2O (30 mL) and extracted with CHCl3 (30 mL). The organic layer was 
washed with 1M HCl (20 mL), saturated aqueous NaHCO3 solution (20 mL), H2O 
(20 mL), brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo.  Drying 
under high vacuum afforded 180 as a yellow syrup (0.25 g, 0.36 mmol, 78%).  




[α]26𝐷 	 	+54.4 (c = 2.1, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.72 (2H, d, J = 7.9 Hz, Ar-H), 7.36-7.30 (13H, m, Ar-
H), 7.27-7.24 (4H, m, Ar-H), 7.23-7.16 (5H, m, Ar-H), 5.39 (1H, d, J = 1.6 Hz, H1), 
4.86 (1H, d, J = 10.7, CH2Ph), 4.65-4.52 (4H, m, CH2Ph), 4.44 (1H, d, J = 10.7 Hz, 
CH2Ph), 4.25 (3H, m, H3, H6, H6’), 3.91 (1H, dd, J = 2.7, 1.6 Hz, H2), 3.87 (1H, appt, 
J = 9.3 Hz, H4), 3.76 (1H, dd, J = 9.3, 3.0 Hz, H5), 2.33 (3H, s, -OphCH3); 
13C NMR (100 MHz, CDCl3) δC 144.7 (Ar-C), 138.1 (Ar-C), 137.9 (Ar-C), 137.8 (Ar-
C), 134.0 (Ar-C), 133.0 (Ar-C), 131.7 (Ar-C), 129.8 (Ar-C), 129.2 (Ar-C), 128.6 (Ar-
C), 128.5 (Ar-C), 128.1 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 85.7 (C1), 80.1 (C5), 76.1 
(C2), 75.2 (CH2Ph), 74.1 (C4), 72.1 (CH2Ph), 72.0 (CH2Ph), 70.9 (C3), 68.8 (C6), 21.7 
(-OphCH3); 
HRMS m/z (ESI+) [Found: (M+Na)+ 719.2152 C40H40O7S2 requires M+Na+, 
719.2113].  
Methyl 2,3,4-tri-O-benzyl-6-deoxy-1-thio-α-D-mannopyranosyl oxime 181 
 
To a solution of 113 (0.98 g, 1.8 mmol, 1.0 equiv.) in THF (18 mL) was added 
dropwise at RT a solution of MeONH2•HCl (0.15 g, 1.8 mmol, 1.0 equiv.) in H2O (3.6 
mL). The reaction mixture was stirred for 10 min, cooled to 0 °C then a solution of 
Na2CO3 (0.23 g, 2.2 mmol, 1.0 equiv.) in H2O (2.2 mL) was added dropwise before 




and extracted with EtOAc (50 mL). The organic layer was washed with H2O (2 × 50 
mL), brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification 
by silica gel column chromatography, eluting with Pet. Ether/EtOAc, (5/1, 4/1) 
afforded 181 as a colourless oil (0.50 g, 0.88 mmol, 48%). 
Rf 0.87 (Pet. Ether/EtOAc, 3/1); 
[α]26𝐷 		+290.6 (c = 0.35, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.41-7.37 (1H, m, HC=N), 7.35-7.31 (4H, m, Ar-H), 
7.30-7.27 (12H, m, Ar-H), 7.23-7.20 (4H, m, Ar-H), 5.44 (1H, d, J = 1.5 Hz, H1), 4.80 
(1H, d, J = 10.9 Hz, CH2Ph), 4.67 (1H, m, H3), 4.63 (2H, m, CH2Ph), 4.61 (2H, m, 
CH2Ph), 4.59 (1H, m, CH2Ph), 3.99-3.90 (2H, m, H2, C4), 3.83-3.81 (1H, m, H5); 
13C NMR (100 MHz, CDCl3) δC 146.9 (C=N), 138.3 (Ar-C), 138.2 (Ar-C), 137.9 (Ar-
C), 134.1 (Ar-C), 131.9 (Ar-C), 129.2 (Ar-C), 128.6 (2C, Ar-C), 128.4 (Ar-C), 128.3 
(Ar-C), 128.1 (Ar-C), 128.0 (2C, Ar-C), 127.9 (Ar-C), 86.2 (C1), 79.6 (C5), 76.6 (C4), 
76.5 (C2) 75.1 (CH2Ph), 72.6 (CH2Ph), 72.4 (CH2Ph), 71.0 (C3), 62.0 (OCH3); 








To a solution of oxime 181 (0.20 g, 0.35 mmol, 1.0 equiv.) in glacial AcOH (17.5 mL) 
was added NaCNBH3 (56 mg, 0.88 mmol, 5.0 equiv.). After stirring for 15 h, the 
reaction mixture was concentrated in vacuo and co-evaporated with Tol to aid 
removal of AcOH.  Purification by silica gel column chromatography, eluting with 
Pet. Ether/EtOAc (5/1) affording 182 as a colourless oil (0.12 g, 0.20 mmol, 57%).  
Rf 0.73 (Pet. Ether/EtOAc, 2/1); 
[α]26𝐷 		+86.6 (c = 1.05, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.44-7.42 (2H, m, Ar-H), 7.34-7.31 (11H, m, Ar-H), 
7.30-7.26 (3H, m, Ar-H), 5.45 (1H, d, J = 1.3 Hz, H1), 4.97-4.92 (1H, m, CH2Ph), 
4.68-4.60 (5H, m, CH2Ph), 4.34-4.30 (1H, m, H5), 3.98 (1H, brs, H2), 3.86-3.84 (2H, 
m, H3, H4), 3.46 (3H, s, -NHOCH3), 3.38 (1H, d, J = 13.3, 2.5 Hz, H6’), 3.02 (1H, dd, 
J = 13.3, 7.8 Hz, H6); 
13C NMR (100 MHz, CDCl3) δC 138.5 (Ar-C), 138.2 (Ar-C), 137.9 (Ar-C), 134.0 (Ar-
C), 132.6 (Ar-C), 132.0 (Ar-C), 129.2 (Ar-C), 129.1 (Ar-C), 128.5 (3C, Ar-C), 128.1 
(2C, Ar-C), 128.0 (2C, Ar-C), 127.9 (3C, Ar-C), 127.8 (Ar-C), 86.1 (C1), 80.3 (C3 or 
C4), 77.0 (C3 or C4), 76.5 (C2), 75.3 (CH2Ph), 72.4 (CH2Ph), 72.3 (CH2Ph), 69.5 (C5), 










6.5.10 Modified GDP-Man analogues 
 
Guanosine diphosphate-6-azido-6-deoxy-mannose (bis-ammonium salt) 91 
 
Prepared as per Procedure G using 119 (4.25 mg, 15.0 µmol, 1.0 equiv.) and GTP 
(7.32 mg, 14.0 µmol, 0.93 equiv.). Reaction time: 16 h. 91 was afforded as a white 
solid (1.48 mg, 2.36 µmol, 16%).  
1H NMR (600 MHz, D2O) δH 8.12 (1H, s, H8’), 5.94 (1H, d, J = 6.1 Hz, H1’), 5.51 (1H, 
d, JH1-P = 8.9 Hz, H1), 4.79 (1H, hidden, H2’), 4.52 (1H, dt, J = 7.3, 3.7 Hz, H3’), 4.35 
(1H, d, J = 10.8 Hz, H4’), 4.24-4.20 (2H, m, H5’a, H5’b), 4.05 (1H, brs, H2), 3.97-3.93 
(1H, m, H5), 3.92 (1H, dd, J = 9.8, 3.4 Hz, H3), 3.68 (1H, appt, J = 8.1 Hz, H4), 3.65 
(1H, d, J = 2.4 Hz, H6’), 3.58 (1H, dd, J = 12.0, 4.0 Hz, H6); 
31P{1H} NMR (161 MHz, D2O) δP –11.5 (1P, s), –14.0 (1P, s);  






Guanosine diphosphate-4-deoxy-4-fluoro-mannose (bis-ammonium salt) 128 
 
Prepared as per Procedure G using 130 (1.38 mg, 5.30 µmol, 1.0 equiv.) and GTP 
(2.57 mg, 4.92 µmol, 0.93 equiv.). Reaction time: 27 h. 128 was afforded as a white 
solid (1.70 mg, 2.80 µmol, 53%). 
1H NMR (400 MHz, D2O) δH 8.12 (1H, s, H8’), 5.94 (1H, d, J = 6.2 Hz, H1’), 5.51 (1H, 
d, JH1-P = 7.5 Hz, H1), 4.98 (1H, hidden, H2’) 4.66 (1H, appt, J = 10.0 Hz, H4), 4.56 
(1H, dd, J = 5.0, 3.3 Hz, H3’), 4.36 (1H, brs, H4’), 4.24-4.19 (2H, m, H5’a, H5’b), 4.19-
4.14 (1H, m, H3), 4.11 (1H, brs, H2), 4.05-3.96 (1H, m, H5), 3.86 (1H, d, J = 12.6 Hz, 
H6), 3.76 (1H, dd, J = 12.6, 3.3 Hz, H6’), 
19F{1H} NMR (376 MHz, D2O) δF –205.6 (1F, s);  
31P{1H} NMR (161 MHz, D2O) δP –12.0 (1P, s), –14.0 (1P, s);  






Guanosine diphosphate-6-amido-6-deoxy-mannose (bis-ammonium salt) 173 
 
Prepared as per Procedure G using 183 (1.70 mg, 6.3 µmol, 1.0 equiv.) and GTP 
(3.02 mg, 5.8 µmol, 0.93 equiv.). Reaction time: 27 h. 173 was afforded as a white 
solid (1.60 mg, 2.6 µmol, 41%).  
1H NMR (400 MHz, D2O) δH 8.11 (1H, s, H8’), 5.94 (1H, d, J = 6.2 Hz, H1’), 5.57 (1H, 
d, JH1-P = 7.0 Hz, H1), 4.89 (1H, hidden, H2’), 4.53-4.48 (1H, m, H3’), 4.35 (1H, brs, 
H4’), 4.27 (1H, d, J = 9.8 Hz, H5), 4.21 (2H, d, J = 4.5 Hz, H5’a, H5’b), 4.06 (1H, brs, 
H2), 3.97 (1H, dd, J = 9.7, 3.2 Hz, H3), 3.85 (1H, appt, J = 9.8 Hz, H4); 
31P{1H} NMR (161 MHz, D2O) δP –11.5 (1P, s), –14.0 (1P, s);  
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